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1 Introduction
During the evolutionary process, development of eukaryotic cells and their membrane-enclosed
organelles enabled the reaction separation within the cells as well as reaction localisation on
membrane surfaces. The impermeability of the lipid bilayers towards most hydrophilic molecules
brought these advantages, but for maintaining the communication within and between the cells,
certain mechanisms to specifically overcome the barrier were needed. One transport possibility
through the lipid bilayer are transport vesicles filled with cargo molecules. The vesicles are
loaded by membrane fission or endocytosis in which the membrane is everted, the corresponding
cargo is surrounded, and subsequently clamped from the source membrane. As soon as the
target membrane is reached, the cargo molecules are released from the vesicle by membrane
fusion or exocytosis. The two opposing membranes of vesicle and target compartment are
pulled in close proximity and water molecules are excluded to enable the fusion process. A
machinery of specialised proteins are necessary for each of these basic mechanisms to enable
cell communication and nutrition by transport vesicles.[1, 2]
Several life essential events are depending on endo- and excocytosis, for example immune
reactions, propagation, and synaptic transmission. For many of these processes, membrane
fission and fusion are executed and regulated by their own set of specialised proteins. One
example is the family of soluble N-ethylmaleimide-sensitive factor attachment protein receptor
(SNARE) proteins which mediate the fusion of transport vesicles along the secretory pathway
of the cells. By anchorage in the opposing membranes and formation of a highly stable coiled
coil, SNARE proteins pull the membranes in close proximity and provide a certain amount of
energy required for fusion.[3, 4] First identified as targets of neurotoxins,[3, 4] SNARE proteins
were especially found to mediate neurotransmitter release at presynaptic nerve terminals.[3–7]
Within the central nervous system, the electrical signals are transferred between nerve cells via
the synaptic cleft, but to overcome this interface, the electrical signal needs to be translated
into a chemical signal. For this purpose, neurotransmitters are stored in synaptic vesicles at
the presynaptic nerve terminal. Upon stimulation, the membrane fusion process is triggered by
Ca2+ influx, the neurotransmitters are released in the synaptic cleft and the signal is thereby
transferred to the postsynaptic nerve terminal. Subsequent binding of the neurotransmitters to
receptors triggers again an electrical signal within the postsynaptic nerve cell.[1, 2] Dysfunctions
of this process cause neuronal and/or neurodegenerative diseases and therefore the process
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Figure 1.1: Model of neuronal SNARE complex resided between synaptic vesicle and plasma
membrane. Synaptobrevin-2 (blue) and Syntaxin-1A (red) are anchored in the membranes
by transmembrane domains (TMD, yellow). The anchorage of SNAP-25 (green) occured by
palmitoylated Cys residues within its linker region (beige). Figure modified from Sutton et al.[9]
Adapted by permission from Macmillan Publishers Ltd: Nature, reference [9], copyright 1998.
is of special interest for research. The mechanism of the highly regulated SNARE-mediated
membrane fusion of synaptic vesicles could offer possible approaches for development of suitable
treatments. Further mechanistic insights might also be transferred to other membrane fusion
events such as bacterial or viral infections.[8]
Since the late 1980s, SNARE proteins are intensively investigated regarding structure, mecha-
nism and regulation. Nowadays, it is generally accepted that the SNARE proteins form the
key components of membrane fusion along the secretory pathway.[3] The neuronal membrane
fusion of synaptic vesicles is mediated by the three SNARE proteins Synaptobrevin-2, also
known as VAMP-2 (vesicle-associated membrane protein), Syntaxin-1A and SNAP-25 (25 kDa
synaptosome-associated protein). The formation of the highly stable four helix bundle, the
so-called SNARE complex, consisting of one helix each of Synaptobrevin-2 and Syntaxin-1A,
and two helices of SNAP-25, provides the required energy for membrane fusion (figure 1.1). A
variety of further executive and regulatory proteins have been identified such as Sec1/Munc18-
like (SM) proteins, CATCHR (complex associated with tethering containing helical rods)
proteins, Complexins and Synaptotagmins, e.g. to maintain the dependency on Ca2+ influx of
the neuronal membrane fusion.[3–7]
After membrane fusion occured, the very stable SNARE complex is dissociated again into
the free SNARE proteins due to energetical reasons and to close the cycle. The hexameric
enzyme N-ethylmaleimide-sensitive factor (NSF) and its cofactors soluble NSF attachment
proteins (SNAPs) catalyse the so-called disassembly reaction upon adenosine triphosphate
(ATP) hydrolysis, and thereby free SNARE proteins are provided again. The enzyme itself
exhibits no direct binding affinity for the SNARE complex. By binding of the cofactor α-SNAP
around the SNARE complex surface, NSF is able to catalyse the reaction.[3–7]
2
1 Introduction
Besides recent progress in solving the structure of the disassembly machinery, the exact
mechanism is still not completely understood. Especially, a specific inhibitor for NSF, which
would facilitate crystallisation studies, is not identified until today. Hence, the first aim of this
study is to synthesise a suitable inhibitor for the SNARE disassembly reaction which is based
on the SNARE protein Synaptobrevin-2. Specific amino acid side chains of the Synaptobrevin-2
SNARE motif contributing in coiled coil formation, will be modified with sterically demanding
side chains. On the surface of the SNARE complex, this sterical hindrance will prevent or
weaken the binding of the cofactor α-SNAP, and consequently, prevent SNARE disassembly
reaction by NSF. The modified Synaptobrevin-2 analogues are synthesised by solid-phase peptide
synthesis (SPPS) and their properties regarding SNARE complex formation and disassembly are
investigated by fluorescence anisotropy. This technique provides the advantage to monitor the
individual steps of the disassembly reaction, such as α-SNAP binding to the SNARE complex,
and upon NSF addition, dissociation into the free SNARE proteins.
Furthermore, the second aim of this study is to investigate the Complexin binding to SNARE
complexes containing the sterically modified Synaptobrevin-2 derivatives. Complexin is a
small regulatory protein of the SNARE-mediated membrane fusion and binds to the groove
between Synaptobrevin-2 and Syntaxin-1A. It is proposed to regulate the Ca2+ dependency
of the neuronal membrane fusion together with the Ca2+ sensor Synaptotagmin. Influence
on Complexin binding provides also influence on the regulation of SNARE complex formation.
Therefore, the Complexin binding to the modified SNARE complexes is also monitored by
fluorescence anisotropy.
In a third part of this study, the SNARE complex formation itself, the so-called zipper-
ing process, is addressed. It is believed that the coiled coil formation starts from the N-terminal
parts of the SNARE motifs and proceeds like a zipper to the C -terminal part and the trans-
membrane domains.[10–12] Some executive or regulatory proteins are discussed to arrest the
SNARE complex during this process to obtain partially zippered intermediates.[13] Especially,
Synaptobrevin-2 mutants were previously investigated to get further insights into the zippering
process.[11, 12, 14–19] The third aim of this study is to develop a Synaptobrevin-2 derivative which
is arrested in the middle of the zippering process, but can be activated again by an external
trigger, and the zippering reaction can proceed. For this purpose, photocleavable protecting
groups (PPGs) are attached at the amino acid side chains contributing in the zippering process.
By irradiation, the PPGs are specifically cleaved and an immediate "jump" in concentration of
the active species can be observed. The modified amino acid building blocks are introduced by
SPPS and the so-called caged Synaptobrevin-2 is investigated regarding the photocleavage
properties of the PPGs and the SNARE complex formation properties before and after irradiation.
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In the last part of this study, Syntaxin transmembrane domains (TMDs) are synthesised
by SPPS and labelled with different fluorophores at the N-terminal end of the sequences. The
labelled TMDs are provided for investigations of Syntaxin clustering within model membrane
systems with fluorescence-based methods, such as fluorescence resonance energy transfer
(FRET).
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The evolutionary formation of membrane-enclosed organelles in eukaryotic cells gave the ad-
vantage of reaction separation and reaction localisation on membrane surfaces due to the
impermeability of the lipid bilayer towards most hydrophilic molecules. For maintenance of
communication between organelles and also between cells, the membrane barrier needed to be
overcome by certain mechanisms. Besides transporter proteins and channels, transport vesicles
filled with impermeable molecules represent one possibility of transport through the lipid bilayer.
The vesicles are filled by the mechanism of endocytosis or membrane fission in which the
corresponding membrane everts, surrounding the cargo molecules, and is subsequently clamped
from the source membrane. On the other hand, the cargo molecules need to be released at
the target compartment by the mechanism of membrane fusion or exocytosis. A machinery of
specialised proteins ensures that the membranes are pulled in close proximity and that water
molecules are excluded to fuse the transport vesicle with the target membrane. These two
processes represent the basic mechanisms for cell communication and nutrition by transport
vesicles.[1, 2]
Several life essential processes depend on endo- and exocytosis, for example immune re-
actions, reproduction, and synaptic transmission. Many of these events exhibit their own
set of specialised proteins for regulation and execution of membrane fission and fusion. One
family of specialised proteins is represented by the SNARE proteins, which mediate membrane
fusion of transport vesicles along the secretory pathway of cells. By anchorage in the opposing
membranes and formation of a highly stable coiled coil, SNARE proteins pull the membranes in
close proximity and provide a certain amount of energy required for fusion.[3, 4] First identified
as targets of clostridial botulinum and tetanus neurotoxins,[3, 4] SNARE proteins were especially
found to mediate neurotransmitter release at presynaptic nerve terminals.[3–7] Neurotransmitters
are stored in synaptic vesicles at the presynaptic nerve terminal and are released into the synaptic
cleft to maintain the communication between nerve cells. This so-called synaptic transmis-
sion is required for transferring of stimuli from one neuron via the synapse to the next neuron.[1, 2]
Dysfunctions of this process cause neuronal and/or neurodegenerative diseases or, like in
the case of neurotoxins, paralysis which can lead to death of the organism.[4, 6] The highly
regulated SNARE-mediated membrane fusion of synaptic vesicles is therefore of special interest
for research as a possible approach for the development of suitable treatments. In addition,
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mechanistic insights into neuronal exocytosis might be transferred to other membrane fusion

























Figure 2.1: Scheme of synaptic transmission from the
presynaptic neuron (top) via the synaptic cleft (middle)
to the postsynaptic neuron (bottom). À Upon stim-
ulation of the presynaptic neuron, an action potential
propagates along the axon (white arrow), generated
by voltage-gated Na+ channels. The opening of these
channels induces Na+ influx, and thereby a local de-
polarisation of the plasma membrane. Propagation is
achieved by triggering the opening of further Na+ chan-
nels in close proximity. Á Arrival of depolarisation at
the nerve terminal triggers opening of Ca2+ channels
and induces Ca2+ influx. Â Increasing Ca2+ concentra-
tion triggers neuronal exocytosis of synaptic vesicles and
thereby neurotransmitter release. The membrane fusion
between the synaptic vesicle and the plasma membrane
is mediated by the SNARE proteins Synaptobrevin-2,
Syntaxin-1A and SNAP-25 in collaboration with further
executive and regulatory proteins, like Synaptotagmin as
Ca2+ sensor. Ã Neurotransmitters are released from the
presynaptic neuron into the synaptic cleft and diffuse
to receptors at the postsynaptic neuron. Ä Binding of
neurotransmitters to receptors triggers opening of ion
channels and Na+ and Ca2+ influx induces depolarisa-
tion and thereby stimulation of the postsynaptic neuron.
By this mechanism of synaptic transmission, the elec-
trical signal of the presynaptic neuron is transformed
to a chemical signal, thereby passed over the synaptic
cleft, and afterwards in the postsynaptic neuron again
transformed to an electrical signal.[2]
The importance of neuronal exocytosis can be illustrated by a closer look on its overall mecha-
nism. The synaptic transmission is necessary for the transfer of a stimulus from one nerve cell
via the synaptic cleft to the next nerve cell (figure 2.1). During this process, the electrical signal,
called action potential, is transformed into a chemical signal within the synaptic cleft. Upon
arrival of an action potential at the nerve terminal (figure 2.1 À), opening of voltage-gated
Ca2+ channels and thereby Ca2+ influx is induced (figure 2.1 Á). The increase in Ca2+ concen-
tration triggers the exocytosis of neurotransmitters from the synaptic vesicles into the synaptic
cleft (figure 2.1 Â). After diffusion through the synaptic cleft, the neurotransmitters bind to
receptors at the plasma membrane of the postsynaptic nerve cell (figure 2.1 Ã) and thereby
trigger the opening of ion channels. Influx of Na+ and Ca2+ ions into the postsynaptic nerve
cell induces depolarisation of the plasma membrane, and consequently stimulation of an action
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potential (figure 2.1 Ä). In this way, the electrical signal is transferred to the postsynaptic
nerve cell and eventually forwarded to the next synapse.[1, 2]
Synaptic transmission is a crucial process as impairments always have critical effects on
the affected organism. For instance, this process is dysfunctional in neurodegenerative diseases
or can be impaired by toxins, such as clostridial botulinum and tetanus toxins. These neurotoxins
cause paralysis and can cause death by apnoea without treatment. The research of the exact
mechanism of neuronal exocytosis can provide possible approaches for treatment of diseases or
intoxications.
The process of neuronal exocytosis describes the membrane fusion between the synaptic
vesicle and the plasma membrane. Interestingly, the influx of Ca2+ ions triggers membrane
fusion of synaptic vesicles within milliseconds. This very fast response is challenging and requires
a machinery of specialised proteins. The key elements are found to be the SNARE proteins
Synaptobrevin-2, Syntaxin-1A and SNAP-25 which mediate the neuronal membrane fusion in
collaboration with further executive and regulatory proteins. For example, Synaptotagmin-1
functions as a Ca2+ sensor.[3–7] In the following chapters, structural and functional aspects of
SNARE proteins as well as the mechanism of SNARE-mediated membrane fusion is discussed.
2.2 SNARE Proteins and SNARE Complex
SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) proteins were
first identified around 1990. Especially, studies with clostridial botulinum and tetanus toxins
revealed them as substrates for these highly specific proteases for inhibiting neurotransmitter
release, and thereby their importance in neuronal membrane fusion was shown.[3, 4, 20–22] The
name is based on the interaction with the previously identified components of membrane fusion
NSF and SNAPs.[23] Today, it is generally accepted that the SNARE proteins form the key
components of membrane fusion along the secretory pathway.[3]
Proteins of the SNARE family comprise a conserved domain of 60 – 70 residues contain-
ing heptad repeats which is referred to as the characteristic SNARE motif.[3–5, 7] In most of
the SNARE sequences, these motifs are C -terminally connected to a transmembrane domain
(TMD) by a small linker region. In addition, different N-terminal domains are among others
the origin of further subgroups of the SNARE protein family.[3, 5]
The neuronal membrane fusion comprises a special case, due to its tight dependency on
Ca2+ influx.[5] The SNARE proteins Synaptobrevin-2, also known as VAMP-2 (vesicle-associated
membrane protein), Syntaxin-1A and SNAP-25 (25 kDa synaptosomal-associated protein) were
identified to mediate neurotransmitter release. Synaptobrevin-2 and Syntaxin-1A exhibit one
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SNARE motif each and a C -terminal TMD, whereas SNAP-25, as well as its homologues,
represents an exception with two SNARE motifs joined by a palmitoylated linker for membrane-
attachment, instead of a TMD (figure 2.2 a). Among these three peptides, Synaptobrevin-2
constitutes the simplest domain structure with a short, unstructured and proline-rich N-terminal
domain besides the SNARE motif and the TMD. In contrast, Syntaxin-1A exhibits a N-terminal
domain that forms an antiparallel three-helix bundle and is referred to as Habc domain. In
addition, at the very N-terminal end, a short sequence called the N-peptide is noteworthy.[3–5, 7]
It can be derived from the structure of Syntaxin-1A that it has more functions in membrane
fusion than the other SNARE proteins.[4]
Syntaxin-1A
1 9 27 62 71 104 111 146 183 256 266 288
N-pep de Habc domain SNARE mo f TMD
SNAP-25
1 7 83 141 204 206
SNARE mo f SNARE mo f
Synaptobrevin-2
1 28 85 96 116
PP SNARE mo f TMD
a b
c
Figure 2.2: (a) Domain structure of neuronal SNARE proteins Syntaxin-1A, SNAP-25 and
Synaptobrevin-2 including SNARE motifs, transmembrane domain (TMD), as well as Habc
domain and N-peptide of Syntaxin-1A, and proline-rich N-terminal part (PP) of Synaptobrevin-2.
Figure modified from Stein et al.[24] Adapted by permission from Macmillan Publishers Ltd:
Nature, reference [24], copyright © 2009. (b) Crystal structure of neuronal SNARE complex
including 16 layers (−7 – +8) as ribbon diagram (pdb code 1sfc). Complex consisting of SNARE
motifs of Synaptobrevin-2 (R, blue), Syntaxin-1A (Qa, red), and SNAP-25 (Qb, Qc, green).
Figure modified from Kloepper et al.[25] Republished with permission of American Society
for Cell Biology, from reference [25], copyright © 2007; permission conveyed through Copyright
Clearance Center, Inc. (c) Detailed structure of central hydrophilic zero layer of neuronal SNARE
complex including Synaptobrevin-2 residue R56, Syntaxin-1A residue Q226, and SNAP-25 residues
Q53 and Q174. Figure adapted from Sutton et al.[9] Adapted by permission from Macmillan
Publishers Ltd: Nature, reference [9], copyright © 1998.
Synaptobrevin-2 is predominantly located in synaptic vesicles, whereas Syntaxin-1A and SNAP-
25 are located in the plasma membrane at the nerve terminals, which led to their original
classification into vesicle-SNAREs (v-SNAREs) and target-SNAREs (t-SNAREs).[3, 6, 7] As
soon as their four SNARE motifs get in contact, a tight and highly stable coiled-coil of four
parallel α-helices is formed which is suggested to pull the opposing membranes into close
proximity as well as to contribute the required energy for mediating membrane fusion.[3–5, 7]
The so-called neuronal SNARE complex was shown to be stable even against adverse conditions
like high temperatures (80 °C) or denaturing agents (8 m urea or 2 % SDS).[3, 26, 27] The
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crystal structure revealed mainly hydrophobic interactions which are subdivided into 16 distinct
layers (figure 2.2 b). The only exception constitutes a central hydrophilic layer (zero layer)
which was found to be highly conserved in all SNARE motif sequences and always consists
of three glutamin (Q) residues and one arginine (R) residue (figure 2.2 c).[9] On this basis,
SNARE proteins were reclassified into Qa-, Qb-, Qc-, and R-SNAREs.[3–5, 7, 28]
Besides the formation of the ternary SNARE complex, which mediates membrane fusion,
in vitro SNARE motifs tend to form a variety of homo- and hetero-oligomeres. Especially,
the formation of the so-called binary complex consisting of SNAP-25’s two SNARE motifs
and two Syntaxin-1A molecules represents a dead-end along the reaction pathway. In this
case, the binding site for Synaptobrevin is blocked and the second Syntaxin-1A cannot be
replaced by Synaptobrevin.[11, 29] In addition, the Habc domain of Syntaxin-1A exhibits an
open or closed conformation (figure 2.3 a and b). In the closed conformation, the three-helix
bundle of the Habc domain is associated to the SNARE motif (or H3 domain), and thereby
suggested to prevent SNARE complex assembly.[30, 31] Additionally, the Habc domain as well
as the N-peptide of Syntaxin-1A were found to bind to the Sec1/Munc18-like (SM) protein
Munc18-1 (figure 2.3 c). SM proteins are under discussion to be part of the SNARE assembly




















Figure 2.3: (a) Crystal structure of the open conformation of the N-terminal Habc domain
of Syntaxin-1A (pdb code 1br0) with the three α-helices Ha (blue), Hb (green), and Hc (red).
Figure modified from Lerman et al.[30] Adapted with permission from reference [30]. Copyright
© 2000 American Chemical Society. (b) Structure of closed conformation in which the Habc
domain (red) is associated to the SNARE motif (H3 domain, purple). Figure modified from
Misura et al.[31] Adapted by permission from Macmillan Publishers Ltd: Nature, reference [31],
copyright © 2000. (c) Crystal structure of Munc18-1-Syntaxin-1A complex (pdb code 3c98)
consisting of Munc18-1 (blue-green) and Syntaxin-1A (red-orange) in the closed conformation.
Dashed lines represent flexible linker regions. Figure modified from Jahn & Fasshauer.[5]
Adapted by permission from Macmillan Publishers Ltd: Nature, reference [5], copyright © 2012.
These conformational as well as dead-end intermediates were among others considered to be
responsible for the very slow in vitro SNARE complex assembly which usually takes several
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hours.[5] To overcome this problem, stabilised acceptor complexes (∆N complex) are used in
vitro consisting of SNAP-25, Syntaxin-1A and a C -terminal Synaptobrevin-2 fragment to obtain
an available N-terminal binding site for full-length Synaptobrevin-2. Indeed, distinctly faster
fragment displacement, and therefore, ternary SNARE complex formation was observed.[5, 11]
2.3 A Closer Look at SNARE Protein Synaptobrevin-2
The neuronal SNARE protein Synaptobrevin-2 or VAMP-2 is a small (∼12 kDa) synaptic vesicle
protein. In 1988, it was firstly identified and isolated by Trimble et al. from synaptic vesicles
of the electromotor system of Torpedo californica.[33] In 1989, Synaptobrevin-2 was named by
Baumert et al. after the greek term synapto (σψναπτo) = to connect and the latin term
brevis = short.[34] Only a few years later, in 1992, it was identified as an essential protein
for membrane fusion because of specific cleavage by neurotoxins.[3, 4, 20] Initially classified as
v-SNARE by Rothman et al.[35] due to main isolation from synaptic vesicles, Synaptobrevin-2
and the whole VAMP family was reclassified as R-SNAREs based on the highly conserved
arginine residue within the zero layer.[28]
Among the neuronal SNARE proteins, Synaptobrevin-2 comprises the simplest domain structure
with its short, unstructured, and proline-rich N-terminal domain (1 – 27), its SNARE motif
(28 – 84), its short linker region (85 – 95), and its C -terminal TMD (96 – 116) (figure 2.2 a).[24]
Together with its neuronal counterparts Syntaxin-1A and SNAP-25, it forms the highly stable
neuronal SNARE complex which mediates membrane fusion.[3–5, 24]
The soluble part of Synaptobrevin-2 (1 – 95) is mainly unstructured in aqueous solution,
whereas the TMD (96 – 116) forms an α-helical structure. During assembly of the SNARE
complex, extraordinary structural changes occur until helical conformation is reached. Studies
using nuclear magnetic resonance (NMR) spectroscopy showed that Synaptobrevin-2 exhibits
three helical regions in micelles of the detergent dodecylphosphocholine (DPC).[36] Two of
these three helices comprises the SNARE motif region, separated by an unstructured region.
The third helix consists of the TMD residues. Helix I (36 – 54) and helix II (77 – 88) are more
flexible than helix III (93 – 115) (figure 2.4 b). This structural arrangement was suggested to
influence the assembly of the SNARE complex, as the N-terminal helix I could function as a
nucleation site for complex formation. This would accelerate the N- to C -terminal propagation
of the coiled-coil by a preformed helical conformation. In addition, hydrophobic moment and
hydropathy of the Synaptobrevin-2 sequence were analysed (figure 2.4 a). As expected, the
TMD exhibits highest hydrophobicity within the sequence, and the SNARE motif shows a
highly amphipathic region, especially around residue 44. When modelled to a helical structure,
the latter exhibits hydrophobic residues on one face and more hydrophilic regions on the other,
which is consistent with hydrophobic residues contributing to SNARE complex formation and
charged residues on the complex surface. Interestingly, a highly hydrophilic region was found
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which includes not only the zero layer but also a region comprising residues ∼56 – 65 with
the highest hydrophilicity at residues 58 – 61. Within the structure in DPC micelles, this
region is unstructured.[36] This is consistent with the identified SNARE complex binding sites












Figure 2.4: Structure of Synaptobrevin-2 (1 – 116) in DPC micelles. (a) Analysis of hydrophobic
moment and hydropathy with octanol-scale used for calculation of the free energy for transfer
from bilayer to water. (b) Structure determined by NMR spectroscopy (pdb code 2kog) with helix
I (blue) at micelle surface, helix II (green) on hydrophilic site, and helix III (red) corresponding to
the TMD on the hydrophobic site. Figure modified from Ellena et al.[36]
More recently, these NMR studies were extended to bicelles and bilayers as well as to the usage
of electron paramagnetic resonance (EPR) spectroscopy. For this purpose, Synaptobrevin-2 was
reconstituted into DMPC/DHPC bicelles and POPC/POPS bilayers, respectively. It was found
that the amount of helical conformation and association to the lipid interface decreases from
micelles via bicelles to bilayers. This indicated that the structural conformation and interaction
with the lipid head groups are strongly dependent on membrane curvature and were suggested
to regulate Synaptobrevin-2’s contribution to SNARE complex assembly.[37]
In 2010, a possible connection between Synaptobrevin-2 and certain neurodegenerative dis-
eases was revealed by the discovery of α-Synuclein binding to the N-terminal domain of
Synaptobrevin-2.[38] α-Synuclein is a small soluble protein which is enriched in presynaptic
terminals. At the N-terminal end it exhibits an amphipathic helix for membrane interaction and
with its C -terminal negatively charged domain it was found to bind to Synaptobrevin-2.[38–40]
α-Synuclein was discovered to be the main component of fibrils in the so-called Lewy bodies
which were identified to play a key role in Parkinson’s disease and dementia. It is therefore of
special interest in the research field of neurodegenerative diseases.[6, 38, 39, 41] The interaction
with Synaptobrevin-2 suggested the physiological function of α-Synuclein as a SNARE complex
chaperone, and hence, loss of this function was thought to initiate neurodegeneration. This
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hypothesis is still debated because there is evidence that the pathological effect of α-Synuclein
by formation of neurotoxic aggregates is not correlated to a loss of physiological function.[39]
In contrast, Choi et al. recently showed that a cooperative effect between β-Amyloid and
α-Synuclein induces oligomerisation of larger α-Synuclein aggregates.[41] β-Amyloid was found
to be the major component of plaques and aggregates associated with Alzheimer’s disease, in
contrast to Parkinson’s disease and dementia. But also combinations were found like β-Amyloid
plaques in dementia patients or Lewy bodies containing α-Synuclein in Alzheimer’s patients,
respectively, which often shows more severe progress of the diseases. Indeed, larger α-Synuclein
aggregates obtained by seeding with β-Amyloid were shown to inhibit SNARE-mediated vesicle
fusion in vitro and in PC12 cells. On the other hand, aggregates formed only by β-Amyloid
or α-Synuclein, respectively, did not inhibit vesicle fusion. In addition, the inhibitory effect of
these aggregates was shown to be based on the interaction with the N-terminal domain of
Synaptobrevin-2. Probably, the large α-Synuclein/β-Amyloid aggregates bind to Synaptobrevin-
2, and thereby prevent interaction with Syntaxin-1A and SNAP-25 to form the SNARE complex.
This was consistent with observed clustering of Synaptobrevin-2-containing vesicles. These
results indicated that not only the aggregates formed by α-Synuclein or β-Amyloid alone,
which are markers for diagnosis of neurodegenerative diseases, have a dramatic effect on
neuronal functions. But also the induced α-Synuclein aggregation by β-Amyloid or other
seeding factors, like dopamin, probably exhibit the highest neurotoxicity due to direct inhibition
of SNARE-mediated neurotransmitter release.[41]
In addition, a variety of studies were performed using Synaptobrevin-2 mutants to inves-
tigate the SNARE zippering process.[11, 12, 14–19] This issue is discussed in detail in chapter 5.1.
2.4 The Cycle of SNARE-Mediated Membrane Fusion
SNARE-mediated membrane fusion proceeds in a cycle of complex formation (SNARE assembly,
chapter 2.5), which was proposed to induce fusion, and afterwards ATP-dependent dissociation
of the SNARE complex (SNARE disassembly, chapter 2.6) catalysed by NSF and its cofactor
α-SNAP (figure 2.5).[3] In more detail, the cycle was suggested to begin from free SNARE
clusters of Qa-, Qb-, and Qc-SNAREs in the acceptor membrane which, probably dependent on
Sec1/Munc18-like (SM) proteins, form the acceptor complex. Upon approach of an R-SNARE-
containing vesicle, the loose trans-SNARE complex is formed by interaction of the N-terminal
parts of the corresponding SNARE motifs. In the trans-configuration, TMDs of contributing
SNARE proteins are anchored in two opposing membranes. Complex assembly is suggested
to proceed from N- to C -terminal end of SNARE motifs to form the tight trans-SNARE
complex, whereby regulatory proteins such as Complexins (chapter 2.7) and Synaptotagmins
(chapter 2.7.3) are proposed to trigger the assembly process in response to Ca2+ influx in
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Figure 2.5: Cycle of SNARE-mediated membrane fusion including free SNARE clusters of
Qa-SNAREs (red), Qb-, and Qc-SNAREs (green) in the acceptor membrane (top left), formed
acceptor complexes (middle left), approaching R-SNARE (blue)-containing vesicle and formation
of loose trans-SNARE complexes (bottom left), possible regulation of the tight trans-SNARE
complex by regulatory proteins (Complexins/Synaptotagmins) (bottom middle), transformation
from trans- to cis-complexes and membrane fusion (bottom right), cis-SNARE complexes within
the acceptor membrane (middle right), association of NSF (brown balls) and α-SNAP (purple
trapezium) around the cis-complexes (top right), and finally, ATP-dependent Disassembly of
cis-SNARE complexes into free SNARE proteins. Figure modified from Jahn & Scheller.[3]
Adapted by permission from Macmillan Publishers Ltd: Nature Reviews Molecular Cell Biology,
reference [3], copyright © 2006.
neuronal exocytosis. The transformation from trans- to cis-SNARE complexes in combination
with Synaptotagmin is hypothesised to open the fusion pore. Within the cis-complex, all
contributing SNAREs are finally anchored in the same membrane, and this highly stable
complex has to be dissociated again into the free SNARE proteins due to energetic reasons.
The cofactor α-SNAP bind around the SNARE complex and induce binding of hexameric NSF
which catalyses, upon ATP-hydrolysis, the so-called disassembly reaction. Finally, free SNARE
proteins are provided again and by various mechanisms sorted to their corresponding target
localisation (e.g. Synaptobrevin-2 anchored in synaptic vesicles).[3–7]
2.5 Priming and Assembly of the SNARE Complex
The cycle of membrane fusion mediated by SNARE proteins was suggested to start from
free SNARE clusters and afterwards formation of the SNARE acceptor complex comprising
Syntaxin-1A and SNAP-25 (figure 2.5).[3] Recently, this starting point was questioned due to
the increasing evidence that SM proteins, such as Munc18, and CATCHR (complex associated
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with tethering containing helical rods) proteins, like Munc13, also play key roles in membrane
fusion.[4–7] It was even pointed out that the assembly of SNARE/SM complexes mediates
fusion.[6] Physiologically, the combination of SNAREs, Munc18s, and Munc13s, as key compo-
nents, is needed for neuronal exocytosis. This was already indicated by studies with Munc18-1
knockout mice[42], and Munc13-1 and -2 double knockout mice[43], respectively, which in both
cases exhibited a total loss of neuronal exocytosis.[4–7]
As already mentioned in chapter 2.2, the SM protein Munc18-1 was found to bind to the Habc
domain of Syntaxin-1A in the closed conformation[31], to the N-peptide of Syntaxin-1A[32],
as well as to the ternary SNARE complex[44] (figure 2.3). Initially, the formed Syntaxin-1A-
Munc18-1 complex was thought to inhibit SNARE assembly due to the blocked SNARE motif
of Syntaxin-1A, but this would be totally contrary to the knockout studies. At this point, the
interaction with the N-peptide of Syntaxin-1A seemed to be crucial because it comprises the
connecting point between the interaction with the closed conformation and Syntaxin-1A in the
open conformation assembled to the SNARE complex. For the transition from closed to open
conformation, Munc13s were suggested to be important.[4–7]
Structurally, Munc13s comprises two C2 domains for calcium binding and the so-called MUN do-
main which represents the key functional unit.[4, 5, 7] It could be shown that the isolated
MUN domain of Munc13-1 interacts with SNARE complexes reconstituted in membranes,[45]
with Syntaxin-1A/SNAP-25 heterodimers (Syntaxin-1A/SNAP-25, 1/1),[45, 46] and also with
low affinity with Munc18-1 and the Syntaxin-1A SNARE motif.[47] In addition, it was shown
that the MUN domain supports the conformational change of the closed Syntaxin-1A-Munc18-1
complex to the ternary SNARE complex, probably by opening the Syntaxin-1A conformation
and thereby increasing the availability of Syntaxin-1A to contribute to SNARE assembly.[47]
Taken together, these recent findings suggested a different starting point for the cycle of
SNARE-mediated membrane fusion, namely the complex consisting of closed Syntaxin-1A
and Munc18-1. Consequently, the assembly of the ternary SNARE complex is arranged by
the cooperation of Munc13s and Munc18s, probably resulting in a partially zippered SNARE
complex in the primed state. In addition, there is increasing evidence that one or both Muncs
remain bound to the tight trans-SNARE complex due to the fact of counteracting premature
disassembly by NSF/α-SNAP.[13] Also their crucial importance for neuronal exocytosis[42, 43]
as well as membrane-dependent affinity[45] militates for their action also after assembly.[4, 5, 7]
Nevertheless, essential questions regarding the starting point remain open. Consequently, no
final definition can be set yet.[7]
The importance of SM and CATCHR proteins in vivo was underlined by the investigation of
SNARE complex formation in vitro. A variety of Q- and R-SNARE combinations were found,
such as Qaabc (binary) complexes,[11, 12] which in vivo needed to be prevented and channeled
towards formation of QabcR-SNARE complexes.
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In addition to setting the starting point, Munc13s were also suggested to contribute in
the localisation of the whole fusion machinery within the so-called active zone. This is the
region where synaptic vesicles are localised in the nerve terminal in their docked and primed
state, ready to release the neurotransmitters upon Ca2+ influx. The active zones of the plasma
membrane contain specialised proteins to guide the synaptic vesicles during this preparing step
prior to membrane fusion. Besides structural organisation of the machinery components, the
close localisation to the Ca2+ channels for fast response upon Ca2+ triggering represents the
second task of active zone proteins. Munc13s were suggested to constitute the connecting point
between these two tasks by interaction with the SNARE/SM protein complexes on the one
hand, and interaction with active zone proteins, such as RIM (Rab3-interacting molecule) and
RIM-BP (RIM-binding proteins), on the other hand.[4–6] The formation of a complex consisting
of Munc13, RIM and RIM-BP results in tethering of plasma membrane and synaptic vesicle,
first by binding of RIM to the vesicular GTPases Rab3 and Rab27, and second by binding of
RIM and RIM-BP to Ca2+ channels (figure 2.6).[4, 6]
Figure 2.6: Schematic localisation of neuronal membrane fusion machinery at the active zone.
Synaptic vesicle (top right) in the docked state including the key functional units for neuro-
transmitter release: (right) SNARE/SM protein complex consisting of Synaptobrevin-2 (red),
Syntaxin-1A (yellow), SNAP-25 (green), and Munc18 (light blue). In addition, regulatory pro-
tein Complexin (light purple) bound to the SNARE complex. (middle) Ca2+ sensor protein
Synaptotagmin-1 (blue), and (left) active zone protein complex containing Munc13 (dark brown),
RIM (dark purple), RIM-BP (light brown) bound to vesicular GTPase Rab3/27 (light green) on
the vesicle site, and to Ca2+ channel (dark blue) on the plasma membrane site. Figure used from
Südhof.[6] Reprinted from reference [6], Copyright © 2013, with permission from Elsevier.
Localisation by active zone proteins as well as interaction with SM proteins arrange SNARE
proteins into close proximity to assemble to the stable four-helix bundle upon contact. With
a variety of studies it was confirmed that the SNARE complex formation begins from the N-
terminal part of the SNARE motifs and proceeds towards the C -terminal part like a zipper.[10–12]
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In this way, SNARE assembly pulls the opposing membranes together and brings them in close
proximity for fusion.[3–5] Especially, Synaptobrevin-2 mutants were investigated to get further
insights into the zippering process.[11, 12, 14–19] These studies is discussed in more detail in
chapter 5.1.
After the synaptic vesicle and the whole participating fusion machinery is set to the docked
and primed state, the system has to react to Ca2+ influx which is known to trigger neuronal
exocytosis. This is found to be mediated by the Ca2+ sensor Synaptotagmin in possible
combination with Complexins which is described in detail in chapter 2.7.3.
To conclude, the shown cycle of SNARE-mediated membrane fusion in figure 2.5 still represents
an up-to-date possible mechanism but focuses only on the key components, the SNARE proteins.
Especially for the SNARE assembly, the starting point, the Q-SNARE acceptor complex, is
under discussion. Nevertheless, it gives a direct overview of the mechanism without causing
confusion by including all participating proteins. However, to understand the whole process of
neuronal exocytosis, it is necessary to investigate each protein as well as the overall interplay
between them which is a challenging task with this amount of contributors. In the following
chapter the SNARE disassembly reaction is discussed in detail.
2.6 The NSF/α-SNAP-Mediated SNARE Disassembly
Reaction
After membrane fusion occurred, SNARE complexes are in cis-configuration, and all proteins of
the complexes are located together in the fused membrane. In this configuration, the SNARE
complexes exhibit a high stability, are inactive and have to be recycled for the next round of
membrane fusion. To dissociate the cis-SNARE complexes, a remarkable amount of energy
is required. The so-called disassembly reaction is catalysed by the enzyme N-ethylmaleimide-
sensitive factor (NSF) and its cofactors soluble NSF attachment proteins (SNAPs) upon
ATP hydrolysis.[3–7] The functional machinery, which is necessary for SNARE disassembly
reaction, consists of NSF, SNAPs and the SNARE complex. It is called 20 S particle or
20 S (super)complex due to its sedimentation coefficient of 20 Svedberg units.[48, 49] The exact
composition, especially the needed number of SNAPs, is still under discussion.
2.6.1 N-ethylmaleimide-sensitive factor (NSF)
In 1988, Rothman et al. firstly identified NSF to contribute in trafficking of eukaryotic
cells.[50–52] From these early studies, NSF derived its name due to the observed inhibition of
protein transport by N-ethylmaleimide, which could be restored by adding NSF-containing cell
extract.[51, 52]
16
2.6 The NSF/α-SNAP-Mediated SNARE Disassembly Reaction
NSF is a homohexameric type II ATPase with a molecular weight of ∼500 kDa and be-
longs to the AAA+ (ATPases associated with various cellular activities) superfamily.[3, 53]
Meanwhile, it is one of the best-investigated members of this family.[53] The AAA+ ATPases all
have in common that they transfer chemical energy from ATP hydrolysis into conformational
changes, and subsequently induce mechanical action on their substrates. The functions of these
enzymes are diversely distributed ranging from protein complex disassembly, like NSF, to e.g.
DNA unwinding.[53, 54] Structurally, the main feature of this protein family is the ATP-binding
domain (AAA domain) with about 200 – 250 amino acid residues.[54]
In the case of NSF, one subunit consists of three domains: the N-terminal N domain (1 – 205),
and two ATPase domains D1 (206 – 477) and D2 (478 – 744) (figure 2.7 and 2.8 a). The
N domain functions as the binding site for the cofactors and substrate, the D1 domains
exhibits most of the ATPase activity, and the D2 domain provides the hexamerisation of the
protein.[53, 55] The crystal structures of the N domain[56] and D2 domain[57] were published in
the late 1990s and showed two subdomains (NA and NB) for the N domain as well as for the
D2 domain (α and α/β), with the latter to be generic for AAA+ domains (figure 2.7).[53]
Nevertheless, crystal structures of the D1 domain or full-length NSF are still not available.
N domain D1 domain D2 domain
1 205 477 744
Figure 2.7: Domain structure of NSF with crystal structures of the N domain[56] (pdb code
1qcs) and the D2 domain[57] (pdb code 1nsf). Structure of the D1 domain[50] is derived by
cryo-EM (pdb code 3j94). Figure modified from Zhao et al.[53]
Continuous improvement of cryo-electron microscopy (EM) and NSF purification led to recently
published near-atomic resolution structures of full-length NSF.[50, 53] In 2015, Brunger et
al. could solve the structures in ATP-bound and ADP-bound state of NSF with a resolution of
4.2 Å and 7.6 Å, respectively (figure 2.8).[50]
From these structures, it was also possible to create a model of the D1 domain, which exhibits
the characteristic α and α/β subdomains. In contrast to the D2 domain, it shows two helices
twisted differently, one longer helix, as well as a pore loop with the typical sequence YVG
(figure 2.7).[50, 53]
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Figure 2.8: (a) Domains of NSF, (b and c) structures of full-length NSF in ATP- and ADP-bound
state as side-views and (d and e) schematics to show topology of the D1 ring with colour-coded
chains A to F. Figure modified from Zhao et al.[50] Adapted by permission from Macmillan
Publishers Ltd: Nature, reference [50], copyright © 2015.
In the recent structure of full-length NSF in the ATP-bound state, the six D2 domains
are arranged as a 6-fold symmetric, planar ring and form the bottom of the structure. The six
D1 domains are arranged like a snap ring on top of the D2 ring. The domains are stepping up
anti-clockwise except for the distance between the subdomains A and F. On top, the N domains
are flexibly arranged and no symmetry was detected (figure 2.8 b and d).[50, 53]
In the ADP-bound state, the bottom D2 ring shows some slight differences, whereas the
D1 ring is broader and exhibits an opening, like an open ring washer. Four N domains are still
on top of the structure, whereas two domains are arranged down along the D1 and D2 domains
(figure 2.8 c and e).[50, 53] The latter finding is consistent with previous cryo-EM structures
from Chang et al. where they proposed the existence of an up (ATP-bound) and down
(ADP-bound) conformation of the N domains.[55]
The comparison of both structures revealed the origin of the ATP-initiated conformational
changes in the D1 domains, whereupon the N domains and D2 domains are restructured. All
these structural movements have to be coupled to the disassembly of the SNARE complex.[50, 53]
With these higher-resolution structures, including the 20 S (super)complex, it was confirmed
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that full-length NSF, especially its N domains exhibits no binding site for the substrate (SNARE
complex) but only for the cofactors (SNAPs).[3, 49, 50, 53]
2.6.2 Soluble N-Ethylmaleimide-Sensitive Factor Attachment
Proteins (SNAPs)
SNAPs are essential for the disassembly reaction due to no direct binding of NSF to the
substrate, the SNARE complex. Without binding of SNAPs, the SNARE complex is not disas-
sembled. On the other hand, NSF only binds to SNAPs, when the SNAP/SNARE subcomplex is
already formed or to a trimerised mutant of SNAPs.[49] Three isoforms of SNAPs are identified:
α-, β- and γ-SNAP.[3, 49] Only β-SNAP is an exception due to its expression limited to the
brain, the other two isoforms are expressed in all cells of an organism.[49]
In the context of the SNARE disassembly reaction, α-SNAP is the most-investigated iso-
form but still there is no crystal structure available. Only the crystal structure of its homologue
from Saccharomyces cerevisiae (Baker’s yeast) Sec17p provides indications for the interaction of
α-SNAP with NSF and the SNARE complex[58] and is still used to refine recent structures.[50, 55]
Sec17p forms 14 antiparallely arranged α-helices and exhibits two main domains: an N-
terminal twisted sheet consisting of nine, anti parallel-arranged α-helices, and a C -terminal
α-helical bundle. The N-terminal domain shows a right-handed twist, consequently, forming a
concave and convex side of the domain. The N- and the C -terminal ends of the protein are
positioned at opposite parts of the structure (figure 2.9).[58]
Figure 2.9: Crystal structure of Sec17 with the 14 α-helices showing the concave (left) and
convex side (right). Figure used from Rice et al.[58] Reprinted from reference [58], Copyright ©
1999, with permission from Elsevier.
In the N-terminal domain, a longer loop connects the first two helices of the twisted sheet and
the loop is arranged further away from the other helices. It exhibits mainly hydrophobic amino
acids (27 – 32) and is found to be the membrane-attachment site of α-SNAP. Winter et
al. could show that α-SNAP binding to the SNARE complex, as well as its efficiency during
disassembly reaction, is increased when the SNARE complex is reconstituted into liposomes.
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They developed two α-SNAP mutants, one lacking the entire N-terminal membrane anchor
region (33 – 295), and the second with two conserved phenylalanines mutated to serines
(F27S, F28S). Both mutants indicated lower disassembly efficiency on liposomes as compared
to the wild-type, and the second mutant was able to promote disassembly in solution at
higher concentrations.[59] More recently published, Park et al. were able to confirm that the
binding efficiency of the α-SNAP (F27S, F28S) mutant to the SNARE complex is comparable
to the wild-type, on lipid-bound complex as well as in solution, but that the disassembly
reaction is slower. On the other hand, the α-SNAP (33 – 295) mutant does not bind to the
SNARE complex at all and no disassembly reaction occurs.[60] These results underline the
influence of the membrane-attachment site of α-SNAP. Consequently, it is necessary for investi-
gations of the disassembly reaction to perform all experiments on lipid-bound SNARE complexes.
Recently, it was also shown by Park et al.[60] that α-SNAPs exhibit an inhibitory effect
on SNARE complex zippering. This issue is discussed in chapter 2.7.4.
α-SNAP is needed for NSF binding, but little was known neither about the distinct interacting
positions (NSF/α-SNAP and α-SNAP/SNARE complex) nor about α-SNAP stoichiometry
within the 20 S complex. However, the question question remains, how the conformational
change of NSF results in SNARE complex disassembly.
2.6.3 Structure of the 20 S (super)complex
Since 1997 it has been attempted to solve the structure of the 20 S (super)complex, first by
quick-freeze/deep-etch EM[61], by negative-staining EM[62], and more recently by cryo-EM[55].
Due to low resolution (>11 Å) and sample preparation, these studies did not show neither clear
structures for the D1 domain of the full-length NSF, nor for SNAPs and the SNARE complex
in the 20 S (super)complex (figure 2.10).[53]
Figure 2.10: Timeline of structural studies on the 20 S (super)complex with representative
images or reconstructions from quick-freeze/deep-etch single particle imaging by Hanson et
al.[61], negative-staining EM by Hohl et al.[62], and cryo-EM by Furst et al.[63], Chang et
al.[55], and Zhao et al.[50]. Figure adapted from Zhao et al.[53]
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With the recently published cryo-EM structures of full-length NSF, it was also possible to
produce higher-resolution structures of the 20 S complex at a resolution of 7.6 Å to 8.4 Å.
The adenosine 5’-(β,γ-imido)triphosphate (AMPPNP)-bound 20 S complex is organised like
a tower with the D2 and D1 rings of NSF hexamer at the basement, and α-SNAPs and the
SNARE complex at the spire encircled by the N domains of NSF. Within the structure, hardly
any symmetry was found: at the basement a roughly six-fold symmetry is identified but at the
top a pseudo four-fold symmetry is present.[50, 53]
In the case of the 20 S complex including the neuronal SNARE complex, Brunger et
al. were able to observe four α-SNAP molecules surrounding the SNARE complex. The distinct
interactions between NSF N domains and α-SNAPs were identified by mutagenesis studies.
Based on the structure of the 20 S complex, α-SNAP mutants were expressed and analysed
regarding their disassembly efficiency. Two binding sites were detected where mutation affected
the disassembly reaction. Both are located at the C -terminal end of α-SNAP and are negatively
charged: binding site I (D217, E249, E252, and E253) and binding site II (D290, E291, E292,
and D293).[50, 53] On the other hand, one N domain exhibits one binding site with positively
charged residues (R10, R67, K68, and K104) (figure 2.11 a).
This leads to a mismatch of binding modi: Four α-SNAPs with an overall of eight binding
sites facing six N domain binding sites. Consequently, each α-SNAP interacts with at least one
N domain. This results in two configurations for the six N domains surrounding four α-SNAPs:
Each N domain pair is arranged as direct neighbours or on opposing sites. The orientation
of N domains is also dependent on the arrangement of the D1 ring, resulting in six possible
patterns for each N domain and in a total of twelve modi (figure 2.11 b). Since the opposing
N domain pair leads to patterns in excess by the factor of two, the resulting total number of
possible patterns is nine. Three of these were observed by cryo-EM studies and were named as
State I, II and III (IIIa and IIIb), respectively (figure 2.11 b and c).[50, 53]
A possible explanation for observing only three states could be that the α-SNAP/SNARE spire
favours a certain position between the N domains. In fact, it exhibits a tendency towards chains
E and F of the N domains which are in the raised position of the split washer D1 structure. This
favoured orientation could facilitate a possible interaction with the pore loops of D1 domains E
and F with the SNARE/SNAP subcomplex. State III was divided into two subclasses, states
IIIa and IIIb, due to a difference in the spire orientation, but not in the α-SNAP/N domain
interaction mode (figure 2.11 c).
To summarise, the 20 S (super)complex was observed in four different states and could
be distinguished by the α-SNAP/N domain interacting modi and the orientation of the spire.
The α-SNAP/SNARE subcomplex and the basement D2 ring did not show any differences in
these states.[50, 53]
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Figure 2.11: (a) Interactions between NSF N domain and α-SNAPs with binding site I and
II of α-SNAP highlighted in red and binding site of N domain highlighted in blue. Figure
modified from Zhao & Brunger.[53] (b) Possible states of the 20 S (super)complex regarding
N domain/α-SNAP interaction patterns. Figure modified from Zhao et al.[50] Adapted by
permission from Macmillan Publishers Ltd: Nature, reference [50], copyright © 2015. (c) Four
observed states of the 20 S (super)complex as sharpened maps (top) and schematically (bottom).
The black arrow highlights the opening between subdomains A and F. Figure modified from
Zhao & Brunger.[53]
The recent 20 S (super)complex structure also reveals new insights into the interaction
between α-SNAPs and the SNARE complex within the subcomplex (figure 2.12). The left-
handed SNARE complex is surrounded by the right-handed α-SNAPs, as shown previously
(Marz et al.[64]). Since the SNARE complex is a heterotetramer, it exhibits a pseudo four-fold
symmetry. So it is not surprising that four α-SNAPs surround the complex in a four-fold
rotational manner. It is assumed that the C -terminal part of the SNARE complex is orientated
towards the top of the structure due to the transmembrane domains. This is supported by
the identified position of the membrane-attachment site of α-SNAPs likewise towards the top
of the spire (figure 2.12 a). The binding sites are based on electrostatic interactions, just
as α-SNAP/N domain binding, consisting of positively charged residues of α-SNAP (K122,
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K163, K203 and R239) and negatively charged residues on the surface of the SNARE complex
(figure 2.12 b). The distinct residues were identified by mutagenesis studies and support
the previously published results by Marz et al.[64] Residues K122 and K163 are orientated
closely to the zero layer of the SNARE complex and residues K203 and K239 are localised at
the C -terminal region of α-SNAP. Mutation of negatively charged residues on the surface of
α-SNAP (E38A, E40A, E43A, and D80A) showed only a slight effect on the non-membrane
bound disassembly reaction. This supports the hypothesis of the positively charged α-SNAP








Figure 2.12: (a) Interactions between α-SNAPs (yellow) and SNARE complex (green) as ribbon
representation based on state I of the 20 S (super)complex. (b) Electrostatic potential of α-SNAP
barrel surface which interacts with the SNARE complex. Positively charged residues interacting
with the SNARE complex are highlighted in green (K122, K163) and purple (K203, R239). (c)
Electrostatic potential of the SNARE complex surface with the zero layer indicated by a dotted
line. (d) Electrostatic potential of the surface of one α-SNAP molecule. Figures modified from
Zhao et al.[50] Adapted by permission from Macmillan Publishers Ltd: Nature, reference [50],
copyright © 2015.
With a different SNARE complex composition (VAMP-7 instead of Synaptobrevin-2), the
so-called V7-20 S complex showed another α-SNAP stoichiometry. In this case, only two
α-SNAP molecules are present in the structure. It was concluded that NSF is also able to
disassemble the SNARE complex with fewer cofactors by aligning its flexible N domains. On
the other hand, more than four α-SNAPs are rather unrealistic due to sterical hindrance.[50, 53]
NSF as well as SNAPs are highly conserved and are able to disassemble various SNARE
complexes.[3] The binding between NSF/α-SNAP as well as α-SNAP/SNARE complex is based
on electrostatic interactions. These are less specific than hydrogen bonds, explaining the
non-specificity of the α-SNAP/NSF system and its ability to disassemble a variety of SNARE
complexes in the secretory pathway.[50, 53]
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2.6.4 Mechanism of NSF/α-SNAP-Mediated SNARE Disassembly
Based on the recent cryo-EM structures, a possible mechanism for the NSF/α-SNAP-mediated
SNARE disassembly reaction was suggested (figure 2.13).[50, 53] Firstly, up to four α-SNAPs bind
to the cis-SNARE complex (figure 2.13 a and b). The number of α-SNAP molecules depends
on the SNARE complex composition. Secondly, ATP-bound NSF binds to the α-SNAP/SNARE
subcomplex leading to the formation of the 20 S (super)complex (figure 2.13 c). Due to
the binding interaction, the NSF D1 and D2 domains are tightened like a compressed spring.
The four observed states of the 20 S (super)complex suggest that the whole system applies a
torsional force to uncoil the SNARE complex while changing the states. ATP hydrolysis triggers
the conformational changes of the N domains, which is transferred via α-SNAPs. Lastly, in
ADP-bound NSF, two N domains are pointed downwards and an opening occurs within the D1
ring, which both may function as an exit for the individual SNARE proteins (figure 2.13 d).
A pore translocation mechanism is unlikely due to the fact of the missing pore loops in the
D2 domains. After the release of the SNARE proteins and α-SNAPs, nucleotides are exchanged
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Figure 2.13: (a – d) Suggested mechanism of NSF/α-SNAP-mediated SNARE disassembly
reaction consisting of four steps. N domains are blurred to indicate flexibility (b and d). Figure
adapted from Zhao et al.[50] Adapted by permission from Macmillan Publishers Ltd: Nature,
reference [50], copyright © 2015.
2.7 Complexin - A Regulatory Protein of
SNARE-Mediated Membrane Fusion
Complexins are a family of evolutionarily conserved proteins which are relatively small (15 –
20 kDa), hydrophilic and mainly found in the neuronal cytosol. They were firstly identified in
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1995 by Takahashi et al.[65] screening a murine brain cDNA library, by Abe et al.[66] due to
constant copurification with the neuronal SNARE complex, as well as by Südhof et al.[67]
due to their binding ability to the neuronal SNARE complex.[68, 69] Abe et al.[66] named them
first "Synaphins" from the latin synaphia, meaning "maintenance of the same rhythm". But
the name "Complexins" suggested by Südhof et al.[67], due to the binding properties to the
SNARE complex, was generally accepted.
The first identified isoforms, Complexin I (Cpx I) and Complexin II (Cpx II) are unusually highly
conserved which is an indication for their importance. Cpx I exhibits 97 % sequence consensus
in human and murine orthologs, and Cpx II is even identical in humans and murines.[67, 69, 70] In
addition, between Cpx I and Cpx II an 80 – 86 % sequence homology shows a close relationship
of these two isoforms.[65, 67, 69] However, they exhibit only 24 – 28 % sequence homology to
Complexin III (Cpx III) and Complexin IV (Cpx IV). Consequently, the latter two set up a second
subfamily. The main difference between the Cpx I/II- and Cpx III/IV-subfamilies constitute
their C -terminal domains. In the case of Cpx III/IV, an extension for lipidation can be found
at the C -terminal ends.[69, 70] All Complexin isoforms are especially expressed in the central
nervous system[65–67, 69, 70], with Cpx IV as an exceptional case, because its expression is mainly
restricted to retinal ribbon synapses.[69, 70] In addition, Cpx IV exhibits a lower binding affinity
to the SNARE complex than the other three isoforms. For its function, membrane anchoring is
essential which leads to higher concentration at the active sites and, therefore, compensation
of the lower binding affinity. Compared to mammals, in invertebrates a smaller number of
Complexin isoforms is expressed. In a sequence-specific manner, they are related to the Cpx I/II
subfamily but additionally exhibit a C -terminal extension containing a farnesylation motif like
Cpx III/IV. It seems that Complexins in mammals are functionally more specialised and evolve
from an ancestral protein with a more general function.[69, 70]
Structurally, Complexins comprise four domains within their sequences. In the case of Com-
plexin I, they are distributed as follows (figure 2.14): a N-terminal domain (1 – 28), an accessory
α-helix (29 – 47), a central α-helix (48 – 70), and a C -terminal domain (71 – 134).[68, 69, 71]
The region between amino acid residues 29 – 86 forms an α-helical structure but overall
Complexins exhibit no tertiary structure. The central part of the α-helix was identified as
the binding motif for the SNARE complex. Complexin I is binding fast and with high affinity
(K d = 10 nm[72]) to the ternary, neuronal SNARE complex, but no binding was observed to
individual SNARE proteins.[68, 69, 72–74]
The research interest for Complexins especially arose when they were suggested to be involved in
neuronal diseases, such as schizophrenia and Huntington’s disease.[74] Although, this correlation
was soon questioned[75], the interest did not diminish within the research field of Complexin
function.
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Figure 2.14: Domain structure of Complexin I (Cpx I) with the N-terminal domain (1 – 28), the
accessory α-helix (29 – 47), the central α-helix (48 – 70), and the C -terminal domain (71 – 134).
2.7.1 Structure of the Complexin/SNARE Complex
The crystal structure of the Complexin/SNARE complex revealed that Complexin binds to
the groove between Synaptobrevin-2 and Syntaxin-1A in an antiparallel orientation and with
a 1/1 stoichiometry (figure 2.15 a – c). This interaction stabilizes the interface between
the Sybnaptobrevin-2/Syxntaxin-1A helices, but no further structural changes of the ternary
complex could be observed.[68, 69, 74] The distinct interacting positions were found to be in the
central α-helix of Complexin (48 – 70), and Syntaxin-1A (214 – 232) and Synaptobrevin-2
(47 – 68) amino acid residues close to the zero layer (figure 2.15 d – f). One lysine residue
(K69), two tyrosine residues (Y52 and Y70) as well as three arginine residues (R48, R59, and
R63) of Complexin were identified to be crucial for binding. Specifically, the lysine residue
(K69) and the tyrosine residue (Y70) of Complexin interact with the aspartic acid residue
(D218) of Syntaxin-1A (figure 2.15 d). In addition, the arginine residues (R59 and R63) of
Complexin interact with the aspartic acid residue (D57) of Synaptobrevin-2 (figure 2.15 e).
Finally, the tyrosine residue (Y52) of Complexin interacts with the aspartic acid residue (D64)
of Synaptobrevin-2 as well as the arginine residue (R48) of Complexin with the aspartic acid
residues (D65 and D68) of Synaptobrevin-2 (figure 2.15 f). To summarise, the Complexin
binding to the SNARE complex is based on electrostatic interactions comparable to the α-SNAP
binding.[74]
For the crystal structure analysis, the Complexin fragment (26 – 83) was used but only
amino acid residues (32 – 72) could be resolved in the structure. This indicated that the
N-terminal part as well as the C -terminal part are highly flexible and exhibit no contribution to
binding.[74] Complexins bind to the ternary, neuronal SNARE complexes, but their function on
neurotransmitter release remains controversially discussed.
2.7.2 Controversially Discussed Function of Complexin
Due to a large number of studies in various model systems concerning the function of Complexin,
which have led to controversial results, it is generally accepted that Complexin comprises a
dual function in neurotransmitter release. Though, it is only a small molecule, an inhibitor as
well as an activator can be found. The inhibitor function is assumed to be needed for sponta-
neous neurotransmitter release and the facilitatory function for Ca2+-triggered release, but the
molecular mechanisms of this dual function are still not understood.[68, 69] It could be shown,
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Figure 2.15: (a) Crystal structure of the Complexin/SNARE complex (pdb code 1kil) as ribbon
diagram and (b and c) as space filling models in two different views. The following color code is
used: yellow = Syntaxin-1A, red = Synaptobrevin-2, blue/green = SNAP-25, pink = Complexin.
(d – f) Close-ups of the binding interface between Complexin, Syntaxin-1A, and Synaptobrevin-
2. Figures used from Chen et al.[74] Reprinted from reference [74], Copyright © 2002, with
permission from Elsevier.
that the domains of Complexin take different parts in regulating neurotransmitter release. The
central α-helix as binding site as well as the binding to the SNARE complex are required for the
overall function of Complexin. The accessory α-helix was shown to contribute to the inhibitory
function, whereas the N-terminal domain facilitates Ca2+-triggered release.[68, 69, 71, 76] Lastly,
the C -terminal domain is suggested to target Complexin to the active site.[68, 76]
Two mechanistic models have been proposed so far: The so-called ’fusion clamp’ model explains
the inhibitory function, whereas the fusion facilitatory function was suggested to be based on
regulating the vesicle fusogenicity.[68, 69]
The ’fusion clamp’ model
The ’fusion clamp’ model was suggested and investigated in detail by Rothman et al.[77–82]
It describes the inhibitory effect of Complexin to be based on the arrest of primed synaptic
vesicles at the nerve terminal which should be released only upon Ca2+ influx. In other words,
Complexin is responsible for ’clamping’ the primed vesicles and prevents premature, spontaneous
fusion. It is thought that Complexin first binds to the incompletely zippered SNARE complex
via its central α-helix (48 – 70) and that its accessory α-helix (29 – 47) can compete with
the C -terminal part of Synaptobrevin-2 to prevent full zippering.[68, 69, 77–79] Giraudo et
al. developed a ’superclamp’ Complexin (scCpx) on the basis of sequence similarities between
the accessory α-helix of Complexin and the C -terminal part of the Synaptobrevin-2 SNARE
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Figure 2.16: (a) Sequence alignment of the C -terminal SNARE motif of Synaptobrevin-2
(residues 61 – 87) and Complexin I accessory α-helix (residues 29 – 47, antiparallel orientation).
Sequence consensuses are highlighted in red, sequence similarities in green, and sequence
adaption for ’superclamp’ Complexin in orange. Figure modified from Giraudo et al.[79] From
reference [79]. Reprinted with permission from AAAS. (b) Overlay of crystal structures of
’superclamp’ Complexin/truncated SNARE complex (prefusion, pdb code 3rk3) and wild-type
Complexin/SNARE complex (postfusion, pdb code 1kil). The following color code is used:
blue = Synaptobrevin-2, yellow = Syntaxin-1A, light and dark green = SNAP-25, light and dark
pink = wild-type Complexin, and light blue and grey = ’superclamp’ Complexin. (c) Side view
of the ’zigzag’ topology formed by ’superclamp’ Complexin/truncated SNARE complex. Figures
modified from Kümmel et al.[81] Adapted by permission from Macmillan Publishers Ltd: Nature
Structural and Molecular Biology, reference [81], copyright © 2011.
motif (layer +1 – +8). In this Complexin mutant, three additional hydrophobic residues (D27L,
E34F, R37A) were introduced to regenerate suitable interaction layers (+5, +6, and +8)
within the SNARE coiled-coil (figure 2.16 a). It was predicted to interact with the incompletely
zippered SNARE complex by binding to the Syntaxin-1A/SNAP-25 interface at the C -terminal
part of the SNARE motifs. Indeed, in vitro cell-cell fusion assays showed an increase in clamping
efficiency.[79] However, on the other hand, in vivo experiments exhibit controversial results.[76, 83]
Kümmel et al. were able to co-crystallize ’superclamp’ Complexin with a truncated SNARE
complex (figure 2.16 b). The crystal structure of Complexin I (26 – 83 D27L, E34F, R37A)
and SNARE∆60 complex consisting of Synaptobrevin-2 (29 – 60), Syntaxin-1A (10 – 82) and
SNAP-25 (10 – 82, 141 – 203) showed an intermolecular interaction. The central α-helix of
Complexin was bound to one SNARE complex, whereas its accessory α-helix was bound to
the C -terminal part of the SNARE motif of a second SNARE complex, and thereby, forming a
’zigzag’ topology (figure 2.16 c).[81] Nevertheless, recently published NMR studies by Trim-
buch et al. were not able to confirm the structure of the ’superclamp’ Complexin/truncated
SNARE complex in solution. Additionally, there is a bare possibility that the charged wild-type
accessory α-helix is really inserting into the hydrophobic Synaptobrevin-2 binding site of the
SNARE complex.[68, 83]
Krishnakumar et al. further tested that Complexin has to be switched from open (prefusion)
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to closed (postfusion) conformation to enable Synaptotagmin/Ca2+-triggered fusion. In the
open or prefusion state, the ’superclamp’ accessory α-helix is able to bind to a second SNARE
complex and blocks the Synaptobrevin-2 binding site.[80] On the other hand, in the closed or
postfusion conformation, the accessory α-helix is more closely located to the SNARE complex
to which its central α-helix is bound.[74, 80] The switching process was monitored by FRET
experiments between donor dye (stilbene) at residue 193 of SNAP-25 and acceptor dye (bimane)
at residue 38 of Complexin. Zippering of Synaptobrevin-2 until layer +4 was found to be crucial
for switching between the two Complexin conformations. With truncated Synaptobrevin-2
mutants (Syb-2 65, Syb-2 69, Syb-2 73, and Syb-2 77), a stepwise zippering was imitated.
Specifically, Synaptobrevin-2 residues D64, D65, and D68 have to be zippered and have to
interact with the central α-helix of Complexin to change the position of the accessory α-helix.
In addition, a Synaptobrevin-2 mutant lacking these three aspartic acid residues (D64A, D65A,
and D68A) fully zippers into the ternary SNARE complex, but leaves Complexin in its open
conformation. On the other hand, the truncated Synaptobrevin-2 mutants for stepwise zippering
revealed that the aspartic acid residues do not only have to be present but also have to be
zippered to act as a conformation switch for Complexin. Only the proceeding zippering of the
ternary SNARE complex can switch the conformation of Complexin, and consequently enable
the interaction with Synaptotagmin/Ca2+ for triggered fusion[80] (see chapter 2.7.3).
As expected, Complexin (Cpx I 48 – 134) binding to the SNARE complex containing Synapto-
brevin-2 (D64A, D65A, D68A) mutant exhibits lower affinity (K d = 620±110 nm[80]) than
to the wild-type ternary SNARE complex (K d = 43±7 nm[82]). The latter still shows lower
affinity compared to full-length wild-type Complexin I (K d = 10 nm[72]).
To summarise, the hypothesis of the underlying mechanism of Complexin’s fusion clamp
function is still hotly debated. The results obtained by FRET, X-ray, NMR and isothermal
titration calorimetry (ITC) to investigate the interaction between the accessory α-helix of
Complexin and the SNARE complex are inconsistent so far. It is generally accepted that the
accessory α-helix contributes to the inhibitory function of Complexin, but despite a huge number
of studies and different hypotheses, no satisfying coincidence of the underlying mechanism has
been found to date.[68, 69, 82, 83]
The fusion facilitatory model
The Reduction of evoked neurotransmitter release in several knock-out studies of Complexin
indicated its additional facilitatory function.[68, 69] However, in comparison to the ’clamp model’,
the underlying mechanism is less investigated. Initially, the hypothesis was proposed that
Complexin acts as a promoter by stabilising the SNARE complex due to the binding of its
central α-helix.[74] Detailed structure-function studies revealed that the N-terminal domain
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a b c d
Figure 2.17: Hypothesised model for facilitatory function of Complexin’s N-terminal domain
and combination with inhibitory function of the accessory α-helix. (a) SNARE complex zippering
starts at the N-terminal part of SNARE motifs. (b) Complexin binds to the SNARE complex
via its central α-helix and stabilizes SNARE assembly. On the other hand, it possibly blocks
Synaptobrevin-2 binding site by its accessory α-helix. This corresponds to the ’clamped’ state.
(c) The inhibition is released by the interaction of Complexin’s N-terminal domain with the
C -terminal part of SNARE complex (exact location of interaction not clear, only schematic
suggestion) and/or by Synaptotagmin-1/Ca2+ (not shown). (d) Full assembly of SNARE complex
and possible stabilisation by Complexin’s N-terminal domain to regulate vesicle fusogenicity.
Figure modified from Xue et al.[84] Adapted by permission from Macmillan Publishers Ltd:
Nature Structural and Molecular Biology, reference [84], copyright © 2010.
(residues 1 – 26) is crucial for the activating function and it was speculated to interact with the
SNARE complex or with lipid membranes.[68, 71, 83, 84] Indeed, NMR studies and fluorescence
spectroscopy revealed that the N-terminal domain of Complexin interacts with the C -terminal
end of the SNARE complex.[84] By this interaction, it was suggested that Complexin stabilises
the C -terminal part of the SNARE complex upon zippering, and thereby supports the SNARE
machinery to provide the energy needed for fusion. Consequently, Complexin influences the
vesicle fusogenicity and regulates spontaneous as well as Ca2+-triggered release. Fusogenicity
describes the height of energy barrier which a primed vesicle has to overcome before membrane
fusion can occur, and can be measured by Ca2+-independent, induced vesicle fusion through
hypertonic solutions. Additionally, interaction of the N-terminal end of Complexin to the
SNARE complex may promote the removal of the inhibitory function by the accessory α-helix
(figure 2.17). It could be shown, that the vesicle fusogenicity is increased possibly at a step prior
to triggering by Ca2+ influx, due to the fact that Complexin facilitates Ca2+-triggered release
even in the absence of Synaptotagmin-1. As a result, the facilitatory function of Complexin
is suggested to act together with Synaptotagmin-1, but the latter was not essential for this
function.[68, 84]
Overall it can be summarised, that the dual function of Complexin is based on the different
contributions of its specific domains. The central α-helix and the N-terminal domain feature
the facilitatory function by stabilisation of the SNARE complex assembly, increase in the vesicle
fusogenicity, and maybe interference with the accessory α-helix interaction. The inhibitory
function or ’fusion clamp’ is contributed by the accessory α-helix through the hypothesised
blockage of Synaptobrevin-2 binding site within the incompletely zippered SNARE complex
and/or electrostatic repulsions with the fusing membranes. In addition, it is generally accepted
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that Complexin and Synaptotagmin-1 cooperate in some way to regulate Ca2+-triggered
neurotransmitter release, which is described in the following chapter 2.7.3.[68, 69, 71, 79–81, 84]
2.7.3 Collaborative Regulation by Complexin and Synaptotagmin
For Ca2+-triggered neurotransmitter release, a tight regulation of the fusion machinery is
necessary. Among other regulatory proteins, the key players in this part are unquestionably
Synaptotagmins as Ca2+ sensors and Complexins due to their direct SNARE complex binding.
Complexin function was also found to be influenced by Ca2+ concentrations which suggests an
collaborative regulation by Complexins and Synaptotagmins.[3, 5–7]
Synaptotagmin-1 (Syt-1), as well as its closely related isoforms Syt-2 and Syt-9, function as
Ca2+ sensors for the fast neurotransmitter release less than 0.5 ms after Ca2+ influx, which is
stated as synchronous release.[5–7, 85] Structurally, Syt-1 comprises a transmembrane domain
and two Ca2+-binding domains, C2A and C2B which bind three and two Ca2+ ions, respectively
(figure 2.18 a and b).[5–7, 85, 86] Within the two domains, loops at the top of a β-sandwich
structure exhibit five aspartic acid residues which are responsible for Ca2+ binding as well as
Ca2+-dependent negatively charged phospholipid binding.[5, 7, 86] The latter induces a membrane
interaction by hydrophobic residues and additional interaction of positively charged residues of
the C2 domains with the phospholipids (figure 2.18 b).[5, 7, 85, 86] Functionally, the membrane
interaction was found to be crucial for Syt-1 supporting Ca2+-dependent SNARE-mediated
membrane fusion.[7, 85] Cryo-EM structures revealed that, upon Ca2+ binding, Syt-1 is able
to bind two opposing membranes and at the same time pulls them together.[5, 7, 87, 88] Before
Ca2+ triggering, the negatively charged aspartic acid residues of the Ca2+ binding region were
suggested to induce repulsive forces towards the phospholipids of the membrane, and thereby
inhibit membrane fusion until the Ca2+ signal.[7] Consequently, it was hypothesised that Syt-1
functions in close collaboration with the SNARE complex to induce membrane fusion.[5–7, 85]
Syt-1 directly binds to the SNARE complex by positively charged residues localised at the side
of the C2B domain β-sandwich (figure 2.18 b and c). The binding site for Syt-1 on the surface
of the SNARE complex was found to be localised at SNAP-25 helices in the middle of the
complex.[7, 89] This implies that the Syt-1 and Cpx I binding sites are not competitive and both
proteins can bind concurrently. Upon binding to the SNARE complex surface, the C2B domain
would be perfectly located for binding to the opposing membranes upon Ca2+ influx. These
interactions could induce repulsive forces between the accessory α-helix of Complexin and the
membranes which may be the explanation for Syt-1 induced removal of Complexin’s ’clamp’
function.[7]
The following model was proposed by Rizo & Xu[7] including the cooperation between SNARE
complex, Syt-1, Complexin and Ca2+-triggering (figure 2.18 c): Prior to the Ca2+ signal, the
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Figure 2.18: (a) Domains and (b) crystal structure of Ca2+-bound Synaptotagmin-1 (Syt-1, pdb
code 1byn and 1k5w) including a transmembrane domain (TMD) and two Ca2+ binding domains
C2A (light blue) and C2B (dark blue). Ca2+ ions are shown in orange. Additionally, positively
charged residues (K and R) of C2B domain are highlighted in dark blue. (c) Hypothesised
model for cooperation between SNARE complex, Syt-1 and Cpx triggered by Ca2+ influx. Figure
modified from Rizo & Xu.[7]
SNARE complex is incompletely zippered with bound Complexin preventing further zippering
by its accessory α-helix. Simultaneously, Syt-1 is bound to the SNARE complex and supports
Complexin’s ’fusion clamp’ by electrostatic repulsion between its negatively charged Ca2+
binding residues of the C2B domain and the negatively charged accessory α-helix of Complexin
(figure 2.18 c, left). As soon as Ca2+ concentration increases, Syt-1 changes to the Ca2+-bound
state and membrane attachment to phospholipids brings the opposing membranes in close
proximity. By this interaction, Complexin’s ’clamp function’ of the accessory α-helix is removed
due to sterical hindrance and zippering of the C -terminal part of the SNARE complex can
proceed. Consequently, the opposing membranes are brought in close proximity by a cooperation
of Syt-1 and SNARE complex membrane interactions which increases the provided energy for
membrane fusion.[7]
The recently published crystal structure of the Syt-1-SNARE complex revealed three interacting
regions between the SNARE complex and the C2A and C2B domains of Syt-1 (figure 2.19
a and b).[85] The first region was shown to be most important for Ca2+-triggered neuronal
exocytosis and comprises mainly electrostatic interactions between SNAP-25, Syntaxin-1A
and C2B domain of Syt-1. In more detail, this region was subdivided into two subregions:
Subregion I exhibits SNAP-25 residues E37, K40, N159, M163, and D166 interacting with
Syt-1 residues E295, K297, N336, and Y338; subregion II exhibits SNAP-25 residues D51, E52,
and E55, Syntaxin-1A residues D231, E234, and E238 interacting with Syt-1 residues R281,
K288, R398, and R399, respectively (figure 2.19 b, left). In subregion II a clear interaction
between the negatively charged SNARE complex surface and positively charged Syt-1 residues
was observed. The second region comprises the interaction between a C2B domain of a second
Syt-1 molecule and mainly Syntaxin-1A residues, namely residues M221, E224, and E228 of
Syntaxin-1A interacting with R281, T285, A286, K288, and R398 of Syt-1 (figure 2.19 b,
middle). Interestingly, the third region partially overlaps with the Complexin binding region to
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the SNARE complex (chapter 2.7.1): Syntaxin-1A residue D218 and Synaptobrevin-2 residue
D57 interact with R199 and R233 of Syt-1’s C2A domain (figure 2.19 b, right).[85]
a b
c d
Figure 2.19: (a) Crystal structure of Ca2+-bound Synaptotagmin-1-SNARE complex (pdb code
5ccg) showing three C2A and C2B domains (termed as I, I’, and II and colored in grey, yellow
and purple) and two SNARE complexes (I and II) including Synaptobrevin-2 (blue), Syntaxin-1A
(red) and SNAP-25 (green). (b) Detailed view of the interacting regions termed as primary (left,
red shaded), secondary (middle, blue shaded), tertiary (right, green shaded) as well as C2A-C2B
(right, grey shaded) interface. (c) Focus on the first interacting region between C2B domain of
Syt-1 and the SNARE complex with positively charged side chains oriented towards suggested
position of the membrane surface including negatively charged phospholipids (indicated by dotted
red line). (d) Proposed model for the function of Syt-1-SNARE complex primary interface during
Ca2+-triggered membrane fusion. Figure modified from Zhou et al.[85] Adapted by permission
from Macmillan Publishers Ltd: Nature, reference [85], copyright © 2015.
Based on these results, a model of the Synaptotagmin-1 function in Ca2+-triggered neuronal
exocytosis was suggested focussing on the first interacting region of the C2B domain (fig-
ure 2.19 c and d): In the primed state, the C2B domain of Syt-1 is already bound to a partially
zippered SNARE complex without contact between the opposing membranes (figure 2.19 d,
left). Upon Ca2+ influx, Ca2+ binding induces membrane interaction of the C2B domain in
the region of the N-terminal part of the SNARE complex, thereby probably pulling the whole
complex in that direction (figure 2.19 d, middle). Thus, it induces membrane curvature and
brings the membranes directly next to the SNARE TMDs in closer proximity to promote fusion
(figure 2.19 d, right).[85]
In addition, the third interacting region including a C2A domain of Syt-1 is suggested to be
involved in replacing the central α-helix of Complexin from the SNARE complex due to the
fact that the interacting region overlaps with the Complexin binding region. Thereby, the C2A
domain of Syt-1 might be involved in ’unclamping’ Complexin from the SNARE complex and
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in triggering complete zippering.[85]
The crystal structure revealed new insights into the interaction of Synaptotagmin-1 and
the SNARE complex, but of course interactions with the membranes were not considered in
these results. Therefore, it might be premature to abolish the first suggested model with
additional membrane-bridging function of Syt-1. Anyhow, further investigations are needed to
elucidate the overall mechanism of Ca2+-triggered neuronal exocytosis.
2.7.4 Does Complexin Compete with α-SNAP?
Complexin binds to the groove between Synaptobrevin-2 and Syntaxin-1A helices of the SNARE
complex between approximately the zero layer and the +4 layer.[74] The same binding region
around the middle of the SNARE complex was observed for α-SNAP as well as specific in-
teracting residues on the SNARE complex surface were revealed by side-specific mutation
studies.[53, 64] Some of these residues binding to α-SNAP (e.g. Syb-2 D55, D65) match or are
in close proximity to the interacting residues of Complexin binding (e.g. Syb-2 D57, D64, D65,
D68).[64, 74]
Already in 1995, it was shown that Complexin and α-SNAP compete for the binding to
the SNARE complex in in vitro binding studies, despite no sequence homology was found.[67] In
2009, these results were confirmed by fluorescence-based in vitro disassembly assays, in which
the SNARE disassembly reaction was strongly inhibited by Complexin. Only with addition of
excess α-SNAP (1.2 eq.), the Complexin inhibition could be overcome.[59] In the same study, it
was shown that α-SNAP efficiency is distinct between soluble and membrane-bound SNARE
complexes, whereas no difference in Complexin binding affinity between solution and lipid-bound
complexes was observed. The authors suggested that whether α-SNAP or Complexin binds to
the SNARE complex is regulated by the membranes: Complexin may favourably bind to the
trans-SNARE complex, whereas α-SNAP exhibits a higher binding affinity to the cis-SNARE
complex due to the position of its membrane-attachment site.[59]
Based on its overlapping binding site with Complexin and Synaptotagmin, α-SNAP was
proposed to interact not only with the tight cis-SNARE complex after fusion but also with the
incompletely zippered trans-complex. In this context, Park et al. were recently able to show
an inhibitory effect of α-SNAP itself on SNARE complex zippering.[60] Certainly, side-specific
mutations revealed a dependency not on α-SNAP binding to the SNARE complex but on
interaction of the membrane-attachment site of α-SNAP with the membrane. Additionally,
experiments with a truncated SNARE complex lacking the N-terminal part of Synaptobrevin-2
(∆N complex) indicated that α-SNAP arrests the SNARE complex zippering right in the
middle of it, due to the fact that the Synaptobrevin-2 fragment (residues 49 – 96) is not
34
2.7 Complexin - A Regulatory Protein of SNARE-Mediated Membrane Fusion
displaced by addition of ’full-length’ Synaptobrevin-2 (1 – 96) in the presence of α-SNAP.
On the other hand, the comparison between chromaffin granules (∼350 nm) and synaptic
vesicles (∼40 nm) in these experiments showed that α-SNAP has nearly no effect on fusion of
synaptic vesicles. Hence, its impairment of SNARE zippering also depends on conditions like
membrane curvature. In summary, it was shown that α-SNAP also exhibits an inhibitory func-
tion on SNARE-mediated membrane fusion to generate primed and docked vesicles which was
attributed so far only to SNARE regulatory proteins such as Complexins and Synaptotagmins.[60]
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3 Photocleavable Protecting Groups
and Their Applications
Biological systems exhibit a striking complexity of dynamic reactions and signalling cascades,
which complicates investigations of these processes. Most challenging is the regulation of such
systems without perturbation or contamination.[90, 91] In addition, affecting multiple reaction
steps simultaneously would provide fundamental insights into biological as well as chemical
problems.[91] In biology, investigations of intracellular pathways were performed by biochemical
and chemical methods for a long time. But as soon as the used inhibitor or activator is injected
into the cellular system no further control of distribution or timing is available.[90] A possibility
to overcome this problem is the usage of photo activatable compounds which were extensively
investigated in the past decades.[90, 91] Light as an external trigger provides the advantages of
high spatio-temporal precision, no contamination, and a non-invasive method. On a molecular
level, two approaches were developed for this purpose: Firstly, so-called photoswitches, which
upon irradiation reversibly isomerise, and secondly, photocleavable protecting groups (PPGs),
which are irreversibly cleaved from the corresponding functionality upon irradiation.[91] A
compound protected by a PPG is also called "caged" compound and the photocleavage reaction
is also stated as "uncaging". In this work, the second approach was applied and is further
described in this chapter.
3.1 General Design of PPGs and Caged
Peptides/Proteins
The design of a good PPG needs to fulfil certain criteria dependent on the application. Generally
in in vivo experiments, a strong absorption at λ > 340 nm is necessary to prevent damage of
biological systems upon irradiation. In addition, usage of longer wavelength provides the advan-
tage of deeper penetration of the biological tissue. Besides a large extinction coefficient ε at the
corresponding wavelength, the photocleavage reaction should exhibit high efficiency or quantum
yield Φ for release. The product of extinction coefficient and quantum yield (εΦ) is proportional
to the amount of photoreleased products, and therefore used to quantify the efficiency of a
PPG. The reaction should be fast, without toxic side products, and the PPG needs to be stable
and soluble in aqueous media.[91, 92] As soon as a suitable PPG is found for the corresponding
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application, the caged compound has to be designed. The functional group responsible for
the biological activity needs to be identified and covalently modified with the PPG. If a direct
modification of the functionality is not possible or the activity is based on, e.g. molecular surface
interactions, two possible alternative approaches can be applied: random multiple modifications
at the interaction side or a single PPG in combination with triggered conformational changes.[90]
In the case of the caged peptide/protein design, direct modification of specific amino acid
side chains is possible for Arg, Asp, Cys, Glu, Lys, Ser, Thr and Tyr via solid-phase peptide
synthesis (SPPS) by introduction of the modified amino acid building block. Analogous to
labeling reactions with fluorophores, the Cys side chain can be selectively modified with PPGs
after peptide synthesis or expression.[93, 94] In addition, introduction of PPGs at the amide
backbone[95] and PPGs for light-induced backbone cleavage[96] were reported. In general, caged
peptides are synthesised by SPPS but also expressed protein ligation (EPL)[97] and genetic
insertion of unnatural amino acids[98] are used to construct caged proteins. EPL provides the
advantage of ligation between small synthesised peptides and larger expressed proteins but has
also the disadvantage of certain sequence and modification restrictions. On the other hand,
expression of proteins containing unnatural amino acids can introduce modifications at any
position but is also technologically more demanding. Which method is used for constructing a
caged peptide/protein depends on various factors, e.g. size and structure of the peptide/protein,
injection or intracellular expression for in vivo applications.[90] In this work, SPPS was used for
construction of a caged peptide.
3.2 Instrumentations for Photocleavage Reactions
Besides the design of a caged compound for a certain biological application, the used instru-
mentation for the photocleavage reaction represents a crucial point to consider. For simple
experiments, a hand-held UV/vis lamp, Hg arc lamp or Xe flash lamp can be sufficient but
often requires long irradiation times. In addition, the reaction volume needs to be taken into
account, e.g. if the light energy is focused on a small area of the sample under a microscope,
the photocleavage might take seconds, whereas in a cuvette the same reaction might take
tens of minutes. The available light sources for uncaging can be categorised into general- and
specific-purpose lamps/lasers.[90]
General-purpose light sources like Hg, Xe and metal halide lamps, are used for imaging
as well as for the photocleavage reaction. These lamps exhibit broad emission spectra between
250 – 700 nm (figure 3.1) which overlap with absorption of PPGs as well as commonly-used
fluorophores, and therefore provide the advantage of two applications in one device by switching
between excitation filters. On the other hand, simultaneous imaging and uncaging as well as
fine-tuning of the intensity for photocleavage is not possible.[90]
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Figure 3.1: Emission spectra of general-purpose light sources: Hg lamp (blue curve), Xe lamp
(red curve) and metal halide lamp (green curve). For comparison, absorption spectra of a
commonly used PPG (6-nitroveratryl, NV) is shown (black curve). Figure used from Lee et al.[90]
Reprinted with permission from reference [90]. Copyright © 2009 American Chemical Society.
Hg lamps provide most power in the UV region including spectral lines at 312, 334, and
365 nm (figure 3.1, blue curve) and minimal excitation in the infrared region (λ > 700 nm)
which results in less heating of the sample. Xe lamps exhibit a homogeneously distributed
excitation spectrum from near UV to infrared light (figure 3.1, red curve). Without intensity
differences between the corresponding channels, a broad range of fluorophores can be excited
and photocleavage reactions can be performed efficiently. However, due to the significant
emission in the infrared region, heating of the sample needs to be prevented by blocking filters.
Metal halide lamps are more and more used for fluorescence imaging but exhibit only low
intensities for λ < 350 nm (figure 3.1, green curve). Due to the fact that most PPGs exhibit
the highest absorption between 320 nm and 370 nm (e.g. 6-nitroveratryl (NV), figure 3.1, black
curve), these lamps are not suitable for most photocleavage reactions. Only when coupled with
a UV laser, metal halide lamps can be applied for separately imaging and uncaging.[90]
Specific-purpose light sources include UV lasers like N2 gas and solid-state lasers and are used for
uncaging alone. These systems coupled with a separate imaging pathway exhibit the following
benefits: The light intensity for uncaging can be specifically adjusted with higher spatial and/or
temporal resolution. With suitable filters and a dichroic design, simultaneous imaging and
irradiation for photocleavage is applicable due to the substantial blue-shift from the imaging
wavelengths. Since the optical pathway for UV irradiation is fixed, no switching of excitation
filters is necessary and the intensity can be independently controlled by the applied laser power.
For even more precision, pulsed UV lasers can be used. In summary, specific-purpose light
sources provide the great advantage of simultaneous imaging and uncaging of fast processes in
one device.[90]
A third category of instruments for uncaging comprises ultrafast IR lasers which can be
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used for two-photon uncaging (chapter 3.4). With this technique, suitable PPGs can be excited
with ∼2λmax, but this also requires laser light sources, such as a pulsed titanium-sapphire laser,
which emit light in the range of 650 – 1100 nm.[90, 99]
3.3 Most Frequently Used Photocleavable Protecting
Groups
3.3.1 o-Nitrobenzyl Groups
Besides the considerable number of disadvantages, o-nitrobenzyl (NB) compounds, especially
the dimethoxy derivative (4,5-dimethoxy-2-nitrobenzyl or 6-nitroveratryl, NV), represent the
most frequently used PPGs (scheme 3.2).[91, 92] The o-nitrobenzyl group was firstly described as
a PPG by Schofield et al.[100] in 1966, followed by the o-nitrobenzyloxycarbonyl (Nboc) and 6-
nitroveratryloxycarbonyl (Nvoc) derivatives attached to amino acids described by Woodward
et al.[101] in 1970.[91, 92] The simple structure and various substitution possibilities provide
straightforward synthetic procedures as well as practical attachment to a variety of functional
groups of the target compounds. In addition, a wide range of substitution patterns for the
NB moiety provides a crucial tool to adjust the absorption spectrum, quantum yield and the
stability of the photocleaved bond. Without further substitution, NB-caged compounds exhibit
a maximal absorption at λmax = 320 nm which is not suitable for in vivo applications. However,
by substitution of the aromatic and/or benzylic positions, a significant bathochromic (red) shift
of the absorption maximum can be achieved. Especially, introduction of a moderate electron-
donating group (e.g. OMe) at the meta- and para-positions, leading to the NV derivatives, was
shown to result in cleavage at considerably longer wavelength (λmax = 345 nm). On the other
hand, benzylic substitutions can result in a significant hypsochromic (blue) shift but mainly
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Scheme 3.2: Structures of the o-nitrobenzyl (NB) moiety and its derivatives used as PPGs:
o-nitrobenzyloxycarbonyl (Nboc), 6-nitroveratryl (NV), 6-nitroveratryloxycarbonyl (Nvoc), and
α-carboxy-6-nitroveratryl (α-CNV) derivatives. The corresponding target molecule is indicated
as residue R.
In addition, this side product is even more problematic as it reacts with amines to form stable
imine derivatives and degradation products which act as an internal filter. The former can
be prevented by addition of semicarbazide hydrochloride as a scavenger.[92] Substitution with
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a methyl group was found to increase the quantum yield and led to the less toxic and less
problematic acetophenone side product.[91, 92, 102] Nevertheless, it needs to be considered that
benzylic substitutions create a chiral center and could complicate caging of chiral molecules.[92]
The water solubility needed for biological applications can be increased by substitution with
CO2H moieties. For this purpose, the α-carboxy-6-nitroveratryl (α-CNV) derivative was
developed which, besides better solubility in aqueous media, exhibits also a red shift of maximal
absorption wavelength (λmax = 356 nm).[92, 103] The third position for adjustment of the
photocleavage properties is the linkage between the PPG and the target molecule. Most target
molecules can be attached directly at the benzylic site, but especially for alcohols and amines,
the attachment as a carbonic acid derivative (e.g. Nvoc) is widely used. This is based on the
straightforward synthesis by the reaction of the alcohol or amine with the PPG chloroformate.
However, the oxycarbonyl linkage was shown to decrease the rate of photolysis significantly, and
thus, is unsuitable for rapid release applications. In summary, although a variety of different
substitution patterns were tested for o-nitrobenzyl derivatives, often contradictory results led
to no clear tendency for the development of new PPGs, due to different excitation wavelengths
or different leaving groups used.[92]
3.3.2 Coumarin-4-ylmethyl Groups
The second most frequently used PPGs are coumarin-4-ylmethyl (CM) derivatives, which
have the advantages of relatively simple synthesis, although not as straightforward as for NB
derivatives (scheme 3.3). These PPGs exhibit high absorption coefficients even at longer
wavelength, fast photocleavage rates, and fluorescent properties for easy reaction monitoring.
In addition, CM provides a variety of substitution possibilities to obtain a library of derivatives























Scheme 3.3: Structures of the coumarin-4-ylmethyl (CM) moiety and its derivatives used as
PPGs: 6,7-dimethoxy(coumarin-4-yl)methyl (DMCM), (7-(diethylamino)coumarin-4-yl)methyl
(DEACM) derivatives, and (E )-2-(3-(7-Diethylamino)-4-(hydroxymethyl)-2-oxo-2H-chromen-3-
yl)acrylamido)succinate (DEACM450). The corresponding target molecule is indicated as residue
R.
Without further substitution, CM-caged compounds exhibit a maximal absorption at 314 nm
which is not suitable for in vivo applications. The first generation of CM PPGs, such as
the 6,7-dimethoxy(coumarin-4-yl)methyl (DMCM) derivative (scheme 3.3), exhibits only low
water solubility but already applicable absorption properties (λmax = 344 nm). For the second
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generation, substitution with amino groups in position 7 were introduced to obtain absorption
maxima between 350 nm and 400 nm, e.g. the (7-(diethylamino)coumarin-4-yl)methyl (DEACM)
derivative with λmax = 396 nm (scheme 3.3).[92, 104] Further substitutions at position 3 were
identified to be crucial for absorption maxima adjustment and different substituents were tested
by Ellis-Davis et al.[105] Especially, substitution with an acrylamido succinic acid moiety led
to a strong red shift of the absorption maximum (λmax = 450 nm) and significantly better water
solubility (DEACM450, scheme 3.3). Attached to the glutamic acid side chain, the DEACM450
compound exhibits very fast and clean photolysis with high quantum yields. In addition, it
is suitable for two-photon excitation at 900 nm.[106] The two-photon uncaging technique for
photolysis provides several advantages and is discussed in the following chapter. Furthermore,
the DEACM450 moiety exhibits only low two-photon-excitation at ∼720 nm in which region
most other PPGs can be excited.[106] Therefore, application of DEACM450 is possible in
combination with a second PPG for wavelength-selective photolysis (chapter 3.5). On the
other hand, a nine step synthesis is needed for DEACM450-caged glutamic acid,[106] whereas an
o-nitrobenzyl-caged glutamic acid, e.g. caged with the 3-(4,5-dimethox-2-nitrophenyl)-2-butyl
(DMNPB) derivative, is obtained in five steps.[107] Hence, a cost-benefit analysis for the
corresponding application needs to be considered.
3.4 Two-Photon Uncaging
Two-photon uncaging is an alternative to the "normal" single-photon excitation of PPGs
and the irradiation is performed at ∼2λmax. For example, o-nitrobenzyl derivatives with
λmax = 365 nm can be excited with light of 730 nm. Not all PPGs are suitable for this method
and the nonlinear optical effect needs high light intensities. However, this method has several
advantages: A precise correlation between image pixel and excitation spot of the laser provides
three-dimensional resolution of the uncaging area. Due to the focussed laser beam, distinct
small areas or volumes (up to 1 fL) of the sample can be addressed for photolysis (figure 3.4 b).
In addition, a deeper penetration of tissue is obtained and less photodamage occurs by the
application of infrared light.[90, 99]
Analogous to the product of extinction coefficient and quantum yield (εΦ) for single-photon
uncaging, the two-photon cross-section δa and action cross-section δu in Goeppert-Mayer
(GM) units are used to quantify the efficiency of the PPG’s two-photon effect. For biological
applications, δu > 0.1 GM was suggested to be necessary.[99] However, although the NV group
exhibits only low two-photon action cross-section (δu = 0.025 – 0.035 GM), it was nevertheless
applied for two-photon uncaging.[99] As already mentioned, the most promising DEACM450
PPG exhibits very good two-photon properties with a two-photon-uncaging cross-section
of 0.5 GM at 900 nm.[106] The two-photon uncaging method provides further application
possibilities for wavelength-selective photocleavage, due to the fact that a wider range of




Figure 3.4: Comparison of single- and two-photon excitation by the example of a fluores-
cein solution. (a) With single-photon irradiation (365 nm) the excitation results in a double
cone. (b) With two-photon irradiation (730 nm) a three-dimensionally resolved excitation spot
can be obtained. Figures adapted from Brieke et al.[99] © 2012 Wiley-VCH Verlag GmbH &
Co. KGaA, Weinheim. (c) Example for application of two-photon excitation: Light-induced
polymerisation of a tiny bull’s figurine (scale bar 2 µm). Figure used from Kawata et al.[108]
Reprinted by permission from Macmillan Publishers Ltd: Nature, reference [108], copyright ©
2001.
of two PPGs in the relatively small range of 350 – 450 nm is more complicated to achieve.
The strategy of wavelength-selective photocleavage is discussed in the following chapter.
3.5 Wavelength-Selective Photocleavage
With the method of wavelength-selective photocleavage, it is possible to address two or more
processes separately (scheme 3.5). By caging two or more functionalities with PPGs exhibiting
e.g. different absorption maxima (λmax), these functionalities can be selectively activated upon
irradiation with the corresponding wavelength.[91] In 2000, the strategy was firstly described
by Bochet[109] and applied to the selective uncaging of a mixture of Nvoc-caged amine and
3,5-dimethoxybenzyl-caged carboxylic acid. As already mentioned in chapter 3.3.1, the Nvoc
PPG could be cleaved by irradiation at λ = 350 nm, whereas the 3,5-dimethoxybenzyl group
needed irradiation at λ =254 nm.[109] Not all PPGs can be applied for wavelength-selective
uncaging, as several requirements were identified: The absorption spectrum should exhibit
a narrow absorption maximum with high quantum yields and low absorption outside this
region. In addition, no intra- and/or intermolecular energy transfer should be observed for the
corresponding PPG. The different molecule classes of PPGs provide a selection of absorption
maxima with the result to combine PPGs with large differences of λmax. For example, the
DEACM450 PPG could be combined with NV or Nvoc derivatives to obtain a high selectivity
and high availability for different functionalities.[91]
However, most of the PPGs cleavable with light of longer wavelength in the visible region
also absorb light in the UV region. Meaning, uncaging of the UV-cleavable PPG will also
partially cleave the putatively selective PPG. Consequently, selective uncaging is only possible
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Scheme 3.5: Principle of wavelength-selective uncaging: (left) Irradiation with wavelength λA
will selectively uncage functionality A (purple) while functionality B (green) remains caged. (right)
Only irradiation with wavelength λB will selectively uncage functionality B. (middle) Irradiation
with both wavelengths will also uncage both functionalities. Scheme used from Hansen et al.[91]
Reproduced from reference [91] with permission of The Royal Society of Chemistry.
in a certain sequence, such as irradiation at longer wavelength followed by irradiation at shorter
wavelength.[91]
An interesting example for wavelength-selective uncaging is the application for SPPS.[110]
As described in chapter 4.2, synthesis of peptides by SPPS requires a variety of orthogonal
protecting groups which need to be selectively cleaved under mild conditions. Application of
PPGs for this purpose provides the advantage of orthogonality and less interference to other
reaction conditions. In 2003, the first attempt led to the successful synthesis of a pentapeptide
by SPPS including PPGs, a photocleavable linker to the solid-support, and without a single
chemical deprotection step.[91, 110] For temporal N-terminal protection of the amino acids,
Nvoc was used as PPG and cleaved by irradiation at 360 nm. The sample was irradiated for
20 min and formation of the aldehyde side product was prevented by addition of semicarbazide
hydrochloride. The photocleavable linker to the solid-support based on a 1,2-dihydroxy-2,4,4-
trimethylpentan-3-one moiety which was cleaved at the end of the synthesis by irradiation at
305 nm. This procedure provides access to the synthesis of peptides containing sensitive side
chains or side chain protecting groups at neutral pH.[110]
More recently, PPGs were applied for solution-phase peptide synthesis to avoid usage of
highly reactive species (e.g. TFA, piperdine) as it would be needed for example for in vivo
synthesis on microchips or automated experiments in space.[111] In this concept, for C -terminal
protection of the amino acid, the 5,7-dinitroindolinyl (Dni) moiety was used (scheme 3.6). As
N-acylated derivative, this PPG was shown to react with a nucleophile by an acyl transfer
upon irradiation at λ > 385 nm. The amino group of the amino acids was protected by
the 3,5-dimethoxy-α,α-dimethylbenzyloxycarbonyl (Ddz) compound which was cleaved by
irradiation at λ < 350 nm (scheme 3.6). By the application of an LED-based reactor for
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Ddz Dni
Scheme 3.6: Example of solution-phase peptide synthesis including wavelength-selective PPGs:
3,5-dimethoxy-α,α-dimethylbenzyloxycarbonyl (Ddz) cleavable by irradiation at λ = 385 nm and
5,7-dinitroindolinyl (Dni) cleavable at λ = 300 nm. Scheme modified from Hansen et al.[91]
Adapted from reference [91] with permission of The Royal Society of Chemistry.
uncaging of Dni at 385 nm, and sequential usage of a Rayonet reactor for uncaging of Ddz
at 300 nm, a pentapeptide was successfully synthesized without additional reagents. However,
further optimisations of this method are needed since purification of intermediates and elaborate
building block synthesis are still required.[91, 111]
3.6 Biological Applications of PPGs in Neuroscience
In neuroscience, PPGs as well as wavelength-selective uncaging were already successfully applied
several times. With caged excitatory (e.g. glutamic acid, Glu) and inhibitory (e.g. γ-amino
butyric acid, GABA) neurotransmitters, neurons and even single synapses were investigated.
In this context, wavelength-selective uncaging of the corresponding neurotransmitter in com-
bination with two-photon uncaging provides high spatio-temporal control of the release, ex-
citatory or inhibitory signalling, and distribution.[91] One recent example is the combination
of DEACM450-caged Glu and 4-carboxymethoxy-7-nitroindolinyl (CDNI)-caged GABA.[112]
As already described in chapter 3.3.2 and 3.4, DEACM450-caged Glu exhibits an absorption
maximum at λmax = 450 nm and a two-photon-uncaging cross-section of 0.5 GM at 900 nm.
On the other hand, the CDNI moiety showed an absorption maximum at λmax = 330 nm and
a two-photon-uncaging cross section of 0.06 GM at 720 nm.[106] When both compounds were
simultaneously applied to a brain slice, it was possible to control the membrane potential in the
excitatory as well as in the inhibitory direction by wavelength-selective two-photon uncaging at
720 nm and 900 nm, respectively. This was also the case for DEACM450-caged GABA and
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CDNI-caged Glu.[112]
Another successful example for caging in neurobiology was initially developed by Neher
& Zucker[113, 114] in 1993. Today, the application of caged Ca2+ is well-established for
studying exocytosis in vivo. By applying a UV flash, this method mimics the jump of Ca2+
concentration as it would occur upon Ca2+ influx into a nerve terminal.[115] Since cations such
as Ca2+ cannot be covalently caged, a variety of photocleavable chelators with high affinity
towards Ca2+ were developed.[116]
In 1988, one of the first caged Ca2+ compounds was 1-(2-nitro-4,5-dimethoxyphenyl)-N,N,N’,N’-
tetrakis[(oxycarbonyl)methyl]-1,2-ethandiamine (DM-nitrophen) which is based on the NV
PPG (scheme 3.7).[117] Soon after, it became commercially available, and consequently, it was
also easily accessible for biologists. Upon irradiation, the backbone and coordination sphere of
the chelator is cleaved which results in a dramatic decrease of Ca2+ binding affinity. Before
uncaging, high affinity for Ca2+ was detected (K d = 5 nm), whereas afterwards, the products of
photocleavage exhibited only low affinity (in average K d = 3 mm). In addition, DM-nitrophen
provides a relatively high quantum yield (Φ = 0.18) at λ = 350 nm and high release rates of
Ca2+ (38 000 s−1). However, the structure of this PPG is based on ethylenediaminetetraacetic
acid (EDTA) and exhibits also non-negligible affinity towards Mg2+ and protons. Surprisingly,
this disadvantage was found to be unimportant for most physiological applications.[116] With
DM-nitrophen and other caged Ca2+ compounds, the basic questions of Ca2+ influence on
neurotransmitter release could be addressed.[116] Nowadays, nitrophenyl-ethylene glycol-bis(2-
aminoethylether-N,N,N’,N’-tetraacetic acid (NP-EGTA, scheme 3.7) is used to investigate the























Scheme 3.7: Examples of photocleavable Ca2+ chelators: 1-(2-nitro-4,5-dimethoxyphenyl)-
N,N,N’,N’-tetrakis[(oxycarbonyl)methyl]-1,2-ethandiamine (DM-nitrophen) and nitrophenyl-
ethylene glycol-bis(2-aminoethylether)-N,N,N’,N’-tetraacetic acid (NP-EGTA).
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Adamantyl-Modified Synaptobrevin
Analogues
The development of a suitable inhibitor for the SNARE disassembly reaction requires, first
of all, a detailed analysis of the interaction between α-SNAP/NSF and the SNARE complex
(chapter 4.1). As a scaffold for the inhibitor, the SNARE protein Synaptobrevin-2 was chosen
due to its simple domain structure in comparison to Syntaxin-1A or SNAP-25. Specific amino
acid side chains of Synaptobrevin-2 SNARE motif had to be identified, which are essential for
the interaction with α-SNAP. The modification of these positions should influence the binding
properties, but on the other hand, should not influence the SNARE complex assembly with the
natural counterparts, Syntaxin-1A and SNAP-25. The design of Synaptobrevin-2 analogues
was developed previously in our group by Dr. A. Groschner.[119]
After successful synthesis of the modified Synaptobrevin-2 derivatives by SPPS (chapter 4.3),
ternary SNARE complexes were formed with their natural counterparts (Syntaxin-1A and
SNAP-25) and reconstituted into small unilamellar vesicles (SUVs, chapter 4.5.1). The
assembly properties were investigated in detail using stabilised acceptor complexes (∆N
complex, chapter 4.5.2). The disassembly reaction of modified ternary SNARE complexes on
SUVs was monitored (chapter 4.5.3). In addition, Complexin binding properties to SNARE
complexes containing modified Synaptobrevin-2 analogues were investigated (chapter 4.6). The
main spectroscopic method used was fluorescence anisotropy which is described in chapter 4.4.
4.1 The Interaction Between α-SNAP and SNARE
Complex
The binding stoichiometry of α-SNAP to the SNARE complex is still under discussion, and
was recently found to be flexible depending on the SNARE complex composition.[50, 53] In
2003, Marz et al. identified the α-SNAP residues which are interacting with the SNARE
complex by site-directed mutagenesis and assumed a 3/1 stoichiometry of the α-SNAP/SNARE
complex.[64] Especially charged residues at the N-terminal concave surface of α-SNAP were
identified to influence binding affinity to the SNARE complex. Mutation of positively charged
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residues to alanines resulted in a decreased binding to the SNARE complex and a less efficient
disassembly reaction, whereas mutation of negatively charged residues to alanines increases
binding to the SNARE complex. Consequently, the binding between α-SNAP and SNARE
complex is based on electrostatic interactions of positively charged lysine residues of α-SNAP
and negatively charged aspartic and glutamic acid residues of SNARE complex.[64]
Marz et al. were able to identify six distinct interaction sites within the α-SNAP sequence:
K56, K93, K94, K122, K163, and K167. These residues are localised like a diagonal tape
across the concave site of α-SNAP (figure 4.1 a). On the surface of the SNARE complex
complementary binding partners were determined. Likewise diagonally oriented, negatively
charged residues define three possible binding sites for α-SNAP (figure 4.1 b). Especially
within the Synaptobrevin-2 SNARE motif sequence, residues D51, E55, and D65 were identified.
These residues are close to the hydrophilic zero layer R56 (figure 4.1 c, left) and cover binding
sites for two α-SNAPs.[64] Considering their orientation, charge, and close proximity to the zero
layer, the additional residues Q58 and E62 were also addressed as possible interaction sites
















Figure 4.1: (a) Structure of α-SNAP (pdb code 1qqe) with positively charged lysine residues
at the site of interaction highlighted in red. (b) Conserved negatively charged residues of
SNARE complex highlighted in yellow. Neuronal SNARE complex (pdb code 1sfc) consisting of
Synaptobrevin-2 (blue), Syntaxin-1A (red), and SNAP-25 (green). (c) Detailed view on possible
interaction sites with α-SNAP on the SNARE complex surface within Synaptobrevin-2 SNARE
motif sequence: D51, E55, Q58, E62, and D65. Hydrophilic zero layer R56 is highlighted in red.
Figure modified from A. Groschner.[64, 119]
With respect to the study by Marz et al.[64] modified Synaptobrevin-2 analogues were
designed.[119] Besides preventing the α-SNAP binding to the SNARE complex surface, these
derivatives should be able to form the ternary SNARE complex with their natural counterparts
Syntaxin-1A and SNAP-25.
The modified Synaptobrevin-2 derivatives consisting of the complete SNARE motif sequence
(aa 28 – 84, figure 4.2 a) were synthesised by solid-phase peptide synthesis (SPPS, chapter 4.2
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and 8.4). The transmembrane domain, the linker region, as well as the proline-rich N-terminal
domain are not essential for ternary SNARE complex formation.[120] However, amino acid
residues 28 – 32 turn out to be critical for complex formation, due to the fact that no complex
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H-SNRRLQQTQAQVDEVVDIMRVNVDKVLERDQKLSELDDRADALQAGASQFETSAAKL-OH
28        32 51        55      58        62     65 84
a b
Figure 4.2: (a) Synaptobrevin-2 SNARE motif sequence (aa 28 – 84) with modified positions
highlighted in blue, zero layer R56 in red, hydrophobic layers −7 to +8 in italic, and SNARE
motif contributing to SNARE complex formation in bold. (b) Unnatural amino acid building
block Fmoc-Asn(Ad)-OH (N(Ad), 4).[119]
Firstly, the three amino acid residues D51, E55, and D65, suggested by Marz et al. to be the
binding site for α-SNAP, were substituted by lysines. These substitutions should change the
charge on the surface and thereby generate a repulsive interaction with α-SNAP. Unfortunately,
no ternary complex formation was observed for this derivative (Syb-2 (28 – 84) D51K, E55K,
D65K).[119]
For further modification, an unnatural amino acid building block 4 with a sterically demanding
side chain (1-adamantane) was designed (figure 4.2 b).[119] This modification should inhibit or
weaken α-SNAP binding to the SNARE complex surface by sterical hindrance. The building
block was developed for application during SPPS following the standard Fmoc protocol. It is
based on the amino acid asparagine (Asn, N) with its side chain modified by an 1-adamantyl
residue. This building block was introduced at each possible interaction site within the sequence.
In addition, derivatives with two or three modifications in one sequence were synthesised (chap-
ter 4.3) and analysed regarding their SNARE complex disassembly properties by fluorescence
anisotropy (chapter 4.5).
4.2 Solid-Phase Peptide Synthesis (SPPS)
The synthesis of adamantyl-modified Synaptobrevin-2 analogues was conducted by SPPS
developed by R. B. Merrifield. The advantage of this synthesis method is the covalent
attachment of the solid support (resin) to the growing peptide sequence. Thereby, during the
synthesis, the peptide sequence is insoluble in the corresponding solvent, but reagents and
by-products can be easily separated by washing and filtration. No further purification step is
needed after the coupling of each amino acid. This procedure essentially increases the yields of
peptide synthesis.[121, 122]
For the stepwise peptide synthesis from C - to N-terminal end, an orthogonal strategy of
protecting groups is necessary. Therefore, the N-terminal end and, if necessary, amino acid side
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Scheme 4.3: Synthesis cycle of solid-phase peptide synthesis (SPPS) using standard Fmoc
protocol. Starting with activation of carboxy function, coupling reaction, followed by capping
reaction to deactivate the uncoupled amine functionalities, and ultimately, deprotection of amine
functionalities. Upon accomplishment of the desired peptide sequence, cleavage from the solid
support and complete deprotection of the amino acid side chains were conducted.
chains, have to be protected with orthogonal protecting groups for specific deprotection. The
standard Fmoc protocol is most commonly used (scheme 4.3): The α-amine group is protected
by 9-fluorenylmethoxycarbonyl (Fmoc) group which can be removed by bases. On the other
hand, the amino acid side chains are protected with protecting groups which can be cleaved by
acids. The advantage of this strategy is that, during synthesis, the Fmoc protecting group can
be specifically removed by piperidine (20 % in NMP), whereas all amino acid side chains remain
protected, avoiding possible side reactions. For all steps, N-methyl-2-pyrrolidinone (NMP) or
dimethylformamide (DMF) are utilised as solvent.[123–125]
The standard Fmoc protocol has the advantage to be easily automated due to non-corrosive
substances used in the synthetic procedure. In addition, Fmoc deprotection releases diben-
zofulvene which exhibits high UV absorption and can be used as an indicator for successful
deprotection and coupling reaction.[125]
After deprotection of the α-amine function, coupling of the next amino acid of the peptide
sequence is performed. For peptide bond formation, it is necessary to first activate the α-
carboxyl function of the incoming amino acid. A variety of activating reagents are commercially
available for the coupling step and for each amino acid building block it has to be considered
which one will lead to the best yields. The mixture of 2-(1H-benzotriazole-1-yl)-1,1,3,3,-
tetramethyluronium-hexafluorophosphate (HBTU) and 1-hydroxybenzotriazole (HOBt) with
diisopropylethylamine (DIPEA) as base is often used for natural amino acids. HOBt is utilised
to accelerate the reaction and to prevent racemisation. The activation reaction with HBTU
proceeds via formation of acyluronium intermediate which reacts with deprotonated HOBt to
1-hydroxybenzotriazol ester. The subsequent acylation of the amine leads to regeneration of
HOBt.[124, 126]
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A more efficient activating reagent is the analogue 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-
tetramethyluronium-hexafluorophosphate (HATU) which is used in combination with the
corresponding additive 1-hydroxy-7-azabenzotriazole (HOAt). The reason for the higher effi-
ciency is the formation of the active ester with HATU, an aza-analogue structure in which the
amine as the coupling partner is favourably oriented.[126]
However, HOBt and HOAt, both have the disadvantage to be classified as explosives, which
leads to transportation difficulties and consequently restricts commercial availability. As an
alternative, ethyl 2-cyano-2-(hydroxyimino)acetate (Oxyma) used in combination with N,N-
diisopropylcarbodiimide (DIC) showed clear advantages over HOBt as well as a comparable
performance to that of HOAt regarding prevention of racemisation and coupling efficiency. In
addition, Oxyma is not classified as explosive due to its slower decomposition rate.[127]
After the coupling reaction, the so-called capping reaction with acetic acid anhydride (Ac2O,
20 % in NMP) is performed, to deactivate possible free amine functions by acylation. This can
also be used in combination with DIPEA for amino acid side chain protecting groups which
are especially unstable towards acids. The synthesis cycle consisting of activation, coupling,
capping and deprotection is repeated as long as the desired peptide sequence is obtained.
Afterwards, the peptide is cleaved from the resin and all amino acid side chains are deprotected.
The procedure for the last step depends on the used resin and the amino acids within the
sequence. In this work, only Wang resins were applied, which contain a p-alkoxybenzyl ester
as linker and after cleavage lead to the free carbonic acid at the C -terminal end of the peptide.
For this resin, cleavage is achieved by trifluoroacetic acid (TFA, 95 %) addition and to transfer
the peptide sequence into the solution-phase.[124]
For cleavage and complete deprotection of the amino acid side chains, a mixture of TFA
(94.0 %), H2O (2.5 %), ethanedithiole (EDT, 2.5 %) and triisopropylsilane (TIS, 1.0 %) was
applied. EDT and TIS were used as so-called scavengers to prevent side reactions by cleaved
fragments of protecting groups.[124] A detailed description of the applied procedure can be
found in chapter 8.4.
4.3 Synthesis of Adamantyl-Modified Synaptobrevin
Analogues
Based on the results from Marz et al.[64] distinct positions of Synaptobrevin-2 SNARE motif
(aa 28 – 84) were modified by introducing the unnatural amino acid building block Fmoc-
Asn(Ad)-OH (N(Ad), 4) using SPPS. In a previous work by Dr. A. Groschner[119] a library
of adamantyl-modified Synaptobrevin-2 analogues was analysed to study SNARE assembly
and disassembly properties by SDS-PAGE (table 4.4). Especially derivative H (Syb-2 28 – 84
Q58N(Ad), 10) showed most promising disassembly properties by retarding the reaction. Based
on these results, five derivatives with different affinities for complex formation were chosen for
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further quantification by fluorescence-based methods.
Table 4.4: Summary of previous results by Dr. A. Groschner regarding SNARE complex







































4.3.1 Synthesis of N-Fmoc Adamantyl Amino Acid Building Block
(4)
The amino acid building block 4 was designed to obtain sterical hindrance on the surface of
SNARE complex. This should lead to the inhibition or weakening of α-SNAP binding. To
obtain a sterically demanding side chain, the side chain of asparagine was modified with a
1-adamantyl residue. Adamantane is a cycloalkane consisting of three condensed cyclohexanes,






























Fmoc-Asp-OtBu (1) 2 Fmoc-Asn(Ad)-OH (4)
Scheme 4.5: Synthesis scheme of unnatural amino acid building block Fmoc-Asn(Ad)-OH
(4).[119]
Synthesis of building block 4 was accomplished in two steps, starting with Fmoc-Asp-OtBu
(1) and 1-aminoadamantane (2, scheme 4.5). Using HBTU, HOBt and DIPEA in DMF, amide
bond formation occurred and Fmoc-Asn(Ad)-OtBu (3) was obtained in good yields (74 %). In
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the second step, tert-butyl ester hydrolysis was achieved by TFA (95 %) addition, and the final
compound Fmoc-Asn(Ad)-OH (4) was also obtained in very good yields (96 %).[119]
4.3.2 Synthesis of Adamantyl-Modified Synaptobrevin-2 (28 – 84)
Modified Synaptobrevin-2 sequences including one or two modification in total were synthesised
with the following positions modified: D51, E55, Q58, E62, and D65. These positions are close
to the zero layer R56, and located on the surface once the SNARE complex is formed.
The following Synaptobrevin derivatives were successfully synthesised: Syb-2 (28 – 84) wild-type
(6), Syb-2 (28 – 84) E55N(Ad), D65N(Ad) (7), Syb-2 (28 – 84) D51N(Ad), E55N(Ad) (8),
Syb-2 (28 – 84) D51N(Ad), E55N(Ad), D65N(Ad) (9), Syb-2 (28 – 84) Q58N(Ad) (10), Syb-2
(28 – 84) E62N(Ad) (11) (table 4.6).
Table 4.6: Sequences of adamantyl-modified Synaptobrevin-2 derivatives (7 – 11) and


























The strategy for synthesising the Synaptobrevin-2 SNARE motif was the following: Firstly,
the C -terminal part Syb-2 (66 – 84) (5, chapter 8.6.1) was synthesised by automated and
microwave-assisted SPPS using the CEM Liberty12 peptide synthesizer, according to GSP 2
(chapter 8.4.2). The obtained resin-bound peptide 5 was subdivided into several batches
to continue synthesis of the different derivatives (peptide 6 – 11, chapter 8.6.2 – 8.6.7) by
manual SPPS according to GSP 1 (chapter 8.4.1). Due to the length of the peptide sequence,
double coupling (2 x 30 min) was performed and from amino acid D51 on the coupling
time was elongated to 2 x 45 min except for R47 (2 x 1 h) and R31, R30 (3 x 1 h). After
complete synthesis, the peptides 6 – 11 were cleaved from the solid-support and completely
deprotected according to GSP 3 (chapter 8.4.3). After purification by HPLC, the influence
of the adamantyl-modified Synaptobrevin-2 analogues on the SNARE complex formation as
well as disassembly reaction was analysed, described in chapter 4.5. The technique used for
monitoring disassembly reactions is described in detail in the following chapter.
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4.4 Fluorescence Anisotropy
Fluorescence anisotropy as well as fluorescence resonance energy transfer (FRET) are widely
used tool to investigate biochemical processes. Compared to FRET where two fluorophores
within the investigated system are needed in a certain distance, the advantage of fluorescence
anisotropy is that only one fluorophore is needed without any distance dependency.
For measurements of fluorescence anisotropy, polarised light is used for excitation which leads
to polarised emission from many samples. The anisotropy (r) describes the dimension of
polarization of the emitted light. For example, a sample with complete polarised emission
exhibits a non zero anisotropy. But this state can not be observed for homogeneous unoriented
probes. Anisotropy is based on the relative orientation of the transition moments for absorption
and emission within the fluorophore structure. In a homogeneous solution, they are orientated
randomly in the ground-state. Upon excitation with polarised light, fluorophores with their
transition moment of absorption oriented parallel to the electric vector of the light, exhibit
the highest probability to be excited. Consequently, fluorophores are partially oriented in the
excited state.[128, 129]
In scheme 4.7 the experimental setup for measuring fluorescence anisotropy is shown. The light
beam for excitation is directed from the source along the x -axis with the linear polarisation
oriented parallel to the z-axis. In the origin, a hypothetical molecule is placed with its transition
dipole for absorption oriented at an angle of θ towards the z-axis. γ indicates the angle between
the absorbing and emitting transition dipole of the molecule. Along the y -axis, the emitted
fluorescence is measured by a polarizer which detects the intensities with polarization parallel
(I‖) and perpendicular (I⊥) to the polarization of the exciting light. By these intensities, the




















Scheme 4.7: Experimental setup for fluorescence anisotropy measurements.[129]
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The resulting value is dimensionless and independent of the total intensity and the fluorophore
concentration. In addition, anisotropy depends on the rotational motion of the fluorophore
during its lifetime at the excited state, since rotational changes influence the orientation of the
transition moments. This dependence is used for many applications in biochemical research,
due to the fact that the rotational diffusion of biomolecules and the decay time of many
fluorophores are on a comparable timescale. As a result direct measurement of the factors
which alter the rotational movement of a biomolecule is possible. For example, the anisotropy
is decreased by increasing rotational diffusion and internal flexibility. The depolarization caused
by rotational diffusion of spherical rotors is described by the Perkin equation[128]:
r0
r
= 1 + τ/θ = 1 + 6Dτ
with the fluoroscence lifetime τ , the rotational correlation time θ and the rotational diffusion
coefficient D. In the case of a much larger correlation time than lifetime (θ  τ), the measured
anisotropy (r) is equal to the fundamental anisotropy (r0). The other way round (θ  τ), the
anisotropy is zero. For globular proteins, a relation between correlation time and molecular






with the viscosity η, the volume of the rotating unit V , the gas constant R, the temperature
T , the specific volume of the protein v̄ and the hydration h.[128, 129] The equation shows
the dependency of rotational movement of the sample on the molecular weight, volume and
hydration, and therefore the possibility to measure changes in these parameters by fluorescence
anisotropy. For example, an increase of molecular weight by a binding event leads to a decrease
of the lifetime/rotational correlation time ratio, and consequently, to an increase in anisotropy.
Two methods are available for fluorescence anisotropy measurements: L-format or single-channel
method (scheme 4.8 a) and T-format or two-channel method (scheme 4.8 c). In the first case,
a single emission channel is used with a monochromator in between which has usually different
transmission efficiencies for vertically and horizontally polarised light. In the second case, two
separate detectors are used for measuring the intensities of parallel and perpendicular polarised
light simultaneously.[128]
For the L-format method, the detected intensities (e.g. IV V , IV H for vertically polarised
excitation (V) and horizontally polarised emission (H)) differ from the desired intensities I‖






and the anisotropy (r) can be calculated as follows:
r = IV V −GIV H
IV V +2GIV H
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a b c
Scheme 4.8: Schematics of different methods for fluorescence anisotropy measurements: (a)
L-format or single-channel measurements with monochromators (MC) and (c) T-Format or
two-channel measurements. (b) Shapes of the excited-state distributions.[128]
Hence, to calculate the anisotropy (r), it is necessary to determine the G factor, which includes
the sensitivities of the emission polarisers. This can be done by using horizontally polarised
excitation, due to the fact that the horizontally and vertically polarised components are equal
and also proportional to I⊥ (scheme 4.8 a). In that case, any intensity differences in IHV and
IHH result from the detection system which is represented in the G factor:
G = IHV
IHH
Without correction of the calculated anisotropy by determination of the G factor, the measured
values will be incorrect.[128]
For the T-format method, which was applied in this work, two separate detectors are used.
Due to no change in the emission polarisers, the sensitivity of each channel remains equal
during the measurements. But nevertheless, the relative sensitivity of the two detectors has to
be determined. Firstly, with vertical polarised excitation, the ratio of parallel and perpendicular




with the sensitivities of the parallel G‖ and perpendicular G⊥ channel. With horizontally
polarised excitation, both emission channels detect I⊥ and the ratio of sensitivities can be









which can be used to calculate the anisotropy (r):
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Due to the simultaneous measurement, possible fluctuations in the intensities are cancelled
with the T-format method and, thus, was preferentially used in the past. Today, the only
advantage of T-format measurements is the decreased time for data acquisition.[128]
4.5 SNARE Assembly and Disassembly Properties of
Adamantyl-Modified Synaptobrevin Analogues
Adamantyl-modified Synaptobrevin-2 analogues were investigated regarding the SNARE complex
assembly and disassembly properties. The natural counterparts (Syntaxin-1A and SNAP-25) for
SNARE complex formation were expressed and purified by Dr. H. Yavuz, Prof. R. Jahn’s work
group, Department of Neurobiology, Max-Planck-Institute for Biophysical Chemistry Göttingen
(chapter 8.3.5) as well as co-floatation assays and fluorescence anisotropy experiments were
conducted in collaboration.
4.5.1 SNARE Complex Formation and Reconstitution into SUVs and
Co-Floatation Assay
For SNARE complex formation of the adamantyl-modified Synaptobrevin-2 analogues with
the natural counterparts, the following peptides were mixed and incubated for 2 h at room
temperature under exclusion of light (chapter 8.3.6): Syntaxin-1A (183 – 288), Oregon Green
(OG)-labelled SNAP-25 (1 – 206) C130-OG, Synaptobrevin-2 (28 – 84) X (1.0/1.0/1.5, n/n/n).
For these experiments, Syntaxin-1A sequence containing the transmembrane domain was used
for further reconstitution into vesicles. To solubilise membrane peptides/proteins in aqueous
solution, addition of detergents is necessary. Consequently, SNARE complex formation was
conducted in a detergent containing HEPES buffer (20 mm, NaCl (300 mm), TCEP (0.1 mm),
CHAPS (2 %)) at pH 7.4.
Due to the membrane-dependent efficiency of α-SNAP binding to the SNARE complex,[59, 60]
all investigated complexes were reconstituted into small unilamellar vesicles (SUVs) by the
co-micellisation method (chapter 8.3.7).[11, 18] With this method, SUVs are obtained by mixing
lipids and proteins in the detergent containing buffer followed by the removal of the detergent
by size-exclusion chromatography. The used lipid mix consisted of phosphatidylcholine (PC,
50 %), phosphatidylethanolamine (PE, 20 %), phosphatidylserine (PS, 20 %) and cholesterol
(10 %) in HEPES buffer (20 mm, KCl (150 mm), EDTA (1 mm), DTT (1 mm), NaCholate
(5 %, w/v), pH 7.4). Lipid mix and protein mix were combined in a protein to lipid ratio of
1/1000. The mixture was applied to a size-exclusion column equilibrated with a detergent
free HEPES buffer (20 mm, KCl (150 mm), EDTA (1 mm), DTT (1 mm), pH 7.4) and the
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vesicle fractions were collected. Due to OG-labelled SNARE complexes, the collected frac-
tion with highest emission under UV lamp was chosen for further experiments (see chapter 8.3.7).
For investigating the quantity of reconstituted SNARE complexes, co-floatation assays were
performed.[18, 60] With this method, proteoliposomes are subjected to a density gradient in which
the vesicles float on top constituting the lowest density fraction and all the non-reconstituted
peptides are localised at the bottom constituting the highest density fraction.
The fractions obtained from size-exclusion chromatography were used for co-floatation assays
(chapter 8.3.8). The eight aliquots (F1 – F8) isolated after the co-floatation assay were analysed
by SDS-PAGE (figure 4.9), whereby F1 constituted of the lowest density fraction and F8 of the
highest density fraction.
Syb-2 (28 - 84) wild-type (6) Syb-2 (28 - 84) E55N(Ad), D65N(Ad) (7)
Syb-2 (28 - 84) D51N(Ad), E55N(Ad) (8) Syb-2 (28 - 84) Q58N(Ad) (10)
Syb-2 (28 - 84) E62N(Ad) (11)
density gradient0 % 40 %
F1 F1
ub




density gradient0 % 40 %
F1 F1
ub*




density gradient0 % 40 %
F1 F1
ub




density gradient0 % 40 %
F1 F1
ub




density gradient0 % 40 %
F1 F1
ub




Figure 4.9: Fractions (F1 – F8) obtained by Co-floatation assays analysed by SDS-PAGE for
SNARE complexes containing peptides 6, 7, 8, 10, and 11. All fractions were boiled in sample
buffer except for fraction F1, which was subdivided into two samples, one was boiled and the
second not boiled (ub). *Sample was boiled for few seconds.
In addition, F1 was divided into two samples: one was boiled and the other was not boiled
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(ub) before loading on the gel. The ternary SNARE complex is resistant towards SDS but not
stable at that high temperatures. Consequently, to estimate whether complexes were formed,
an unboiled fraction was needed. For all SNARE complexes, an upper band (∼35 – 40 kDa)
in the unboiled top fraction F1 could be observed. Meaning, all investigated Synaptobrevin-2
analogues were able to form the ternary SNARE complex and were successfully reconstituted
into SUVs. In the case of SNARE complex containing Syb-2 (28 – 84) D51N(Ad), E55N(Ad)
(8), fluorescence intensity of the bands was low due to the overall low concentration used in
comparison to the other derivatives.
The two top fractions (F1 and F2) of each co-floatation assay were combined and used for the
disassembly experiments by fluorescence anisotropy (chapter 4.5.3). Thereby, the assay was
also used as a purification method prior to disassembly reaction.
4.5.2 Fluorescence Anisotropy Experiments of SNARE Complex
Formation
SNARE assembly properties of adamantyl-modified Synaptobrevin-2 derivatives were analysed
by fluorescence anisotropy using a soluble, truncated SNARE complex consisting of Syntaxin-1A
(183 – 262), SNAP-25 (1 – 206) no Cys mutant, and Synaptobrevin-2 (49 – 96) C79-OG.
Previous publications showed that, with this stabilised acceptor complex (∆N complex),
SNARE complex formation properties can be measured indirectly by displacement of the Syb-2
fragment.[11, 18, 60] SNARE complex assembly was shown to start at the N-terminal part of the
SNARE motifs. Therefore, the Synaptobrevin-2 comprising a longer N-terminal part of the
SNARE motif can displace the C -terminal Syb-2 fragment of the ∆N complex (figure 4.10 a).[11]
The binding event can be monitored by time-dependent fluorescence anisotropy: The labelled
Syb-2 fragment assembled in the ∆N complex exhibits a certain anisotropy level, whereas
the free labelled Syb-2 fragment shows a distinct lower anisotropy level. Upon addition of a
longer Syb-2 peptide, the anisotropy decreases due to the displacement event. Based on the
time-dependent anisotropy curve, it is possible to determine the kinetics of the displacement
reaction.[11, 18, 60]
The following synthesised Synaptobrevin-2 derivatives were analysed at 20 °C by time-dependent
fluorescence anisotropy (figure 4.10 b): Syb-2 (28 – 84) wild-type (6), Syb-2 (28 – 84)
E55N(Ad), D65N(Ad) (7), and Syb-2 (28 – 84) Q58N(Ad) (10). The first 1.5 eq of Syb-2
derivatives (120 nm) were added to the ∆N complex (80 nm) after ∼200 s of measurement.
The concentration of Syb-2 was subsequently increased to 2.25 eq (180 nm) after ∼575 s of
measurement. However, no significant change in reaction speed was observed by the second
addition, concluding that 1.50 eq excess of Syb-2 is sufficient for SNARE complex formation.
For direct comparison of the kinetics with the shorter wild-type sequence, Syb-2 (1 – 96) was
also added to the ∆N complex. It was shown that Syb-2 (28 – 84) wild-type (6, black curve)
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Figure 4.10: SNARE assembly experiments with OG-labelled truncated SNARE complex (∆N
complex). (a) Scheme of performed experiments with ∆N complex consisting of Syntaxin-1A
(red), SNAP-25 (green) and Syb-2 fragment (blue) labelled with OG (pink star). By addi-
tion of synthesised Synaptobrevin-2 sequences, the short Synaptobrevin-2 fragment will be
displaced. (b) fluorescence anisotropy experiments with ∆N complexes. Additions of correspond-
ing Synaptobrevin-2 derivative (Syb-2 (28 – 84) wild-type (6, black), Syb-2 (1 – 96) (red), Syb-2
(28 – 84) E55N(Ad), D65N(Ad) (7) (blue), or Syb-2 (28 – 84) Q58N(Ad) (10) (green)) are
indicated by the arrows. First addition of Syb-2 derivatives (120 nm) to the OG-labelled ∆N
complex (80 nm) was conducted after ∼200 s of measurement, followed by a second addition
of Syb-2 derivatives to increase the concentration to 180 nm after ∼575 s of measurement.
Synaptobrevin-2 fragment displacement is traced by the decrease in anisotropy.
exhibits a similar kinetic profile to displace the Syb-2 fragment as the longer version Syb-2
(1 – 96) wild-type (red curve). As a consequence, Syb-2 (28 – 84) wild-type containing the
whole SNARE motif sequence is comparable in its properties to Syb-2 (1 – 96). In addition,
two of the adamantyl-modified Synaptobrevin-2 derivatives were investigated. Syb-2 (28 – 84)
E55N(Ad), D65N(Ad) (7) (blue curve) as well as Syb-2 (28 – 84) Q58N(Ad) (10) (green curve)
showed clearly retarded fragment displacement. Even addition of further excess (2.25 eq) after
∼575 s showed no acceleration of the reaction.
To summarise, the synthesised wild-type sequence comprising only the SNARE motif of
Synaptobrevin-2 is sufficient as it is comparable in its SNARE assembly properties to the
longer version. Secondly, adamantyl modifications showed clear impairment of SNARE complex
formation using ∆N complexes. The positions of the modifications (E55N(Ad), Q58N(Ad),
D65N(Ad)) are close to the beginning of the C -terminal Syb-2 fragment (49 – 96) which
might be the reason for the clear retardation of fragment displacement. Probably, SNARE
complex formation with adamantyl-modified Synaptobrevin-2 species from monomers did not
get impaired to this extent, as SNARE complexes were successfully assembled and reconstituted
after 2 h incubation with monomeric species (chapter 4.5.1).
60
4.5 SNARE Assembly and Disassembly Properties of Adamantyl-Modified Synaptobrevin
Analogues
4.5.3 Fluorescence Anisotropy Experiments of SNARE Disassembly
Reaction
All disassembly reactions were performed in disassembly buffer consisting of HEPES (50 mm),
potassium acetate (KAc, 20 mm), potassium glutamate (KGlu, 120 mm) at pH 7.4 and
37 °C. SNARE complexes reconstituted into SUVs and isolated from the two top fractions
(F1, F2) obtained during the co-floatation assays were used (chapter 4.5.1). Time-dependent
fluorescence anisotropy measurements were performed using Fluorolog 3 spectrometer. Excita-
tion and emission wavelengths were set to 488 nm and 520 nm for Oregon Green (chapter 8.3.9).
Firstly, influence of co-floatation assay on anisotropy measurements was analysed in the
case of SNARE complex containing Syb-2 (28 – 84) wild-type (6) (figure 4.11 a). Therefore,
samples before and after the assay were used for disassembly reaction. In general, the dis-
assembly reaction could be observed by an increase in anisotropy upon α-SNAP binding to
the SNARE complex (figure 4.11 a, ∼200 s). After subsequent addition of NSF (∼400 s),
an decrease in anisotropy below the initial level was monitored, which indicates complete
disassembly of the SNARE complex into the individual peptides.
The comparison of the samples before and after the co-floatation assay shows a clearer increase
in anisotropy upon α-SNAP binding for the sample after the assay (figure 4.11 a, black and
green curves). Meaning, the separation of non-reconstituted peptides by co-floatation assay is
reasonable for these experiments.
Furthermore, control experiments for the disassembly reaction were conducted. In the first con-
trol experiment buffer was added instead of MgCl2 (figure 4.11 a, no Mg (control), red curve).
Since Mg2+ is necessary for ATP hydrolysis by NSF, the enzyme is not able to disassemble
the SNARE complex without addition of MgCl2. This was exactly observed in the control
experiment: α-SNAP was still able to bind to the SNARE complex (increase in anisotropy),
but after NSF addition no decrease in anisotropy was observed and the SNARE complex was
not disassembled.
In the second control experiment buffer was added instead of α-SNAP (figure 4.11 a, no
α-SNAP (control), blue curve). As mentioned before, NSF is not able to bind to the SNARE
complex without prior binding of α-SNAP. In other words, without α-SNAP in the solution,
NSF will not disassemble the SNARE complex. This was confirmed by the observation made
in the control experiment: wherein, no increase in anisotropy in the absence of α-SNAP was
observed, and no decrease in anisotropy after NSF addition.
Disassembly experiments of SNARE complexes containing adamantyl-modified Synaptobrevin-2
analogues were performed exactly like in the wild-type case described above. For the SNARE
complex containing Syb-2 (28 – 84) E55N(Ad), D65N(Ad) (7) as well as for the SNARE
complex containing Syb-2 (28 – 84) Q58N(Ad) (10), the disassembly reaction proceeded
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similar to the wild-type (figure 4.11 b and c, black curves): An increase in anisotropy was
observed upon α-SNAP binding and a decrease in anisotropy was observed upon NSF addition.
In spite of the adamantyl modifications, α-SNAPs were still able to bind to the SNARE complex
surfaces, and NSF disassembled the SNARE complexes. The two control experiments were
similar to the wild-type experiments (figure 4.11 b and c, red and blue curves).
The overlay of all performed disassembly experiments (figure 4.11 d) shows that none of the
adamantyl modification had an influence on the α-SNAP binding to the SNARE complex
surfaces, and all the SNARE complexes were disassembled by the NSF/α-SNAP machinery.
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Figure 4.11: Disassembly reaction of SNARE complex containing synthesised Syb-2 (28 – 84)
derivatives (Syb-2 (28 – 84) wild-type (6), Syb-2 (28 – 84) E55N(Ad), D65N(Ad) (7), Syb-2
(28 – 84) D51N(Ad), E55N(Ad) (8), Syb-28 (28 – 84) Q58N(Ad) (10), and Syb-2 (28 – 84)
E62N(Ad) (11)) analysed by fluorescence anisotropy. (a) Disassembly experiment of SNARE
complex containing Syb-2 (28 – 84) wild-type (6). Samples used before (green) and after (black)
co-floatation assay as well as control experiments with buffer addition instead of MgCl2 addition
(red) and instead of α-SNAP addition (blue). Addition of α-SNAP and NSF is indicated by
corresponding arrows. (b) Disassembly experiments of SNARE complex containing adamantyl-
modified Syb-2 (28 – 84) E55N(Ad), D65N(Ad) (7, black) and (c) Syb-28 (28 – 84) Q58N(Ad)
(10, black) including corresponding control experiments (red and blue). (d) Overlay of all
performed disassembly reactions excluding control experiments.
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4.6 Complexin Binding Studies with Adamantyl-Modified
Synaptobrevin Analogues
Complexin binding studies of adamantyl-modified Synaptobrevin-2 analogues-containing SNARE
complexes were carried out due to the fact that α-SNAP and Complexin compete for SNARE
complex binding.[59, 67] Specifically, Synaptobrevin-2 residues on the SNARE complex surface
interacting with α-SNAP (D51, E55, and D65)[64] and with Complexin (D57, D64, D65, and
D68)[74] are in close proximity or even match (see chapter 2.7.4).
Consequently, some of the synthesised adamantyl-modified Synaptobrevin derivatives potentially
influence the binding of Complexin to the SNARE complex surface. To investigate this issue,
time-dependent fluorescence anisotropy experiments for visualisation of Complexin binding
were performed. First of all, a test reaction for detection of Complexin binding by fluores-
cence anisotropy was conducted as a proof of principle (chapter 4.6.1). Afterwards, SNARE
complexes containing synthesised Syb-2 (28 – 84) wild-type (6) were investigated regarding
their Complexin binding ability (chapter 4.6.2) and subsequently, Complexin binding to SNARE
complexes containing Syb-2 (28 – 84) E55N(Ad), D65N(Ad) (7) and Synaptobrevin-2 (28 – 84)
Q58N(Ad) (10) was analysed (chapter 4.6.3). These two derivatives were chosen due to a
match or close proximity between their site of modification and the identified interaction sites.
Furthermore, SNARE complex formation especially for Synaptobrevin-2 (28 – 84) Q58N(Ad)
(10) was verified by SDS-PAGE as a result of the problems associated with SNARE assembly.
SNARE complex formation with kindly provided natural counterparts, SDS-PAGE as well
as fluorescence anisotropy experiments were conducted in collaboration with Dr. H. Yavuz,
Prof. R. Jahn’s work group, Department of Neurobiology, Max-Planck-Institute for Biophysical
Chemistry, Göttingen.
All Complexin binding reactions were performed as stated in chapter 8.3.9 using HEPES
buffer and the Fluorolog 3 spectrometer with excitation and emission wavelength set to 488 nm
and 520 nm, respectively, for Oregon Green.
4.6.1 Fluorescence Anisotropy Experiments of Complexin
Binding — Proof of Principle
First, a test experiment was performed as a proof of principle, to study if the binding of
Complexin to the ternary SNARE complex could be measured by fluorescence anisotropy
(figure 4.12). Due to available OG-labelled, purified ternary SNARE complexes (SNAP-25
(1 –206) C130-OG, Syntaxin-1A (183 – 288), Synaptobrevin-2 (1 – 96)), it was first tested,
whether by addition of unlabelled Complexin I (1 – 134) a decrease in anisotropy was detectable
(figure 4.12 a, top). Unfortunately, this was not the case (data not shown).
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Figure 4.12: Complexin binding studies by fluorescence anisotropy as a proof of principle. (a)
Schemes of performed Complexin binding reactions with same color code as in figure 4.10 except
for Complexin (purple). (b) Complexin binding reactions measured by fluorescence anisotropy. (a,
top) Binding event of OG-labelled SNARE complex with unlabelled Cpx I (1 – 134) resulted in no
observable change in Anisotropy. (a, middle), and b) By addition of unlabelled SNARE complex
to OG-labelled Cpx I (1 – 134) E39C, C105S, the binding event was detectable. Addition is
indicated by the arrow. Different molar ratios of CpxOG (80 nm) and SNARE complex were tested.
(a, bottom and b) Control experiment: Excess of unlabelled Cpx (11.3 eq) were combined with
CpxOG (80 nm) prior to the addition of SNARE complex (320 nm). (c) Titration experiment
of CpxOG and unlabelled SNARE complex. (d) Complexin binding reaction with lower CpxOG
concentration (40 nm).
Consequently, a cysteine mutant of Complexin (Cpx I (1 – 134) E39C, C105S) was expressed
and purified as previously published[72], and labelled with Oregon Green. Finally, addition of un-
labelled ternary SNARE complex (SNAP-25 (1 –206) no Cys mutant, Syntaxin-1A (183 – 288),
Synaptobrevin-2 (1 – 96) S28C) to the OG-labelled Complexin (CpxOG) resulted in a clear
increase in anisotropy (figure 4.12 a, middle, and b), as previously described[72]. Furthermore,
when different molar ratios of CpxOG and SNARE complex were tested, it was found that the
addition of SNARE complex (80 nm) to CpxOG (80 nm) in a ratio of 1/1 showed already a
distinct increase in anisotropy (figure 4.12 b, black curve). Comparable results were provided
by ratios of 1/1.25 for CpxOG (80 nm)/SNARE complex. (100 nm) and 1/2.50 for CpxOG
(80 nm)/SNARE complex (200 nm) (figure 4.12 b, red and blue curves). In addition, a control
experiment was performed by addition of SNARE complex (320 nm) to a combination of
CpxOG (80 nm) and excess unlabelled Cpx (900 nm, 11.3 eq) (figure 4.12 a, bottom, and b,
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green curve). Only a slight increase in anisotropy was observed which might be because of
excess SNARE complex available (molar ratio 1/4) in the reaction, but overall, the increase is
clearly smaller compared to experiments without unlablled Cpx. This experiment shows that
unlabelled Cpx blocks the binding site for CpxOG and that the increase in anisotropy in the
other experiments is based on CpxOG binding event to the SNARE complex.
Furthermore, a titration experiment was performed by consecutive addition of unlabelled
SNARE complex with the following final concentrations: 80 nm (∼125 s), 160 nm (∼225 s),
240 nm (∼310 s), 320 nm (∼410 s)) to CpxOG (80 nm) (figure 4.12 c). The curve exhibits
a second increase in anisotropy upon addition of SNARE complex resulting in molar ratio of
1/2. No further significant increase was observed for molar ratios of 1/3 and 1/4. Based on
this experiment, a molar ratio of at least 1/1.5 was used for the following experiments with
SNARE complexes containing synthesised Synaptobrevin-2 derivatives.
Finally, it was tested, whether the Complexin binding reaction is still detectable with overall
lower concentrations (figure 4.12 d). Therefore, CpxOG (40 nm) was used and unlabelled
SNARE complex (100 nm and 200 nm) was added to obtain ratios of 1/2.5 and 1/5.0.
The increase in anisotropy observed was comparable to the experiments with CpxOG (80 nm),
indicating that the overall concentration is not influencing the anisotropy signal (see chapter 4.4).
4.6.2 Complexin Binding to SNARE Complexes Containing Syb-2
(28 – 84) Wild-Type (6)
For SNARE complex formation of the synthesised Synaptobrevin-2 derivatives with the natural
counterparts, purified ∆N complexes, consisting of Syntaxin-1A (183 – 162), SNAP-25 (no
Cys mutant) and Synaptobrevin-2 (49 – 96) were used (chapter 4.5.2 and 8.3.6). Due to
retarded assembly properties of the adamantyl-modified Synaptobrevin-2 derivatives 7 and 10
(chapter 4.5.2), the incubation time for complex formation was extended to overnight at 4 °C.
First of all, ternary SNARE complexes containing Syb-2 (28 – 84) wild-type (6) were obtained
by overnight incubation with ∆N complexes at 4 °C and are further referred to as ∆N/Syb-2
wt (6). Complexin binding properties were investigated by fluorescence anisotropy by addition
of ∆N/Syb-2 wt (6) (200 nm) to CpxOG (80 nm) (figure 4.13 b, black curve). As expected,
Complexin binds to the wild-type complex which is evident by anisotropy increase. Furthermore,
two control experiments were conducted: 1) By combination of CpxOG and excess unlabelled
Cpx (900 nm) prior to addition of the SNARE complex (figure 4.13 b, red curve). No increase
in anisotropy was observed due to the blockage of the binding site by unlabelled Cpx. 2) By
addition of only ∆N complex to CpxOG (figure 4.13 b, blue curve). Surprisingly, Complexin also
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Figure 4.13: Complexin binding studies of SNARE complexes containing Syb-2 (28 – 84)
wild-type (6), referred to as ∆N/Syb-2 wt (6). (a) Scheme of performed binding reactions.
(b) Fluorescence anisotropy experiments of Complexin binding (black curve) including control
experiment with excess unlabelled Complexin (red curve). In addition, Complexin binding to the
∆N complex was analysed (blue curve).
exhibits no binding to the ∆N complex although the Syb-2 fragment (49 – 96) comprises all
interaction sites for Complexin (chapter 2.7.1). As a consequence, ternary SNARE complexes
formed using ∆N complexes are suitable for Complexin binding studies.
4.6.3 Complexin Binding to SNARE Complexes Containing
Adamantyl-Modified Synaptobrevin-2 Analogues
SNARE complex formation including Syb-2 (28 – 84) E55N(Ad), D65N(Ad) (7) was obtained
by incubation overnight at 4 °C with the same ∆N complex as for Syb-2 (28 – 84) wild-type (6)
(chapter 4.6.2). The derived SNARE complexes are further referred to as ∆N/Syb-2(55/65, 7).
Complexin binding properties were analysed by fluorescence anisotropy by addition of ∆N/Syb-
2(55/65, 7) (200 nm) to CpxOG (80 nm) (figure 4.14 b, black curve). Surprisingly, Complexin
is binding to the SNARE complex containing Syb-2 (28 – 84) E55N(Ad), D65N(Ad) (7) despite
of the modification of the direct interaction site D65 of Synaptobrevin-2 by a hydrophobic and
sterically demanding adamantyl moiety. In addition, a control experiment was performed with
an excess unlabelled Cpx (900 nm) (figure 4.14 b, red curve) and indicated that the increase in
anisotropy in the first experiment is derived from CpxOG binding to the complex.
Furthermore, Complexin binding to SNARE complexes including Syb-2 (28 – 84) Q58N(Ad) (10)
was investigated. SNARE complex formation was initially performed by overnight incubation at
4 °C with the same ∆N complex as for Syb-2 (28 – 84) wild-type (6) (chapter 4.6.2). The
possibly derived SNARE complexes are further referred to as ∆N/Syb-2(58, 10). Complexin
binding properties were analysed by fluorescence anisotropy with an addition of ∆N/Syb-
2(58, 10) (200 nm) to CpxOG (80 nm) (figure 4.15 b, black curve). Indeed, no increase
in anisotropy was observed for the binding reaction of Complexin to the ∆N/Syb-2(58, 10)
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Figure 4.14: Complexin binding studies of SNARE complexes containing Syb-2 (28 – 84)
E55N(Ad), D65N(Ad) (7), referred to as ∆N/Syb-2(55/65, 7). (a) Scheme of performed binding
reactions. (b) Fluorescence anisotropy experiments of Complexin binding (black curve) and
control experiment including an excess of unlabelled Complexin (red curve).
complex as well as no signal was detected for the control experiment with excess of unlabelled
Cpx (figure 4.15 b, red curve). Complexin exhibits no binding affinity to individual SNARE
proteins or binary SNARE complexes consisting of two Syntaxin-1A helices and SNAP-25.[72, 73]
In such a case, it has to be validated that the ternary SNARE complex was formed and that
the absence of the signal is not derived from unsuccessful complex formation. For this purpose,
labelled and unlabelled complexes were formed, using OG-labelled ∆N complex (∆NOG) and
unlabelled ∆N complex as described in chapter 4.5.2 by overnight incubation at 4 °C. The
comparison of anisotropy levels between ∆NOG and the probes ∆N/Syb-2wt (6) and ∆N/Syb-
2(58, 10) provides a rough estimation of the quality of complex formation (figure 4.15 b,
inset). By displacement of the labelled Syb-2 fragment from the ∆N complex, the anisotropy
decreased due to lower molecular weight of dissociated Syb-2 fragment (cf. chapter 4.4). Hence,
successful complex formation and displacement should exhibit a significantly lower anisotropy
level then the ∆NOG before. A comparison of anisotropy levels of ∆NOG (figure 4.15 inset,
black curve) and ∆N/Syb-2 wt (6) (figure 4.15 inset, red curve) shows that the successfully
assembled complex ∆N/Syb-2 wt (6) exhibited a significantly lower anisotropy level (∼0.16)
then the ∆NOG complex (∼0.25). Additionally, in this case the complex formation was already
proved due to successful Complexin binding to ∆N/Syb-2 wt (6) (chapter 4.6.2). Unfortunately,
in the case of ∆N/Syb-2(58, 10) the anisotropy level was only insignificantly lower (∼0.24)
then for ∆NOG (∼0.25) which resulted in the assumption of unsuccessful complex formation
for ∆N/Syb-2(58, 10) (figure 4.15 inset, black and blue curves). Consequently, no Complexin
binding was observed in this case because Complexin did not bind to individual SNARE proteins
or to the ∆N complex.
Further investigations were conducted to optimise conditions for SNARE complex formation
with Syb-2 (28 – 84) Q58N(Ad) (10). Eventually, the same conditions as used prior to
disassembly experiments (chapter 4.5.3) were again successful and ternary SNARE complexes
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Figure 4.15: Complexin binding studies of SNARE complexes containing Syb-2 (28 – 84)
Q58N(Ad) (10), referred to as ∆N/Syb-2(58, 10). (a) Scheme of performed binding reactions
(top and middle) as well as ternary SNARE complex formation using labelled ∆N complex
(bottom). (b) Fluorescence anisotropy experiments of Complexin binding (black curve) and
control experiment including an excess of unlabelled Complexin (red curve). (inset) Rough
validation of ternary SNARE complex formation with labelled ∆N complex (∆NOG).
containing Syb-2 (28 – 84) Q58N(Ad) (10) were obtained from monomers, further referred to
as SN25/Syx1A/Syb(58, 10). It turned out that usage of monomers, detergent-containing
buffer (CHAPS) as well as Syntaxin-1A (183 – 288) is crucial for complex assembly with this
derivative. The experimental details are described in chapter 8.3.6 including conditions which
were not successful. For better comparison, SNARE assembly with Syb-2 (28 – 84) wild-type
(6) was also derived from monomers without detergents and Syx-1A-TMD. The properties of
the formed complexes were investigated in parallel to SN25/Syx1A/Syb(58, 10) complexes.
Wild-type complexes from monomers are further referred to as SN25/Syx1A/Sybwt (6).
Successful ternary complex formation was validated by SDS-PAGE using 12 % Schaegger gel
and Coomassie Blue staining (figure 4.16 a), due to the fact that the ternary SNARE complex is
SDS resistant.[27] An upper band (∼35 – 40 kDa) was observed for SN25/Syx1A/Sybwt (6) as
well as for SN25/Syx1A/Syb(58, 10) which proved the presence of ternary SNARE complexes.
Note that in the case of SN25/Syx1A/Sybwt (6) a diluted sample was used which resulted
in overall lower band intensities. In addition, the complex band was slightly shifted to lower
molecular weight compared to SN25/Syx1A/Syb(58, 10) due to Syntaxin-1A lacking the TMD.
Finally, Complexin binding to these two complexes was investigated by fluorescence anisotropy
(figure 4.16 b). As expected, Complexin binds to the wild-type complex (SN25/Syx1A/Syb
wt (6)) (figure 4.16 b, black curve) but surprisingly, no increase in anisotropy was observed for
the complex SN25/Syx1A/Syb(58, 10) (figure 4.16 b, red curve). This absence of anisotropy
increase probably resulted from the influence of the Synaptobrevin-2 modification on Complexin
binding due to the fact that the presence of ternary complex was already validated by SDS-PAGE
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Figure 4.16: (a) Validation of complex formation of ternary SNARE complex from monomeric
species containing Syb-2 (28 – 84) wild-type (6), referred to as SN25/Syx1A/Sybwt (6), and
containing Syb-2 (28 – 84) Q58N(Ad) (10), referred to as SN25/Syx1A/Syb(58, 10), by SDS-
PAGE (12 % Schaegger gel stained with Coomassie blue). Note that SN25/Syx1A/Sybwt (6)
(<10 µL) was diluted with HEPES buffer (30 µL) and mixed with sample buffer (6 µL) prior to
loading on the gel, in contrast to SN25/Syx1A/Syb(58, 10) (24 µL) mixed with sample buffer
(6 µL). Hence, dilution is the reason for overall lower intensities of gel bands in the case of
SN25/Syx1A/Sybwt (6). Samples were not boiled in sample buffer. (b) Complexin binding
studies with SN25/Syx1A/Sybwt (6) (black curve) and SN25/Syx1A/Syb(58, 10) (red curve) by
fluorescence anisotropy.
and possible non-binding to individual SNARE proteins can be excluded. The last possibility
that the absent anisotropy increase was not based on the modification, was by formation of
the binary complex, instead of ternary, consisting of SNAP-25 and two Syntaxin-1A helices. It
was previously reported that Complexin did not bind to the binary complex.[72]
To exclude this possibility, unlabelled and labelled binary complexes were formed by mix-
ing SNAP-25/OG-labelled SNAP-25 and Syntaxin-1A in a molar ratio of 1/2 (chapter 8.3.6),
incubated overnight at room temperature, and investigated by SDS-PAGE and fluorescence
anisotropy (figure 4.17). As previously reported, the binary complex SN25/Syx1A was not SDS-
resistant and consequently exhibited no upper band at ∼40 kDA (figure 4.17 a, lane 3), whereas
the complexes SN25/Syx1A/Sybwt (6) and SN25/Syx1A/Syb(58, 10) without detergent (fig-
ure 4.17 a, lane 1 and 2) revealed upper bands, and consequently formation of SDS-resistant
ternary complexes. Note that in this case for complex formation of (SN25/Syx1A/Syb(58, 10)
no detergents were used, and therefore, less ternary complexes were present than in the
successful case with detergents (figure 4.16 a). In addition, binary complex formation was
roughly validated by fluorescence anisotropy using OG-labelled SNAP-25 (SN25OG) for labelled
complexes as well as comparison of anisotropy levels (figure 4.17 b, inset). In this case, upon
complex formation the anisotropy level increases due to increasing molecular weight. Hence,
formed binary complex should exhibit a higher anisotropy level than the free SN25OG. Indeed,
fluorescence anisotropy experiment revealed for SN25OG a lower anisotropy level (∼0.18)
than for the probe after incubation with Syntaxin-1A (∼0.22) which is a rough confirmation
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of a binary complex formation. Finally, Complexin binding properties to SN25/Syx1A were
investigated by fluorescence anisotropy (figure 4.17 b). Addition of SN25/Syx1A (200 nm)
to CpxOG (80 nm) resulted in no increase in anisotropy which confirmed that Complexin did





























































































































































































Figure 4.17: (a) Validation of complex formation of selected ternary and binary SNARE complexes
by SDS-PAGE (pre-casted 4 % – 12 % gradient gel stained with Coomassie blue). The binary
complex SN25/Syx1A was not SDS-resistant and did not show an upper band on the SDS
gel (lane 3). (b) Fluorescence anisotropy experiment of Complexin binding to binary complex
SN25/Syx1A (black curve) and control experiment with excess unlabelled Complexin (red curve).
(bottom) Scheme of performed Complexin binding reaction. (inset) Rough validation of the
binary complex formation with labelled SNAP-25 (SN25OG) by fluorescence anisotropy.
To conclude, non-binding of Complexin to SNARE complexes containing Syb-2 (28 – 84)
Q58N(Ad) (10) had to base on the modification of position Q58 with admantyl-modified amino
acid due to the following facts:
1. Successful ternary SNARE complex formation including Syb-2 (28 – 84) Q58N(Ad) (10)
was confirmed by SDS-PAGE. An upper band (∼35 – 40 kDa) was observed which had
to be the ternary complex due to the SDS-resistance (figure 4.16 a).
2. Possible non-binding resulting from the presence of only individual SNARE proteins can
be excluded due to the upper band in the SDS gel.
3. Non-binding resulting from the presence of binary complex alone can also be excluded
due to the fact that the binary complex was not SDS-resistant and did not exhibit an
upper band in SDS gels (figure 4.17 a).
Consequently, Complexin did not bind to the SNARE complex containing Syb-2 (28 – 84)
Q58N(Ad) (10) due to the adamantyl-modification. Surprisingly, the position of modification
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Q58N(Ad) was totally inhibiting Complexin binding although it was not found to be a direct
interaction site and was only in close proximity to one (D57).
To summarise, Complexin binding experiments with SNARE complexes containing Syb-2
(28 – 84) wild-type (6), Syb-2 (28 – 84) E55N(Ad), D65N(Ad) (7), or Syb-2 (28 – 84)
Q58N(Ad) (10) were performed and analysed by fluorescence anisotropy (figure 4.18). As
expected, Complexin was binding to the wild-type SNARE complex, but surprisingly also to
complex ∆N/Syb-2(55/65, 7), although the direct interaction site D65 was modified with an
adamantyl moiety. Interestingly, Complexin binding was totally inhibited by SNARE complexes
containing Syb-2 (28 – 84) Q58N(Ad) (10). Complex formation with these derivatives emerged
to be challenging but eventually the appropriate conditions could be determined. In addition,
it was shown that Complexin did not bind to the binary complex SN25/Syx1A or to the ∆N
complex.











































CpxOG + SNARE complex
Figure 4.18: An overview of measured Complexin binding experiments with fluorescence
anisotropy. Corresponding SNARE complexes (200 nm) were added to CpxOG (80 nm). The
addition is indicated by an arrow.
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4.7 Conclusion
The motivation of this study was to validate the properties of adamantyl-modified Synaptobrevin-
2 analogues designed by Dr. A. Groschner.[119] The modification was introduced to develop
an inhibitor for α-SNAP/NSF-mediated disassembly reaction of SNARE complex, and thereby,
acquire further insights into mechanism of this process. Based on identified interaction sites
between α-SNAP and Synaptobrevin-2,[64] suitable sequence positions were chosen for modifi-
cation. A sterically demanding side chain on the surface of SNARE complex was thought to
prevent or at least weaken α-SNAP binding. The admantyl-modified amino acid building block
Fmoc-Asn(Ad)-OH (4)[119] was synthesised for site-specific modification of Synaptobrevin-
2 SNARE motif by solid-phase peptide synthesis. A selection of five previously published
Synaptobrevin-2 derivatives[119] was made based on their affinity to form ternary SNARE
complexes and influences on disassembly reactions, to validate these properties by fluorescence-
based methods. Beside the synthesis strategy with combined automated microwave-assisted
and manual SPPS, the wild-type Synaptobrevin-2 analogue 6 was also successfully synthesised
using only automated microwave-assisted SPPS. For this long peptide sequences (56 amino
acids), purification by HPLC is still challenging. Further improvement in SPPS strategies are
needed to decrease the time-consumption and increase the yields of the syntheses.
Ternary SNARE complexes with the natural counterparts were successfully formed for all
investigated adamantyl-modified Synaptobrevin-2 derivatives. Especially for derivative Syb-2
(28 – 84) Q58N(Ad) (10), complex formation emerged to be challenging, and the appropriate
conditions had to be found. It proved necessary to use detergent-containing buffer (CHAPS,
1 %) and Syntaxin-1A (183 – 288) including the TMD (chapter 4.6.3 and 8.3.6).
To summarise, SNARE assembly properties were investigated with OG-labelled, stabilized ac-
ceptor complexes (∆N complex) consisting of SNAP-25 (1 – 206) no Cys mutant, Syntaxin-1A
(183 – 262), and Synaptobrevin-2 (49 – 96) C79-OG. Upon addition of longer Synaptobrevin-2
sequences, the small fragment will be displaced and ternary SNARE complex is formed rapidly.
With OG-labelled Syb-2 fragment, the displacement can be measured by fluorescence anisotropy
and complex formation can be indirectly monitored.[11] Investigation of SNARE assembly
properties of Syb-2 (28 – 84) wild-type (6) showed that this derivative is comparable to the
normally used soluble Syb-2 (1 – 96). On the other hand, assembly properties of Syb-2 (28 – 84)
E55N(Ad), D65N(Ad) (7) and Syb-2 (28 – 84) Q58N(Ad) (10) showed clear retardation of
complex formation due to the modifications. The adamantyl modifications in these derivatives
were close to the N-terminal end of Syb-2 fragment (49 – 96) and may disturb the displacement
process. Probably, SNARE complex formation using monomers would not be impaired in this
extend.
The formed ternary SNARE complexes containing adamantyl-modified Syb-2 derivatives were
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successfully reconstituted into SUVs by co-micellisation method. Reconstitution was necessary
prior to disassembly experiments, due to the membrane-dependent efficiency of α-SNAP.[59] By
co-floatation assay, successful reconstitution and complex formation was confirmed as well as
rough purification of liposomes was obtained.
Reconstituted SNARE complexes containing Syb-2 derivatives were investigated regarding
their ability to impair α-SNAP binding, and consequently, disassembly reaction mediated
by NSF/ATP. Due to OG-labelled SNAP-25 used for complex formation, α-SNAP binding
was detected by an increase in fluorescence anisotropy, whereas the complex disassembly
was monitored by a decrease in anisotropy. Unfortunately, α-SNAP was able to bind to all
investigated SNARE complexes containing adamantyl modification. Especially, Syb-2 (28 – 84)
Q58N(Ad) (10) had no effect on α-SNAP binding as well as disassembly reaction which was
previously found to be the most promising derivative for inhibitor development.[119] Possible
explanations for these results are: Firstly, even if one binding site for α-SNAP is blocked due
to the modifications, the SNARE complex could be disassembled by NSF with less than three
or four α-SNAPs, like it was shown for the V7-20 S complex.[50, 53] Secondly, the modified
positions in the Synaptobrevin-2 sequence based on a 3/1 stoichiometry of α-SNAP/SNARE
complex,[64] and were thought to cover binding sites of two α-SNAPs. Probably, with four
α-SNAPs binding around the SNARE complex, the modifications may cover only the binding
site of one α-SNAP. Absence of one α-SNAP may be overcome easily by the system.
Previously, investigations of disassembly properties were performed by time-dependent SDS-
PAGE which had a rough time-resolution of ∼5 min. SNARE disassembly reaction was detected
in the range of 10 – 15 min.[119] With this currently performed fluorescence anisotropy mea-
surements, time-resolution was in the range of seconds and fast binding of α-SNAP as well
as fast disassembly by NSF within seconds was observed. Using stopped-flow and higher
amounts of synthesised Synaptobrevin-2 derivatives, rapid kinetics could be measured with
these methods. Gel band intensities were previously used for quantitatively visualising the
influence of modifications on the disassembly reaction.[119] With fluorescence anisotropy clear
determination of α-SNAP binding and disassembly of SNARE complexes was made, due to
distinct and fast increase and decrease in anisotropy, respectively. In addition, fluorescence
anisotropy is not as perturbed by minor changes in concentrations as gel band intensities are.
In conclusion, the results obtained by fluorescence anisotropy are more significant than by
SDS-PAGE and adamantyl modifications had no effect on α-SNAP binding.
Due to suggested competitive binding of α-SNAP and Complexin to the SNARE complex
surface, some adamantyl-modified Synaptobrevin-2 derivatives were investigated regarding
Complexin binding. Using OG-labelled Complexin, binding event was successfully monitored
upon addition of corresponding SNARE complexes by an increase in fluorescence anisotropy. As
expected, Complexin was binding to SNARE complexes containing Syb-2 (28 – 84) wild-type
(6), but also to complexes containing Syb-2 (28 – 84) E55N(Ad), D65N(Ad) (7). The latter
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result is surprising, due to the fact that a direct interaction site with Complexin (D65) is
modified by a sterically demanding and hydrophobic adamantyl moiety. Probably, the interaction
with the neighbouring residues D64 and D68 was able to overcome this disturbance. It would
be interesting to investigate the binding kinetics of Complexin to this modified SNARE complex
due to the fact that already the insertion of alanine mutations (Syb-2 D64A, D65A, D68A)
resulted in ten-fold lower binding affinities of Complexin.[80, 82] Additionally, these residues were
proposed to be the conformational switch region for Complexin to change its accessory α-helix
from open to closed state.[80, 82] Investigation of D65N(Ad) regarding this issue, especially
regarding the binding kinetics, would be interesting.
More importantly, SNARE complexes containing Syb-2 (28 – 84) Q58N(Ad) (10) were totally
inhibiting Complexin binding, although the position of modification was no direct interaction
site and was only in close proximity to one (D57). This derivative exhibited the most problems
with complex formation which might lead to the hypothesis that the position Q58 is crucial
for SNARE zippering, Complexin binding, and might be energetically critical. Previously, it
was suggested as the most promising derivative for α-SNAP inhibition,[119] which was now
found not to be the case, but definitely this modification had an impact on SNARE complex
properties.
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5 Synthesis and Impact on SNARE
Zippering of a Soluble Caged
Synaptobrevin-2 Analogue
The aim of designing a soluble caged Synaptobrevin-2 derivative was to obtain a Synaptobrevin-
2 inactive towards SNARE assembly in the caged state, and upon UV irradiation, reactivation
towards SNARE complex formation. In vesicle fusion assays in vitro, the soluble Synaptobrevin-2
(1 – 96) is used as a competitive inhibitor. It competes with the Synaptobrevin-2 reconstituted
into liposomes for the binding site of the Q-SNARE complex and thereby inhibits vesicle fusion.
It is often used as a control experiment to confirm that the measured vesicle fusion is derived
from SNARE complex assembly (e.g. Park et al.[60]). In addition, resistance against the
inhibitory function indicates presence of already zippered complexes.
For in vivo studies, however, injection of suitable inhibitors needed long incubation times of
10 – 30 min before inhibition was detectable in chromaffin cells[130], probably due to slow
diffusion of the molecules. In the case of soluble Synaptobrevin-2, inhibition and indirect testing
for acceptor complexes needed to occur fast due to the presence of NSF/α-SNAP in vivo which
would quickly dissociate inhibited complexes again.
With a caged version of soluble Synaptobrevin-2, an inactive inhibitor can be injected and
preincubated in the cells, and upon irradiation, a jump in concentration of the active inhibitor
enables an immediate detection of acceptor complexes before disassembly. In addition, a caged
Synaptobrevin-2 derivative which arrests the SNARE complex formation in the middle of the
SNARE motifs, and upon irradiation, zippering is proceeded, gives novel opportunities to study
the process of SNARE zippering. Furthermore, the action of executive and regulatory proteins
like Munc18s, Complexins or Synaptotagmins on arrested SNARE complexes can be investigated.
One successful example for caging was initially developed by Neher & Zucker[113, 114]
in 1993, and in the meantime, the application of caged Ca2+ was well-established for studying
exocytosis in vivo. It provides the advantage of mimicking the jump of Ca2+ concentration as
it would occur upon Ca2+ influx into a nerve terminal.[115] More recently, caged phosphatidyl-
inositol 4,5-bisphosphate (PIP2) was developed by Sørensen et al. for investigation of the
interaction with Synaptotagmin-1 (unpublished results).
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To design a caged soluble Synaptobrevin-2, the following points had to be considered: First
of all, suitable amino acid residues had to be identified for modification with photocleavable
protecting groups. The caged version should prevent complete zippering but ideally exhibit
a partially zippered state. Available studies of Synaptobrevin-2 mutants were investigated
in chapter 5.1 regarding this issue. Second, photoclevable protecting groups can only be
introduced at limited positions. Possible amino acid side chains for a modification are: Asp,
Arg, Cys, Glu, Lys, Ser, Thr, and Tyr. Hence, hydrophobic amino acid residues, mainly
contributing to SNARE complex assembly, are not suitable for attachment of caging groups.
Third, a photoremovable protecting group had to be chosen providing straightforward synthesis
of the corresponding amino acid building block and compatibility with Fmoc-SPPS. Lastly,
the caging groups had to provide fast photocleavage or so-called uncaging properties and UV
absorption λ > 345 nm to be suitable for possible in vivo application.
In chapter 5.2, the final design and synthesis strategy for soluble caged Synaptobrevin-2
will be described as well as the synthesis strategies for the used photocleavable amino acid
building blocks (chapter 5.2.1). After successful synthesis, photocleavage properties were
analysed (chapter 5.2.2 and 5.2.3) and preliminary binding studies regarding SNARE complex
assembly were performed and analysed by fluorescence anisotropy (chapter 5.3).
5.1 SNARE Zippering Studied by Synaptobrevin-2
Mutants
A variety of SNARE zippering studies with Synaptobrevin-2 mutants were performed using
truncated sequences[11, 12, 19] as well as point mutations[14–18]. The former mutants are shown
in figure 5.1 and the latter are summarized in table 5.2.
The zippering studies including truncated Synaptobrevin-2 sequences early revealed the problem
of binary complex formation consisting of Syntaxin-1A/SNAP-25 (2/1). This finding resulted in
development of the stabilized acceptor complex, the so-called ∆N complex, including the Syb-2
(49 – 96) fragment.[11] Zippering processes of various truncated Syb-2 sequences were indirectly
investigated by monitoring labelled Syb-2 (49 – 96) fragment displacement (cf. chapter 4.5.2).
The first study by Pobbati et al.[11] indicated a C -terminal overlap with the fragment was
not sufficient but the N-terminal zippering was necessary for displacement (figure 5.1 a). The
fastest displacement was observed for the whole cytosolic part of Syb-2 (1 – 96). In addition, it
was shown that two non-overlapping fragments bind simultaneously (Syb-2 (1 – 59) and Syb-2
(60 – 96)).[11] A following study by Wiederhold & Fasshauer[12] additionally revealed
that, besides N-terminal zippering, the overlapping region needed to comprise several helix
turns for displacement. Syb-2 (1 – 52) did not exhibit fragment displacement but was shown
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Figure 5.1: Overview of investigated Syb-2 truncated sequences regarding SNARE assembly
properties. (a) Syb-2 (42 – 96), Syb-2 (1 – 65), Syb-2 (1 – 70), and Syb-2 (1 – 96) investigated
by fluorescence anisotropy regarding labelled Syb-2 (49 – 96) fragment displacement of ∆N
complex. Figure used from Pobbati et al.[11] From reference [11]. Reprinted with permission
from AAAS. (b) Syb-2 (1 – 52), Syb-2 (1 – 65), Syb-2 (1 – 87), and Syb-2 (1 – 96) investigated by
fluorescence anisotropy regarding labelled Syb-2 (49 – 96) fragment displacement of ∆N complex.
Figure used from Wiederhold & Fasshauer.[12] (c) Syb-2 (28 – 47), Syb-2 (28 – 50), Syb-2
(28 – 55), Syb-2 (28 – 57), and Syb-2 (28 – 60) investigated by fluorescence anisotropy regarding
concentration-dependent binding to Syntaxin-1A and SNAP-25. Figure modified from Li et
al.[19] This is an unofficial adaptation of an figure that appeared in an ACS publication. ACS has
not endorsed the content of this adaptation or the context of its use.
to bind to the ∆N complex (figure 5.1 b). The comparison of SNARE complexes containing
Syb-2 (1 – 52)/Syb-2 (49 – 96) and Syb-2 (1 – 59)/Syb-2 (60 – 96), respectively, revealed a
higher stability in the longer C -terminal portion for the former resulting in easier dissociation of
the N-terminal part. In the second case, the C -terminal Syb fragment was able to dissociate
reversibly. In contrast, binding of Syb-2 (71 – 96) to a so-called ∆C complex containing Syb-2
(1 – 70) exhibited only low affinity analysed by ITC indicating that the N-terminal zippering
plays a more important role than the C -terminal part.[12]
A third study by Li et al.[19] investigated the binding properties of N-terminal Syb-2 fragments
to Syntaxin-1A and SNAP-25 (figure 5.1 c). A dramatic reduction in binding affinity was
observed for Syb-2 (28 – 47) and Syb-2 (28 – 50), whereas longer fragments exhibited higher
affinities. The authors suggested a crucial function of the region around layer −1 (residue
53) for SNARE zippering. In addition, N-terminal Syb-2 fragments pre-bound to Syntaxin-
1A/SNAP-25 and reconstituted into liposomes were investigated regarding their activation
properties in liposome fusion assays with liposomes containing C -terminal Syb-2 fragments.
In more detail, Syb-2 (60 – 116) was reconstituted into liposomes and mixed with liposomes
containing Syntaxin-1A/SNAP-25 with or without pre-bound N-terminal Syb-2 fragments.
Without pre-bound Syb-2 fragment, no fusion was observed, indicating that the N-terminal
zippering is necessary to trigger the C -terminal assembly and enable fusion. With pre-bound
Syb-2 (28 – 55) or Syb-2 (28 – 57) activation of the complex for fusion was observed, whereas
Syb-2 (28 – 44), Syb-2 (28 – 47), or Syb-2 (28 – 50) did not exhibit any activation. These
results suggested that the N-terminal zippering needed to reach approximately layer −1 to
enable the whole SNARE complex machinery for fusion. Hence, the middle layers represent a
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crucial part for SNARE complex assembly.[19]
Syb mutant Layer Effect on Assembly Effect on exocytosis




I45A -3 slight defect
M46A -3 slight defect
V39A, V42A -5/-4 almost no effect
L32A, T35A -7/-6 almost no effect
R56Q 0 - no effect
R56A/R56P 0 almost no effect no effect
no rescue 
rescue up to 20 %








-7         -6            -5        -4           -3         -2            -1     0 1       2          3        4           5        6         7       8
H-SNRRLQQTQAQVDEVVDIMRVNVDKVLERDQKLSELDDRADALQAGASQFETSAAKL-OH
28       32 84
L70A +4 - no rescue 
Table 5.2: Summary of Synaptobrevin-2 point mutation studies regarding SNARE complex
formation and effect on exocytosis. SNARE assembly properties of Syb-2 (1 – 96) N49A, V50A,
Syb-2 (1 – 96) I45A, M46A, Syb-2 (1 – 96) I45A, and Syb-2 (1 – 96) M46A[17] as well as
Syb-2 (1 – 96) V39A, V42A, Syb-2 (1 – 96) L32A, T35A, Syb-2 (1 – 96) L70A, Syb-2 (1 – 96)
F77A[16] and Syb-2 (1 – 96) ∆84[18] were investigated by fluorescence anisotropy using ∆N
complex including labelled Synaptobrevin-2 (49 – 96) fragment. In addition, several mutants
were investigated in vivo by rescue experiments using double knockout (Syb-2/Cellubrevin)
mice chromaffin cells. The most pronounced effect showed double mutation of layer −3 (Syb-2
(1 – 96) I45A, M46A).[17] The effect of Synaptobrevin-2 (1 – 116) R56Q on exocytosis was
investigated using rescue experiments in cultured Syb-deficient neurons and exhibited comparable
rescue properties as the wild-type.[15] Investigations of Synaptobrevin-2 (1 – 116) R56A and
Synaptobrevin-2 (1 – 116) R56P showed almost no effect on SNARE assembly in vitro analysed
by fluorimetry as well as in vivo analysed by immunoprecipitation of cell lysates from HeLa
cells.[14]
In most of the point mutation studies, alanine mutants were investigated due to alanine’s small
and hydrophobic side chain preventing strong impairments of the ternary SNARE complex
stability.[17] Especially, alanine mutations in layer −2 and −3 of the Synaptobrevin-2 SNARE
motif were investigated due to highly conserved residues among R-SNAREs. Indeed, these
mutants exhibited disturbed SNARE complex assembly analysed by fluorescence anisotropy
using ∆N complexes containing labelled Syb-2 (49 – 96) fragment. Specifically, Syb-2 (1 – 96)
I45A, M46A showed the most pronounced defect in Syb-2 fragment displacement of all tested
mutants as well as no rescue of neurotransmitter release by overexpression in double knockout
(Syb-2/Cellubrevin) mice chromaffin cells. In addition, the double mutant Syb-2 (1 – 96) N49A,
V50A exhibited also a clearly retarded Syb-2 fragment displacement which both indicated a
so-called "trigger site" for coiled coil formation between layer −2 and −4.[17] These results were
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at least partially consistent with the truncated sequences suggesting layer −1 to be critical.[19]
In contrast, double mutations of layer −5/−4 (Syb-2 (1 – 96) V39A, V42A) and layer −7/−6
(Syb-2 (1 – 96) L32A, T35A) exhibited almost comparable SNARE assembly properties as the
wild-type and also partially rescued neurotransmitter release in double knockout chromaffin
cells. Interestingly, single mutants of layer +4 (Syb-2 (1 – 116) L70A) and layer +6 (Syb-2
(1 – 116) F77A) exhibited both dramatic effects on exocytosis in chromaffin cells but with the
latter comparable SNARE assembly properties like the wild-type.[16]
The deletion mutant of layer +8 (Syb-2 (1 – 116) ∆84) showed the same complex formation
properties as wild-type Syb-2 but was found to prevent fusion of large liposomes in vitro and
arrested them in a docked state. Hence, complete zippering of the SNARE motifs was possible
with this mutant but to induce fusion further zippering of the linker and transmembrane regions
was concluded to be necessary[18]
Surprisingly, mutations of the highly conserved zero layer exhibited almost no effect in vitro as
well as in vivo.[14, 15]
To summarize, modifications with photocleavable protecting groups should be localised in the
middle of the SNARE motif from layer −1 to +1 to impair SNARE zippering. Especially, layer
−1 was shown to exhibit a critical function. Regarding the pronounced effect of layer −3 double
mutant Syb-2 I45A, M46A on SNARE assembly[17], these positions would presumably perfectly
impair SNARE zippering, but unfortunately Ile and Met are not suitable for caging group
attachment. The same was true for the double mutant of layer −2 (Syb-2 N49A, V50A)[17]
with Asn possible accessible for caging but Val not. Single modification of Asn would probably
reduce impairment of SNARE zippering. Consequently, residues directly participating in the
layer formation of SNARE complex cannot be modified with photocleavable protecting groups
due to their hydrophobic side chains. The only exception comprises the hydrophobic zero layer.
Hence, neighbouring residues contributing to coiled coil formation by electrostatic interactions
need to be addressed for modification.
5.2 Design and Synthesis of Soluble Caged
Synaptobrevin-2
The synthesis of the whole cytosolic part of Synaptobrevin-2 (1 – 96) is too long for SPPS. Con-
sequently, it was focused on synthesis of the SNARE motif (28 – 84). If necessary, elongation
could be performed by suitable ligation strategies. According to the Synaptobrevin-2 mutation
studies described in the previous chapter, three possible regions within the Synaptobrevin-2
SNARE motif might be suitable for modification with caging groups to prevent or at least impair
SNARE zippering: layer −2/−3, layer −1 to +1, or layer +6. Due to the fact that the hydropho-
bic residues directly participating in layer formation are not available for caging (except for the
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Scheme 5.3: Helical-wheel of a parallel coiled
coil dimer including a heptad repeat of amino
acids labelled from a to g. Main interactions are
represented by the hydrophobic a/d interfaces
(green) and the hydrophilic e/g interface (yel-
low). Scheme modified from Robsen Mars-
den & Kros.[131] © 2010 Wiley-VCH Verlag
GmbH & Co. KGaA, Weinheim.
The main interaction interfaces in a parallel
coiled coil dimer are represented, which can also
be transferred to a parallel tetramere as it is
the case for the ternary SNARE complex. The
hydrophobic a/d interfaces form the core of the
coiled coil, whereas mainly charged residues con-
tribute to the e/g interface by electrostatic inter-
actions. Exactly the latter residues are accessible
for modification with photocleavable protecting
groups and represent a possible approach for
soluble caged Synaptobrevin-2. Based on the
mutation studies and the helical-wheel analysis,
possible modification positions are summarized
and categorised in three regions in scheme 5.4. Region I. comprises layer −3/−2 which
exhibited most pronounced effects in the alanine mutation studies. Nevertheless, in this region
no suitable position for caging was found. Modification of M46 to a caged Cys residue and
N49 to a caged Asp would be a compromise but the M46A single mutant exhibited only a
slight defect in SNARE assembly experiments. Additional mutation of directly neighbouring
residues was shown to be crucial within these layers but is not possible with photocleavable
protecting groups. Region III. comprises layer +6/+7 and three possible modifcation positions:
F77, E78, and S80. The single mutant F77A exhibited no effect on SNARE assembly but
dramatic reduction in exocytosis which indicated normal SNARE zippering until layer +6 but
impairments in mediating fusion. Hence, these positions are not suitable to obtain a soluble
caged Synaptobrevin-2 exhibiting partial SNARE zippering but would arrest SNARE complexes
in a docked state. Lastly, region II. comprises layer −1 to +1 and is located approximately
in the middle of the SNARE motif. Possible modification positions are: K52, R56, D57, and
K59. Including the hydrophilic zero layer, this region includes four residues for photocleavable
protecting groups and will be used for synthesis of a soluble caged Synaptobrevin-2 (28 – 84)
K52K*, R56R*, D57D*, K59K* derivative.
-7         -6            -5        -4           -3         -2            -1     0 1       2            3          4             5         6          7        8
H-SNRRLQQTQAQVDEVVDIMRVNVDKVLERDQKLSELDDRADALQAGASQFETSAAKL-OH
28         32 84
da ae gg d e gdag
I. II. III.
Scheme 5.4: Suitable regions of amino acid residues for modification of Synaptobrevin-2 (28 –
84) SNARE motif. Modification positions are categorised into three regions (I., II., III.) and
coiled coil residues are labelled according to their contribution to the a/d (green) or e/g (yellow)
interface. The hydrophobic layers contributing to SNARE complex coiled coil are highlighted and
labelled in blue.
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For synthesis of the caged Syb-2 derivative, amino acid building blocks bearing photocleav-
able protecting groups at the side chains suitable for Fmoc-SPPS had to be synthesised
(chapter 5.2.1). To test the properties of these building blocks, short test peptide sequences
were synthesised and analysed regarding synthesis performance and photocleavage properties
(chapter 5.2.2). Building blocks which passed these tests were used for synthesis of final caged
Synaptobrevin-2 derivative (chapter 5.2.3), and photocleavage as well as binding properties to
∆N complexes were investigated (chapter 5.3).
5.2.1 Synthesis of Photocleavable Amino Acid Building Blocks
Due to the straightforward syntheses in few steps and UV absorption >345 nm, 6-Nitroveratryl-
oxycarbonyl (Nvoc) was chosen as PPG for the amino acid building blocks. The simple synthesis
and convenient handling outweigh the disadvantages of this caging group as it is used in this
work as a proof of principle and to acquire experiences with caged compounds. For the synthesis
of soluble caged Synaptobrevin-2 (28 – 84) K52K*, R56R*, D57D*, K59K* the following
amino acid building blocks are required: Fmoc-Lys(Nvoc)-OH, Fmoc-Arg(Nvoc)-OH and
Fmoc-Asp(Nvoc)-OH. Synthesis strategies for Fmoc-Lys(Nvoc)-OH[132] (16), Fmoc-Asp(Nvoc)-
OH[133] and Arg(Nvoc)[134] were already published. Nevertheless, Asp(Nvoc) was shown to
be unstable under SPPS conditions[90] leading to development of the 3-(4,5-dimethoxy-2-
nitrophenyl)-2-butyl (DMNPB) moiety as caging group for aspartic (Fmoc-Asp(DMNPB)-OH
(27)) and glutamic acid.[107, 135] Arg(Nvoc) was generated by incubation of Orn side chains
within the peptide sequence with a so-called guanylating agent to obtain the caged amino
acid.[134] In this work, the synthesis strategy was transferred to obtain Fmoc-Arg(Nvoc)-OH
(21). The synthesised caged amino acid building blocks are summarized in scheme 5.5 and in





































Scheme 5.5: Caged amino acid building blocks needed for synthesis of soluble caged Syb-
2: Fmoc-Lys(Nvoc)-OH (16, K(Nvoc))[132], Fmoc-Arg(Nvoc)-OH (21, R(Nvoc)) and Fmoc-
Asp(DMNPB)-OH (27, D(DMNPB)).[107, 135]
Synthesis of Fmoc-Lys(Nvoc)-OH (16)
In the published procedure[132], Fmoc-Lys(Nvoc)-OH (16) was obtained by a two-step synthesis
starting from 6-nitroveratrylalcohol (NV-OH, 12) via generation of 6-nitroveratryl chloroformate
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Scheme 5.6: Synthesis procedure of the caged Lysine building block Fmoc-Lys(Nvoc)-OH
(16).[132, 136, 137]
(Nvoc-Cl) and finally substitution by addition of Fmoc-Lys-OH (15) to obtain the target
compound (scheme 5.6). For the first step, solution of phosgene in toluene was used in
the literature, which was tried to substitute by slightly less toxic triphosgene/triethylamine in
THF[136] in this work, but without success. As an alternative, activation of 6-nitroveratrylalcohol
(12) was obtained by addition of p-nitrophenyl chloroformate (p-NPCl, 13) and DIPEA in
DCM to obtain 6-nitrovertaryl-4’-nitrophenyl carbonate (14).[137] Finally, under slightly basic
conditions using NaHCO3, substitution with commercially available Fmoc-Lys-OH (15) in
dioxane/MeCN/H2O (1/1/1, v/v/v) successfully lead to the target compound Fmoc-Lys(Nvoc)-
OH (16, K(Nvoc)) in good yields (76 %, chapter 8.7.1).





















































14 17 "guanylating agent" (18)
18
Scheme 5.7: Synthesis procedure of the caged arginine building block Fmoc-Arg(Nvoc)-OH
(21).[134, 137]
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The caged arginine amino acid building block was obtained by adapting the published
procedure[134] to the synthesis of a Fmoc building block (scheme 5.7). Originally, the synthe-
sis strategy started from Nvoc-Cl which was also changed to the alternative compound 14.
Substitution with S-methylisothiourea semisulfate (17) under basic conditions using NaOH
(4 n) in DCM yielded the corresponding "guanylating agent" 18 in moderate yields (60 %).
Previous to the next step, Fmoc-Orn(Boc)-OH (19) was deprotected using TFA/DCM (1/1,
v/v) to obtain Fmoc-Orn-OH (20) in high yields (99 %).[138] The side chain of compound
20 was substituted with the "guanylating agent" 18 under basic conditions using 2,6-lutidine
in DMF yielding the target compound Fmoc-Arg(Nvoc)-OH (21, R(Nvoc)) (chapter 8.7.2).
Due to concerns regarding the TFA stability of this building block, a small amount of 21 was
stirred for 2 h in TFA and afterwards analysed by TLC and ESI-MS. No instability towards
TFA was detected.
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Scheme 5.8: Synthesis procedure of the caged aspartic acid building block Fmoc-Asp(DMNPB)-
OH (27).[107, 135]
The caged aspartic acid building block was obtained by a published procedure[107, 135] in five
steps (scheme 5.8). Starting from 3,4-dimethoxyphenylacetone (22) which was methylated
using sodium hydride and methyl iodide in THF, 3-(3,4-dimethoxyphenyl)-butan-2-one (23)
was obtained in excellent yields (99 %). Reduction of ketone 23 to the alcohol 3-(4,5-
dimethoxphenyl)-butan-2-ol (24) was achieved using sodium borohydride in THF/2-propanol
and subsequent addition of HCl (1 n), leading to a erythro/threo (1/2) mixture of the target
compound 24. Nitration in ortho-position was obtained using nitronium tetrafluoroborate and
2-picoline in MeCN, yielding 3-(4,5-dimethoxy-2-nitrophenyl)-butan-2-ol (25). Esterification
of alcohol 25 and the unprotected side chain of Fmoc-Asp-OtBu (1) by activation with
N,N’-dicyclohexylcarbodiimide (DCC) and 4-dimethylaminopyridine (DMAP) resulted in the
tert-butyl protected caged amino acid Fmoc-Asp(DMNPB)-OtBu (26) in good yields (77 %).
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In the final step, deprotection of C -terminal tert-butyl ester was achieved by addition of
TFA/DCM (1/1, v/v) and the target compound Fmoc-Asp(DMNPB)-OH (27, D(DMNPB))
was obtained in good yields (73 %, 11 % over five steps) (chapter 8.7.3).
5.2.2 Synthesis and Photocleavage of Caged Test Peptides 28 – 31
Short Synaptobrevin-2 sequences including caged amino acid building blocks were synthesised
by SPPS to test the synthesis performance and photocleavage properties of the caging groups.
Synthesis of Caged Test Peptides 28 – 31
The following test sequences were synthesised by manual SPPS (chapter 8.4.1): Syb-2 (54 –
60) R56R(Nvoc) (28), Syb-2 (54 – 60) K59K(Nvoc) (29), Syb-2 (51 – 60) K52K(Nvoc),
K59K(Nvoc) (30), and Syb-2 (54 – 60) D57D(DMNPB) (31). The non-caged sequences
Syb-2 (54 – 60) (32), Syb-2 (51 – 60) (33) were additionally synthesised for compari-
son (table 5.9, chapter 8.8.1). Due to the high hydrophobicity of the caging groups, it
was avoided to synthesize a test peptide including three caged amino acid building blocks.
Table 5.9: Overview of synthesised caged test peptides

























The caged arginine-containing peptide
sequence (28) was synthesised us-
ing a batch size of 25 µmol on a
preloaded Fmoc-Leu-Wang resin LL
(0.32 mmol/g). Single coupling was per-
formed with a reaction time of 30 min
(45 min for Fmoc-Arg(Nvoc)-OH (21))
and successful coupling was checked by
performing Kaiser test (chapter 8.4.4).
After complete synthesis, the peptide
was cleaved from the resin, completely
deprotected by a TFA cleavage mix-
ture (chapter 8.4.3) and purified by RP-
HPLC.
For the caged lysine-containing peptide sequences, the synthesis strategy was the following:
Firstly, the short sequence Syb-2 (54 – 60) K59K(Nvoc) (29) was synthesised using a batch
size of 50 µmol on a preloaded Fmoc-Leu-Wang resin LL (0.32 mmol/g). Single coupling was
performed with a reaction time of 30 min (45 min for Fmoc-Lys(Nvoc)-OH 16) and successful
coupling was checked by performing Kaiser test. After complete synthesis, the resin was
divided into two portions: From portion 1, the peptide was cleaved, completely deprotected by
a TFA cleavage mixture and purified by RP-HPLC. Portion 2 was used for further synthesis of
Syb-2 (51 – 60) K52K(Nvoc), K59K(Nvoc) (30) in a batch size of ∼25 µmol using the same
conditions as before.
The caged aspartic acid-containing peptide sequence 31 was synthesised using a batch size of
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25 µmol on a preloaded Fmoc-Leu-Wang resin LL (0.32 mmol/g). Just as previously, single
coupling was performed with a reaction time of 30 min (45 min for Fmoc-Asp(DMNPB)-OH
27) and successful coupling was checked by performing Kaiser test. After complete synthesis,
the peptide was cleaved from the resin, completely deprotected by a TFA cleavage mixture and
purified by RP-HPLC.
The non-caged sequences Syb-2 (54 – 60) (32) and Syb-2 (51 – 60) (33) were synthesised using
the same strategy as for the two caged lysine-containing peptides 29 and 30 but with applying
Fmoc-Lys(Boc)-OH instead of Fmoc-Lys(Nvoc)-OH (16) at the corresponding positions.
All peptides were successfully obtained except for Syb-2 (54 – 60) R56R(Nvoc) (28). After
purification by RP-HPLC, a compound was obtained with a difference of mass to charge ratio of
∆m
z
= −50 according to ESI-MS which could not be assigned to a possible truncated sequence
or other side products. A possible TFA instability of Fmoc-Arg(Nvoc)-OH (21) was excluded
previously. Due to this result, two test reactions were performed using Fmoc-Gly-Wang-resin
LL (0.36 mmol/g) in a batch size of 30 µmol each and coupled with Fmoc-Arg(Nvoc)-OH










































































Scheme 5.10: Test reactions investigating stability of Fmoc-Arg(Nvoc)-OH (21) under standard
Fmoc-SPPS conditions.
Reaction 1 was performed by deprotection, coupling and cleavage steps, whereas reaction 2
comprised deprotection, coupling, deprotection and cleavage steps. After analytical RP-HPLC
no product was detectable by ESI-MS and due to the overall very low yield, especially for
reaction 2, NMR spectroscopy was not possible. These results led to the hypothesis, that the
building block Fmoc-Arg(Nvoc)-OH (21) might be stable under cleavage conditions, but is
probably unstable under coupling and/or deprotection conditions. A second possibility was
that the products of the test reactions were soluble in cold diethylether and were therefore
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not precipitated by ether precipitation. Nevertheless, the consequence was that building block
21 was not suitable for Fmoc-SPPS and could not be used for the synthesis of caged soluble
Synaptobrevin-2.
Analysis of Test Peptides 29 – 31 by UV/Vis Spectroscopy
The successfully synthesised test peptides Syb-2 (54 – 60) K59K(Nvoc) (29), Syb-2 (51 – 60)
K52K(Nvoc), K59K(Nvoc) (30), and Syb-2 (54 – 60) D57D(DMNPB) (31) were investigated
by UV/vis spectroscopy using the NanoDrop 2000c spectrophotometer from Thermo Fisher
Scientific (figure 5.11). The main absorption was observed between 190 – 260 nm which is
also based on the peptide backbone absorption (figure. 5.11 inset). Two additional absorption
maxima were observed for all three test peptides between 275 – 400 nm with the following
wavelength maxima: Syb-2 (54 – 60) K59K(Nvoc) (29) 300 nm and 347 nm, Syb-2 (51 – 60)
K52K(Nvoc), K59K(Nvoc) (30) 303 nm and 353 nm, Syb-2 (54 – 60) D57D(DMNPB) (31)
304 nm and 348 nm, respectively. These data supported the suitability of these caging groups
for photocleavage at λ > 345 nm. Interestingly, a red shift was observed for modification
with two Lys(Nvoc) in comparison to one Lys(Nvoc). In addition, the DMNPB caging group
exibited a slightly more red shifted absorption maxima than Nvoc.















UV/vis spectra of caged testpepdes 29 - 31
















 Syb-2(54-60) K59K* (29)
 Syb-2(51-60) K52K*, K59K* (30)
 Syb-2(54-60) D57D* (31)
Figure 5.11: UV/vis absorption spectra (260 – 450 nm) of caged test peptides 29 – 31 (500 µm)
in H2O/MeCN (9/1, v/v) and H2O/MeCN (1/1, v/v) for 30, respectively. (inset) UV/vis
absorption spectra 200 – 450 nm.
Photocleavage Properties of Test Peptides 29 – 31
For investigating the photocleavage properties of the caged test peptides 29 – 31, the peptides
were solved in H2O/MeCN (9/1, v/v, for 29 and 31; 1/1, v/v, for 30) and diluted to 10 µm.
This concentration represented the highest possible dilution which was still detectable by HPLC.
Each sample (500 µL) was transferred to a quartz cuevette and irradiated by a mercury UV
lamp from Newport equipped with a mirror filter (280 – 460 nm) and set to 650 W for the
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corresponding times (30 s – 180 s). Directly after irradiation, the sample was injected and
analysed by analytical RP-HPLC. The obtained HPLC chromatograms are summarized in figure
5.12.








































































































 Syb-2 (54-60) (32)




d  Non-caged testpep!des 32 and 33
Figure 5.12: Photocleavage experiments of (a) Syb-2 (54 – 60) K59K(Nvoc) (29), (b) Syb-2
(51 – 60) K52K(Nvoc), K59K(Nvoc) (30), and (c) Syb-2 (54 – 60) D57D(DMNPB) (31), 10 µm
each, analysed by analytical RP-HPLC after irradiation for corresponding times (UV traces at
215 nm). (d) Analytical RP-HPLC chromatograms of non-caged test peptides Syb-2 (54 – 60)
(32) and Syb-2 (51 – 60) (33) for comparison of retention times. HPLC gradient: 10 – 60 % B
in 30 min.
All three test peptides were successfully uncaged with this method. The corresponding peak of
the caged peptide (cPep) decreased with increasing irradiation times, whereas a peak emerged
with a similar retention time as the non-caged peptide. For investigation at which irradiation
time a complete photocleavage of the caging groups was obtained, the UV traces were analysed
according to the proportion of caged peptide in the sample. Therefore, the corresponding
HPLC peaks of the caged peptide were integrated and expressed in percentage to the peak
area of the caged peptide at 0 s (table 5.13).
Almost complete photocleavage was obtained after 180 s for Syb-2 (54 – 60) K59K(Nvoc)
(29), after 120 s for Syb-2 (51 – 60) K52K(Nvoc), K59K(Nvoc) (30), and most pronounced
already after 90 s for Syb-2 (54 – 60) D57D(DMNPB) (31). Consequently, the DMNPB
caging group exhibted faster photocleavage compared to Nvoc, and in addition, with two Nvoc
groups considerably more side products were detected (figure 5.12 b).
In summary, Fmoc-Lys(Nvoc)-OH (16) and Fmoc-Asp(DMNPB)-OH (27) were proved suit-
able for synthesis of soluble caged Synaptobrevin-2 for preliminary experiments in vitro. For
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Table 5.13: Proportion of caged peptide for corresponding photocleavage experiments of Syb-2
(54 – 60) K59K(Nvoc) (29), Syb-2 (51 – 60) K52K(Nvoc), K59K(Nvoc) (30), and Syb-2
(54 – 60) D57D(DMNPB) (31). Proportions were determined by intergration of corresponding

































applications in vivo, usage of a different caging groups with faster photocleavage properties in
the range of milliseconds to seconds should be considered.
5.2.3 Synthesis Strategy and Photocleavage of Soluble Caged
Synaptobrevin-2 (28 – 84) (36)
The original design of soluble caged Synaptobrevin-2 (28 – 84) K52K*, R56R*, D57D*, K59K*
had to be adapted to the obtained results from syntheses and photocleavage experiments of the
caged test peptides. Due to the incompatibility of the building block Fmoc-Arg(Nvoc)-OH (21)
to Fmoc-SPPS conditions, it was not possible to modify position R56. Therefore, it was decided
to synthesize Syb-2 (28 – 84) K52K(Nvoc), D57D(DMNPB), K59K(Nvoc) (36). The following
synthesis strategy was applied: First, the C -terminal part Syb-2 (61 – 84) (34, chapter 8.8.2)
was synthesised by automated, microwave-assisted SPPS using the CEM LibertyBlue peptide
synthesizer according to GSP 2 (chapter 8.4.2). Second, the synthesis was continued under
light-exclusion by manual SPPS according to GSP 1 (chapter 8.4.1), including double coupling
and elongated coupling times (2 x 45 min) for the caged amino acid building blocks 16 and 27,
to obtain Syb-2 (51 – 84) K52K(Nvoc), D57D(DMNPB), K59K(Nvoc) (35, chapter 8.8.3).
The last part of the sequence was again synthesised by automated, microwave-assisted SPPS
using the CEM LibertyBlue peptide synthesizer to obtain the target peptide 36 (chapter 8.8.4).
After each synthesis segment, a test cleavage of the resin-bound peptide was performed and
synthesis performance analysed by analytical RP-HPLC (figure 5.14).
As expected, the synthesis performance decreased the longer the peptide sequence and lower
synthesis performance for the caged amino acid building blocks was observed. Nevertheless,
after complete synthesis a huge tendency to peak broadening was detected which might
result from possible aggregation of the peptide due to the highly hydrophobic caging groups.
In fact, the caging groups had an impact on solubility: Whereas the adamantyl-modified
Synaptobrevin-2 derivatives (6 – 11) were easily soluble in H2O/MeCN (9/1, v/v), the caged
soluble Synaptobrevin-2 36 was hardly soluble in H2O/MeCN (1/1, v/v). Retrospectively, the
usage of the new peptide synthesizer CEM LibertyBlue was faster, on the one hand, but on
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H-SNRRLQQTQAQVDEVVDIMRVNVDKVLERDQKLSELDDRADALQAGASQFETSAAKL-OH
28        32 40 50  60 70 84













































































































































Syb-2 (61-84)Syb-2 (51-84) K52K*, D57D*, K59K* Syb-2 (28-84) K52K*, D57D*, K59K* 
Figure 5.14: Synthesis strategy of soluble caged Synaptobrevin-2 (36) divided into three segments:
Syb-2 (61 – 84) (34, green), Syb-2 (51 – 84) K52K(Nvoc), D57D(DMNPB), K59K(Nvoc) (35,
blue), and Syb-2 (28 – 84) K52K(Nvoc), D57D(DMNPB), K59K(Nvoc) (36, purple). (bottom)
Analytical RP-HPLC chromatograms of the test cleavages after each segment.
the other hand, the missing capping step in the synthesis protocol was a serious disadvantage.
Especially for the N-terminal part of the synthesis, with possible lesser synthesis performance
due to aggregation, this seemed to be crucial for better purification results. Purification of a 56
amino acid long peptide was always challenging, but unfortunately, with additional aggregation,
this problem could not be solved by RP-HPLC even with elution at higher temperature (60 °C).
Due to time limitations and small amounts, it was tried to purify the peptide only crudely
to perform preliminary photocleavage as well as binding experiments. Regarding the high
hydrophobicity of the peptide 36, introduction of less than three and/or more hydrophilic
caging groups should be considered for further applications.
Photocleavage Experiments of Soluble Caged Synaptobrevin-2 (36)
























Figure 5.15: Photocleavage experiments of soluble caged Syb-2 (28 – 84) K52K(Nvoc),
D57D(DMNPB), K59K(Nvoc) (36, 20 µm), analysed by analytical RP-HPLC after irradia-
tion for corresponding times (UV traces at 215 nm). For comparison, UV trace of Syb-2 (28 – 84)
wild-type (6, purple). HPLC gradient: 20 – 80 % B in 30 min, room temperature.
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Preliminary photocleavage experiments were performed with the crude peptide 36 using the
same protocol as for the caged test peptides 29 – 31. The peptide 36 was solved in H2O/MeCN
(1/1, v/v) and diluted to 20 µm with H2O/MeCN (9/1, v/v). The sample (200 µL) was
transferred to a micro quartz cuvette and irradiated with the mercury UV lamp at 650 W for
the corresponding times. Directly after irradiation, the samples were injected and analysed by
analytical RP-HPLC (figure 5.15). The crude peptide 36 at 0 s already exhibited a broad peak
due to the insufficient purity. With increasing irradiation times, peak broadening increased
and shifted to higher polarities, as expected upon cleavage of hydrophobic caging groups.
Nevertheless, a distinct peak for the uncaged peptide was not detectable. The proportion of
caged peptide for the corresponding times was not possible to investigate due to the huge peak
broadening.
5.3 Binding Studies of Soluble Caged Synaptobrevin-2
(28 – 84)
Despite the non-satisfactory purity and results of the photocleavage experiments, binding
properties of soluble caged Syb-2 (28 – 84) K52K(Nvoc), D57D(DMNPB), K59K(Nvoc) (36)
to the ∆N complex were investigated by fluorescence anisotropy. As already described in
chapter 4.5.2, a soluble, truncated SNARE complex consisting of Syntaxin-1A (183 – 262),
SNAP-25 (1 – 206) no Cys mutant, and Synaptobrevin-2 (49 – 96) C79-OG, was used as
stabilized acceptor complex. SNARE complex formation properties can be measured indirectly
by displacement of the labelled Syb-2 fragment.[11, 18, 60]
Prior to the binding experiments, samples (100 µL) of caged Syb-2 36 in H2O/MeCN (9/1, v/v)
were irradiated with the mercury UV lamp in a micro quartz cuvette for the corresponding times,
and afterwards, transferred to Eppendorf tubes, frozen in liquid nitrogen and transported
on ice.
Binding experiments were performed in detergent-containing HEPES buffer, starting with
∆NOG (80 nm) and addition of corresponding caged Syb-2 sample (125 nm) after ∼100 s
(chapter 8.3.9). A second addition was performed after ∼600 s (fc. 200 – 250 nm). For
comparison, binding of Syb-2 (28 – 84) wild-type 6 was performed under the same conditions.
As anticipated, caged soluble Syb-2 (28 – 84) K52K(Nvoc), D57D(DMNPB), K59K(Nvoc)
(36) did not bind to the labelled ∆NOG complex as no significant decrease in anisotropy was
observed (figure 5.16 red curve). Unfortunately, for the irradiated samples of peptide 36, also
no binding was detected as all samples exhibited the same curve shape. Hence, photocleavage
was not possible due to the insufficient purity of the peptide. The latter might have also
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Syb-2 (28-84) K52K(Nvoc), D57D(DMNPB), K59K(Nvoc) (36)
Syb-2 X
Syb-2 X
Figure 5.16: Binding experiments of ∆NOG complex and soluble caged Syb-2 (28 – 84)
K52K(Nvoc), D57D(DMNPB), K59K(Nvoc) (36) irradiated for corresponding times (0 s (red),
30 s (blue), 60 s (green), 90 s (purple), and 120 s (orange)) in detergent-containing HEPES
buffer. For comparison, binding experiment of ∆NOG and Syb-2 (28 – 84) wild-type (6) (black)
performed under the same conditions. First addition of Syb-2 derivatives (125 nm) to the
OG-labelled ∆N complex (80 nm) was conducted after ∼100 s, followed by a second addition of
Syb-2 derivatives (fc. 200 – 250 nm) after ∼600 s (except for 6). Additions are indicated by
arrows. Labelled Syb-2 fragment displacement was traced by the decrease in anisotropy.
contributed to prevention of binding due to truncated and/or defective sequences within the
samples. In addition, in a crude peptide sample more unexpected and unwanted side products
could be produced by irradiation and photocleavage. Hence, the purification problem of soluble
caged Synaptobrevin-2 needs to be solved prior to further applications.
5.4 Conclusion
The motivation of these investigations was to design and synthesise a soluble caged Synaptobrevin-
2 derivative inactive towards SNARE complex zippering, but reactivated upon irradiation.
Following the application of caged Ca2+ for in vivo exocytosis investigations, the caged
Synaptobrevin-2 should be tested first in vitro but also be applicable for in vivo studies. To
design a modified Synaptobrevin-2 analogue with these properties, Synaptobrevin-2 mutant
studies were investigated to identify suitable residues for attachment of photocleavable protect-
ing groups. The limitations of suitable amino acid side chains for so-called caging led to the
design of caged soluble Syb-2 (28 – 84) K52K*, R56R*, D57D*, K59K*.
As caging group, the 6-nitrovertryloxycarbonyl (Nvoc) moiety was chosen due to the straight-
forward synthesis protocols of corresponding caged amino acid building blocks comprising
91
5 Synthesis and Impact on SNARE Zippering of a Soluble Caged Synaptobrevin-2 Analogue
only few synthesis steps and UV absorption λ > 345 nm. The caged amino acid building
blocks Fmoc-Arg(Nvoc)-OH (21) and Fmoc-Lys(Nvoc)-OH (16) were synthesised based on
previously published synthesis protocols.[132, 134, 137] For aspartic acid, Fmoc-Asp(DMNPB)-OH
(27) was synthesised due to instability of Asp(Nvoc) under SPPS conditions.[90, 107, 135] The
synthesised caged amino acid building blocks were successfully incorporated into short test
peptide sequences (29 – 31) by SPPS, except for Fmoc-Arg(Nvoc)-OH (21) which was
identified as unstable under SPPS conditions. Nevertheless, UV/vis absorption spectra of test
peptides 29 – 31 were measured as well as photocleavage experiments were performed. All
test sequences exhibited absorption maxima λmax > 345 nm, and were therefore suitable for
possible in vivo experiments. Interestingly, incorporation of two Lys(Nvoc) modifications in
one sequence led to a red shift in absorption maxima. Fastest photocleavage was observed for
Asp(DMNPB)-containing peptide 31 after 90 s of irradiation at 650 W. However, for in vivo
application complete photocleavage in the time scale of milliseconds to seconds is required.
For application of soluble caged Synaptobrevin-2 in vivo, it is necessary to use caging groups
with faster photocleavage properties. Preliminary in vitro investigations could be performed
with incorporated Nvoc and DMNPB groups.
Based on the results of test peptide synthesis, caged soluble Syb-2 (28 – 84) K52K(Nvoc),
D57D(DMNPB), K59K(Nvoc) (36) was synthesised in three segments. Synthesis performance
was monitored after each segment by test cleavages and analytical RP-HPLC. Until the second
segment, synthesis proceeded with satisfactory performance. Unfortunately, after complete
synthesis of the 56 mer peptide sequence 36, purification was even more challenging than for
adamantyl-modified Synaptobrevin-2 derivatives (6 – 11). Possible aggregation of peptide
36 led to highly broadened peaks in RP-HPLC chromatograms. In addition, compared to
adamantyl-modified peptides, the caging groups had a great impact on solubility indicating
that the hydrophobicity of the peptide significantly increased by the modifications. To decrease
this effect, incorporation of less than three or more hydrophilic caging groups needs to be
considered. In addition, for synthesis of such long sequences implementation of capping during
SPPS is still required for better purification results. Purification by RP-HPLC even at a higher
temperature (60 °C) led to only unsatisfactory purity of peptide 36. Nevertheless, due to time
limitations and small amounts, preliminary photocleavage and binding studies were performed.
As expected, the crude peptide 36 exhibited inconclusive results in the photocleavage exper-
iments. With increasing irradiation times even broader peaks were detected and no precise
peak for the uncaged peptide could be identified. Consequently, no clear statement about
the time needed for complete photocleavage could be made. The binding experiments with
labelled ∆N complexes exhibited no binding for peptide 36 which was intended, but for the
irradiated samples also no binding was detected. This might be due to the impurity of the
sample and/or possible aggregate formation of the caged soluble Syb-2 (28 – 84) K52K(Nvoc),
D57D(DMNPB), K59K(Nvoc) (36). The irradiated samples were frozen in liquid nitrogen
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directly after irradiation to stop the radical photocleavage reaction but this procedure might
also have supported aggregate formation. Despite overall aggregation tendency, the problem
of storage and transportation needs to be solved by a coupled method of UV photocleavage
and fluorescence anisotropy measurement in one device. This has the advantage of monitoring
photoactivation reactions in faster time scales, and therefore, also fast binding events would be
accessible to analyse.
To conclude, for synthesis and in vivo application of caged soluble Synaptobrevin-2, a different
caging group should be used with better solubility properties, faster photocleavage and higher
absorption wavelength, such as DEACM450. In addition, for the synthesis of these long
peptide sequences, the capping step should be maintained during SPPS to enhance purification
performance. Lastly, a better suitable UV lamp/laser coupled to a fluorescence spectrometer is
necessary to perform and monitor photoactivation reactions simultaneously.
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6 Synthesis of Labelled Syntaxin
Transmembrane Domains for
Investigations of Syntaxin Clustering
A selection of Syntaxin transmembrane domains (TMDs) was synthesised by SPPS, N-terminal
labelled with different fluorophores (chapter 6.1), and used for fluorescence-based investigations
of Syntaxin clustering by Dr. D. Milovanovic, Prof. R. Jahn’s work group, Department of
Neurobiology, Max-Planck-Institute for Biophysical Chemistry Göttingen (chapter 6.3).[139–141]
In addition, labelled VAMP TMDs were synthesised and provided (chapter 6.2).
6.1 Synthesis of Labelled Syntaxin TMDs
The syntheses of Syntaxin (Syx) TMDs were performed by automated and microwave-assisted
SPPS using the CEM Liberty12 peptide synthesizer, according to GSP 2 (chapter 8.4.2). Four
different sequences were synthesised with different length, mutations and of different isoforms
or species (table 6.1): Syntaxin-4 (262 – 297) Homo sapiens (37, chapter 8.9.1), Syntaxin-1A
(254 – 288) Homo sapiens (38, chapter 8.9.2), and Syntaxin-1A (254 – 288) K264A, K265A
Homo sapiens (39, chapter 8.9.3), Syntaxin-1A (257 – 288) M267A, C271A, I279A Rattus
norvegicus [142] (40, chapter 8.9.4). Due to the hydrophobic character of the peptides, the
corresponding low-loaded Wang resins (0.30 – 0.38 mmol/g) were used as well as double
coupling and capping were performed.
Table 6.1: Sequences of Syntaxin TMDs 37 – 40. The synthesis of peptide 40 was previously
performed by Dr. K. Meyenberg.[142]
37 Syx-4 (262 - 297) H.s. ALENQKKARKKKVLIAICVSITVVLLAVIIGVTVVGH OH
40
Syx-1A (257 - 288) M267A, 
C271A, I279A R.n.
YQSKARRKKIAIIIACVILGIIAASTIGGIFGH OH
38 Syx-1A (254 - 288) H.s. AVKYQSKARRKKMIIICCVILGIVIASTVGGIFAH OH
39
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After complete syntheses, the resin-bound peptides 37 – 40 were N-terminal labelled with two
fluorophores, Atto647N (AttoTec) and Rhodamine Red™ (Invitrogen). These two dyes can be
applied as FRET pair due to an overlap of donor emission and acceptor excitation spectra. In
addition, peptides 38 and 40 were also labelled with Oregon Green® 488 for photobleaching
applications.
6.1.1 Labelling reaction with Atto647N
For attachment of the fluorophore Atto647N to the resin-bound and side chain protected
peptides 37 – 40, the final Fmoc protecting group was removed by piperidine (20 %) in NMP
(2 x 15 min). After washing of the resin, Atto647N-NHS-ester (AttoTec), benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) and DIPEA in NMP were added
and the resin was shaken at room temperature under light exclusion overnight (scheme 6.2).
The resin was filtrated, washed and the Atto647N-labelled peptides were cleaved from the
solid-support and completely deprotected according to GSP 3 (chapter 8.4.3). The precipitated
and dried peptides were suspended in H2O/MeCN (1/1, v/v), frozen in liquid nitrogen and
lyophilised. The detailed synthetic procedures for the Atto647N-labelled Syx TMDs (table 6.5)
are described in the following chapters: Atto647N-Syx-4 (262 – 297) Homo sapiens (41,
chapter 8.9.5), Atto647N-Syx-1A (254 – 288) Homo sapiens (42, chapter 8.9.6), Atto647N-
Syx-1A (254 – 288) K264A, K265A Homo sapiens (43, chapter 8.9.7), and Atto647N-Syx-1A
































Atto647N-labelled resin-bound peptide X
Scheme 6.2: N-terminal labelling reaction of a resin-bound and side chain protected peptide
X with Atto647N-NHS-ester (AttoTec). The structure of the fluorophore is patented but was
previously published by Eggeling et al.[143]
6.1.2 Labelling reaction with Rhodamine Red
For attachment of the fluorophore Rhodamine Red™ (RhoRed) to the resin-bound and side
chain protected peptides 37, 38 and 40, the final Fmoc protecting group was removed by
piperidine (20 %) in NMP (2 x 15 min). After washing of the resin, Rhodamine Red™-X
succinimidyl ester 5-isomer (Invitrogen) and DIPEA in NMP were added and the resin was
shaken at room temperature under light exclusion overnight (scheme 6.3). The resin was
filtrated, washed and the RhoRed-labelled peptides were cleaved from the solid-support and
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completely deprotected according to GSP 3 (chapter 8.4.3). The precipitated and dried peptides
were suspended in H2O/MeCN (1/1, v/v), frozen in liquid nitrogen and lyophilised. The
detailed synthetic procedures for the RhoRed-labelled Syx TMDs (table 6.5) are described in
the following chapters: RhoRed-Syx-4 (262 – 297) Homo sapiens (45, chapter 8.9.9), RhoRed-
Syx-1A (254 – 288) Homo sapiens (46, chapter 8.9.10), and RhoRed-Syx-1A (257 – 288)



























Rhodamine Red-X succinimidyl ester 5-isomer RhoRed-labelled resin-bound peptide X
Scheme 6.3: N-terminal reaction of a resin-bound and side chain protected peptide X with
Rhodamine Red-X™ succinimidyl ester 5-isomer (Invitrogen).
6.1.3 Labelling Reaction with Oregon Green
For attachment of the fluorophore Oregon Green® 488 (OG) to the resin-bound and side chain
protected peptides 38 and 40, the final Fmoc protecting group was removed by piperidine (20 %)
in NMP (2 x 15 min). After washing of the resin, Oregon Green® 488-X succinimidylester
6-isomer (Invitrogen) and DIPEA in NMP were added and the resin was shaken at room
temperature under light exclusion overnight (scheme 6.4). The resin was filtrated, washed
and the OG-labelled peptides were cleaved from the solid-support and completely deprotected
according to GSP 3 (chapter 8.4.3). The precipitated and dried peptides were suspended
in H2O/MeCN (1/1, v/v), frozen in liquid nitrogen and lyophilised. The detailed synthetic
procedures for the OG-labelled Syx TMDs (table 6.5) are described in the following chapters:
OG-Syx-1A (254 – 288) Homo sapiens (48, chapter 8.9.12) and OG-Syx-1A (257 – 288)





























Oregon Green 488-X succinimidyl ester 6-isomer OG-labelled resin-bound peptide X
Scheme 6.4: N-terminal reaction of a resin-bound and side chain protected peptide X with
Oregon Green® 488-X succinimidylester 6-isomer (Invitrogen).
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6.1.4 Labelled Syntaxin Transmembrane Domains
The lyophilised crude peptides were used without further purification. Only the complete
peptide sequences were fluorescently labelled due to the protected amino acid side chains and
acetylation of possible truncated sequences by the capping step during synthesis. In table 6.5,
all synthesised and labelled Syntaxin TMD sequences are summarised.
Table 6.5: Sequences of labelled Syntaxin TMDs 41 – 49. Synthesis and/or application was







Ao647N-Syx-4 (262 - 297) H.s.
RhoRed-Syx-4 (262 - 297) H.s.
42
Ao647N-Syx-1A (257 - 288) 
M267A, C271A, I279A R.n.
YQSKARRKKIAIIIACVILGIIAASTIGGIFG OHAo647N
46
RhoRed-Syx-1A (257 - 288) 
M267A, C271A, I279A R.n.
YQSKARRKKIAIIIACVILGIIAASTIGGIFG OHRhoRed
48
OG-Syx-1A (257 - 288) 
M267A, C271A, I279A R.n.
YQSKARRKKIAIIIACVILGIIAASTIGGIFG OHOG
44
Ao647N-Syx-1A (254 - 288) H.s. AVKYQSKARRKKMIIICCVILGIVIASTVGGIFA OHAo647N
47
RhoRed-Syx-1A (254 - 288) H.s. AVKYQSKARRKKMIIICCVILGIVIASTVGGIFA OHRhoRed
49
OG-Syx-1A (254 - 288) H.s. AVKYQSKARRKKMIIICCVILGIVIASTVGGIFA OHOG
43
Ao647N-Syx-1A (254 - 288) 
K264A, K265A H.s.
AVKYQSKARRAAMIIICCVILGIVIASTVGGIFA OHAo647N
6.2 Synthesis of Labelled VAMP TMDs
Analogous to the Syntaxin TMDs, syntheses of VAMP TMDs were performed by automated
and microwave-assisted SPPS using the CEM LibertyBlue peptide synthesizer, according to
GSP 2 (chapter 8.4.2). Two sequences from different isoforms and one hybrid sequence were
synthesised (table 6.6): VAMP-3 (70 – 100)+CVS R.n. (50), VAMP-8 (63 – 100) R.n. (51),
and VAMPext (52). Due to the hydrophobic character of the peptides, the corresponding
low-loaded Wang resins (0.31 – 0.35 mmol/g) were used as well as double coupling procedure.
Unfortunately, capping procedure is not possible with the CEM LibertyBlue peptide synthesizer.
First, it was intended to synthesise shorter sequences (VAMP-3 (78 – 100)+CVS R.n. and
VAMP-8 (71 – 100) R.n.) but these peptides were not soluble in trifluoroethanol (TFE) or any
other solvent. Hence, elongation of the sequences was necessary. After complete synthesis, the
resin-bound peptides 50 – 52 were N-terminal labelled with the two fluorophores Atto647N
and Rhodamine Red™ analogous to the procedures described in chapters 6.1.1 and 6.1.2. The
detailed synthetic procedures for the Atto647N- and RhoRed-labelled VAMP TMDs (table 6.6)
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are described in the following chapters: Atto647N-VAMP-3 (70 100)+CVS Rattus norvegicus
(53, chapter 8.9.17), Atto647N-VAMP-8 (63 – 100) Rattus norvegicus (54, chapter 8.9.18),
Atto647N-VAMPext (55, chapter 8.9.19), RhoRed-VAMP-3 (70 – 100)+CVS Rattus norvegicus
(56, chapter 8.9.20) and RhoRed-VAMP-8 (63 – 100) Rattus norvegicus (57, chapter 8.9.21).
With these derivatives investigations of VAMP clustering in membranes by FRET is planned.
Table 6.6: Sequences of synthesised unlabelled and labelled VAMP TMDs 50 – 57.
No. Name Sequence
KLKRKYWWKNCKMWAIGISVLVIIVIIIIVWCVSH OH50 VAMP-3 (70 - 100)+CVS R.n.
KVARKFWWKNVKMIVIICVIVLIIVILIILFATGTIPTH OH51 VAMP-8 (63 - 100) R.n.
KLKRKYWWKNCKMWAIGISVLVIIVIIIIVWCVSTIPTH OH52 VAMPext
KLKRKYWWKNCKMWAIGISVLVIIVIIIIVWCVSA!o647N OH53




(63 - 100) R.n.
KLKRKYWWKNCKMWAIGISVLVIIVIIIIVWCVSTIPTA!o647N OH55 A!o647N-VAMPext
KLKRKYWWKNCKMWAIGISVLVIIVIIIIVWCVSRhoRed OH56




(63 - 100) R.n.
6.3 Application of Labelled Syntaxin TMDs
The synthesised and labelled Syntaxin TMDs were used by Dr. D. Milovanovic, Prof. R.
Jahn’s work group, Department of Neurobiology, Max-Planck-Institute for Biophysical Chem-
istry Göttingen for fluorescence-based investigations of Syntaxin clustering.[139–141]
First, he studied the clustering of Syntaxin in the dependence of membrane thickness.[139, 141]
Therefore, he reconstituted the synthesised and labelled Syntaxin-1A TMDs, Atto647N-Syx-1A
(254 – 288) H.s. (42) and RhoRed-Syx-1A (254 – 288) H.s. (46), in PC liposomes with
different thicknesses and monitored the clustering by a FRET assay. He compared this to
Syntaxin-4 TMD clustering by reconstituting Atto647N-Syx-4 (262 – 297) H.s. (41) and
RhoRed-Syx-4 (262 – 297) H.s. (45). The Syntaxin-4 isoform exhibited a 1 – 2 amino acid(s)
longer TMD than Syntaxin-1A. In combination with imaging ellipsometry, membrane thickness
of 3.6 nm (Syx-1A) and 3.7 nm (Syx-4), respectively, were found to induce the lowest clustering.
In eukaryotic cells the plasma membrane exhibits a thickness of ∼4 nm, hence, Syntaxin
TMD clustering is driven by the mismatch between TMD length and membrane thickness, the
so-called hydrophobic mismatch, which was also found to be independent on the presence or
absence of cholesterol.[139, 141]
Due to the fact that Syntaxin-1A TMDs exhibit homodimerisation which is known to dependent
on specific protein-protein interactions, the labelled dimerisation mutants Atto647N-Syx-1A
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(257 – 288) M267A, C271A, I279A (44) and RhoRed-Syx-1A (257 – 288) M267A, C271A,
I279A (47) were used to measure clustering by FRET. The peptides were reconstituted into
membranes with hydrophobic mismatch conditions and showed similar clustering properties
as for the wild-type. Hence, membrane thickness is more important for clustering than the
protein-protein interactions.[139, 141]
Syntaxin-1A as well as Syntaxin-4 include a polybasic motif in the linker region next to the TMD
which is known to interact with phosphoinositides, such as phosphatidylinositol 4,5-biphosphate
(PI(4,5)P2). In addition, Syntaxin clusters were shown to be enriched with PI(4,5)P2. To
study the co-clustering, Atto647N-Syx-4 TMD (41) and RhoRed-Syx-1A TMD (46) were
reconstituted into membranes in the presence or absence of PI(4,5)P2 and clustering was
measured by FRET. The presence of PI(4,5)P2 increased TMD clustering independently of
cholesterol.[139, 141]
Besides PI(4,5)P2, Ca2+ ions are also known to enhance Syntaxin clustering. This was confirmed
by reconstituting Atto647N-Syx-1A TMD (42) in membranes with matching thickness and
lowest clustering. Using stimulated emission depletion (STED) microscopy, it was monitored
that clustering was induced by Ca2+ only in the presence of PI(4,5)P2. Additional FRET
experiments with reconstituted Atto647N-Syx-1A TMD (42) and RhoRed-Syx-1A TMD (46)
before and after Ca2+ addition confirmed the interaction between the polybasic motif of
Syntaxins and PI(4,5)P2 which is even increased by Ca2+ addition. Mutation of this motif
and usage of Atto647N-Syx-1A (254 – 288) K264A, K265A (43) clearly showed a reduced
interaction with PI(4,5)P2 and a reduced effect of Ca2+ addition.[140, 141]
In conclusion, it was possible to investigate Syntaxin clustering in membrane model sys-
tems dependent on membrane thickness, cholesterol, PI(4,5)P2 and Ca2+ with the provided
synthesised labelled Syx TMDs.
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The SNARE-mediated membrane fusion is the essential mechanism for many processes in
eukaryotic cells. For example in synaptic transmission, dysfunctions of this basic tool cause
neuronal and/or neurodegenerative diseases. Mechanistic insights into this process could of-
fer approaches for development of suitable treatments which might be transferred to other
membrane fusion events such as bacterial or viral infections.[8] Due to the high complexity
of the system and despite the extensive research in this field, critical mechanistical questions
still remain unanswered. Especially, the mechanisms of SNARE complex zippering and of the
SNARE disassembly reaction require further investigations. Recent improvements in cryo-EM
provided higher resolution structures of the enzyme NSF and the disassembly machinery, the
so-called 20 S (super)complex.[50, 53] However, crystallisation studies of NSF or the 20 S
complex have not been reported so far, probably due to no effective inhibitor available for the
reaction until today.
The first aim of this study was to synthesise an inhibitor for the α-SNAP/NSF-mediated
disassembly reaction of the SNARE complex. Based on identified interaction sites between
α-SNAP and Synaptobrevin-2,[64] suitable sequence positions (D51, E55, Q58, E62, D65) of
Synaptobrevin-2 were already previously chosen for modification.[119] One or more sterically
demanding side chains were introduced on the surface of the SNARE complex to prevent or at
least weaken the α-SNAP binding which is essential for the disassembly reaction. For the site-
specific modification of the Synaptobrevin-2 SNARE motif by SPPS, the adamantyl-modified
amino acid building block Fmoc-Asn(Ad)-OH (4)[119] was synthesised. SNARE assembly and
disassembly properties were investigated by time-dependent fluorescence anisotropy. Ternary
SNARE complexes with the natural counterparts, Syntaxin-1A and SNAP-25, were successfully
formed for all investigated adamantyl-modified Synaptobrevin-2 derivatives. Only for Syb-2
(28 – 84) Q58N(Ad) (10), complex formation was more challenging and it proved necessary to
use detergent-containing buffer and Syntaxin-1A including its transmembrane domain.
SNARE assembly properties were investigated using a Oregon Green® 488 (OG)-labelled
stabilised acceptor complex (∆N complex) which enables to monitor the complex formation
indirectly via displacement of the Sby-2 fragment by fluorescence anisotropy.[11] The wild-type
sequence Syb-2 (28 – 84) (6) showed comparable SNARE assembly properties to the normally
used soluble Syb-2 (1 – 96). The adamantyl-modified Syb-2 (28 – 84) E55N(Ad), D65N(Ad)
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(7) and Syb-2 (28 – 84) Q58N(Ad) (10), however, exhibited clearly retarded complex formation
properties. The modifications of these derivatives were close to the N-terminal end of the Syb-2
(49 – 96) fragment used in the ∆N complex and might disturb the displacement reaction.
Prior to the disassembly experiments, the ternary SNARE complexes formed from monomeric
species were reconstituted into SUVs due to the membrane-dependent efficiency of α-SNAP.[59]
The successful complex formation and reconstitution was confirmed by performing a co-floatation
assay. The influence of reconstituted modified SNARE complexes on the disassembly reaction
mediated by α-SNAP and NSF was investigated by time-dependent fluorescence anisotropy.
Due to OG-labelled SNAP-25 used for complex formation, α-SNAP binding was detected by
an increase in fluorescence anisotropy, whereas the complex disassembly upon NSF addition
was monitored by a decrease in anisotropy. The adamantyl-modified Syb-2 derivatives should
already prevent or at least weaken the α-SNAP binding to the SNARE complex. Unfortunately,
α-SNAP bound to all investigated SNARE complexes containing adamantyl modifications.
Especially, Syb-2 (28 – 84) Q58N(Ad) (10) which was previously found to be the most promising
derivative for inhibitor development,[119] had no effect on α-SNAP binding and the disassembly
reaction. The modifications of the Synaptobrevin-2 SNARE motif based on a 3/1 stoichiometry
of α-SNAP/SNARE complex[64] were thought to cover two binding sites of α-SNAPs. With
the recently revealed structure of four α-SNAPs binding around the SNARE complex,[50, 53] the
adamantyl modifications might cover only one α-SNAP binding site. In addition, even if one
binding site for α-SNAP was blocked due to the modifications, the SNARE complex could be
disassembled by NSF with less than three or four α-SNAPs, like it was shown for the V7-20 S
complex.[50, 53] Due to the higher time-resolution of fluorescence anisotropy measurements and
distinct determination of the reaction by increase/decrease in anisotropy level, the obtained
results are summarised as more significant than reaction monitoring by SDS-PAGE. Hence,
the introduced adamantyl modifications had no influence on α-SNAP binding to the modified
SNARE complexes.
The second aim of this study was to study the influence of the adamantyl-modified Syb-2
analogues on the Complexin binding to the SNARE complex, due to the suggested competitive
binding of α-SNAP and Complexin to the SNARE complex surface.[59] The binding reaction
was investigated by time-dependent fluorescence anisotropy and monitored by an increase in
anisotropy upon addition of the SNARE complex to OG-labelled Complexin.[72] Surprisingly,
Complexin did bind to the SNARE complex containing Syb-2 (28 – 84) E55N(Ad), D65N(Ad)
(7), despite sterically demanding modification of a direct interaction site with Complexin
(D65). Probably, the interaction with the neighbouring residues D64 and D68 was able to
overcome this disturbance. With respect to studies suggesting a conformational switch region
of Synaptobrevin-2 for Complexin to change the orientation of its accessory α-helix,[80, 82]




More importantly, SNARE complexes containing Syb-2 (28 – 84) Q58N(Ad) (10) were totally
inhibiting Complexin binding, although the position of modification was not a direct interaction
site and only close to one (D57). The derivative 10 exhibited the most problems with SNARE
complex formation which might lead to the hypothesis that the position Q58 is crucial for
SNARE zippering, Complexin binding, and might be energetically critical. Previously suggested
as the most promising precursor for inhibition of α-SNAP binding,[119] which could not be
confirmed by this study, the modification has definitely an impact on SNARE complex properties.
In a third part of this study, the SNARE complex formation itself, the SNARE zippering
process was investigated. By introducing photocleavable protecting groups, a soluble caged
Synaptobrevin-2 derivative was designed and synthesised which was inactive towards SNARE
complex zippering, and could be reactivated upon irradiation. Analogous to the application of
caged Ca2+ ions for in vivo exocytosis investigations, the caged Synaptobrevin-2 was preliminary
tested in vitro but should also be applicable for in vivo studies. Due to the limitations for attach-
ment of PPGs to suitable amino acid side chains, the soluble caged Syb-2 (28 – 84) K52K(Nvoc),
D57D(DMNPB), K59K(Nvoc) was designed. As caging group, the 6-nitroveratryloxycarbonyl
(Nvoc) moiety and the related 3-(4,5-dimethoxy-2-nitrophenyl)-2-butyl (DMNPB) moiety were
chosen due to straightforward synthetic procedures of corresponding caged amino acid building
blocks comprising only few synthesis steps and UV absorption λ > 345 nm. The caged amino
acid building blocks for SPPS Fmoc-Lys(Nvoc)-OH (16)[132, 137] and Fmoc-Asp(DMNPB)-OH
(27)[107, 135] were synthesised based on previously published synthesis protocols. Short test
peptides 29 – 31 with incorporated caged amino acids were synthesised by SPPS and their pho-
tochemical properties investigated by UV/vis spectroscopy as well as photocleavage reactions
monitored by RP-HPLC. The fastest uncaging reaction was observed for the Asp(DMNPB)-
containing peptide 31 after 90 s of irradiation. For preliminary in vitro investigations of caged
Synaptobrevin-2, this was sufficient but for in vivo applications complete photocleavage in
the time scale of milliseconds to seconds is required. After synthesis of the complete Syb-2
(28 – 84) K52K(Nvoc), D57D(DMNPB), K59K(Nvoc) sequence 36, purification by RP-HPLC
was even more challenging than for the adamantyl-modified Syb-2 derivatives 7 – 11. Possible
aggregation of peptide 36 led to highly broadened peaks in the RP-HPLC chromatograms
which could not be optimised by elution at higher temperature (60 °C). Consequently, peptide
36 was obtained in only unsatisfactory purity to perform preliminary experiments. As expected,
the crude peptide 36 exhibited inconclusive results in the photocleavage experiments and no
clear statement about needed irradiation times could be made. Binding experiments with
labelled ∆N complex monitored by time-dependent fluorescence anisotropy revealed as intended
no binding for peptide 36. However, for the irradiated samples of caged Syb-2 (36) also
no binding to the ∆N complex was detected which is possibly based on the impurity of the
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samples and/or aggregate formation. Due to necessary transportation between irradiation
and fluorescence anisotropy measurements, the samples were frozen in liquid nitrogen to stop
the radical photocleavage reaction but this procedure might also have supported aggregate
formation. Despite overall aggregation tendency, the problem of storage and transportation
needs to be solved by a coupled method of UV photocleavage and fluorescence anisotropy
measurement in one device. This has the advantage of monitoring photoactivation reactions in
faster time scales, and therefore also fast binding events would be accessible to analyse.
To conclude the third part of this study, for in vivo applications of caged soluble Synaptobrevin-2,
a caging group with better solubility properties, faster photocleavage and higher absorption
wavelength should be used. Despite the considerable expenditure for the synthesis of the
amino acid building block, DEACM450[106, 112] is a promising candidate for this application. In
addition, a better suitable UV lamp/laser coupled to a fluorescence spectrometer is essential to
simultaneously perform and monitor photoactivation reactions.
In the last part of this study, Syntaxin transmembrane domains (TMDs) were easily ac-
cessible by SPPS and attachment of fluorophores to the N-terminal end of the sequence on
the solid-support were successfully performed. With the provided synthesised and labelled
Syx TMDs, it was possible to investigate Syntaxin clustering in membrane model systems




8.1 General Synthetic Methods and Materials
Reagents
All starting materials and reagents were of highest grade available and obtained from the
following companies: ABCR, Acros-Organics, Alfa Aesar, Bachem, Fisher Scientific, Fluka,
Merck, NovaBiochem, Roth, Sigma-Aldrich, TCI and VWR. Amino acids, resins and coupling
reagents were purchased from ABCR, Bachem, GL Biochem, IRIS Biotech and NovaBiochem.
Solvents
All technical solvents were distilled prior to use. Anhydrous solvents of extra dry or puriss.
absolute grade (over molecular sieves) were obtained from Acros Organics, Fluka and Sigma-
Aldrich. Acetonitrile and methanol used for HPLC were of the respective grade and purchased
from Fisher Scientific, Sigma-Aldrich and VWR. For HPLC and all buffers, water was purified
using a Simplicity water purification system from Millipore. All other solvents used were of
the grade puriss. p. a. and obtained from Acros Organics, Fisher Chemical, Merck, Roth,
Sigma-Aldrich and VWR.
Reactions
All air- and water-sensitive reactions were conducted under inert atmosphere. For large scale
reactions glassware was heat-dried.
Lyophilization
Freeze-drying of compounds from aqueous solutions containing minimal amounts of methanol
or acetonitrile was performed using a Christ-Alpha-2-4 lyophilizer attached to a high vacuum
pump. An evacuable Christ RCV-2-18 ultracentrifuge connected to the lyophilizer was used
for lyophilization of small volumes from centrifuge tubes. All solutions were frozen with liquid
nitrogen before being attached to the lyophilizer.
Chromatography
Thin Layer Chromatography (TLC)
All reactions were monitored by TLC if possible. TLC was conducted on aluminium backed
plates of silica gel 60 F254 (layer thickness: 0.20 mm) from Merck. Spots were detected by
fluorescence quenching at 254 nm. Non-fluorescence quenching substances were visualized by
staining the plate in one of the solutions described in table 8.1 and subsequent careful heating.
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Table 8.1: Staining solutions for Thin Layer Chromatography (TLC)
Name Ninhydrin MOPS PPh3/Ninhydrin
Components Ninhydrin (3 %, w/v) (NH4)6Mo7O24 (5 %, w/v) 1) PPh3 (10 %, w/v)
in Ethanol H2SO4 (10 %, v/v) in DCM
CeSO4 (0.3 %, w/v) 2) Ninhydrin (3 %,
w/v) in Ethanol
Used for: Amines Most functionalites Azides
Flash Chromatography
Purification by flash chromatography was conducted using Sigma-Aldrich FLUKA Silica Gel 60
(particle size: 63 – 200 µm). The crude product was added to the column as adsorbent on
threefold amount of silica gel. Eluents are stated in each individual protocol. An overpressure
of 0.2 – 1.0 bar was applied for the separation.
High performance liquid chromatography (HPLC)
Purification by HPLC was performed at Amersham Pharmacia Biotech systems (Äkta basic,
pump-type P–900, variable UV detector UV–900). All runs were conducted with a linear
gradient of eluent A (H2O/TFA (100/0.1, v/v)) to B (MeCN/H2O/TFA (80/20/0.1, v/v/v))
in 30 min. UV absorption was detected at 215 nm, 254 nm and 280 nm for regular peptides
and at 215 nm, 254 nm and 345 nm for amino acids or peptides containing caging groups.
All columns used are stated in the analysis of the corresponding compound. Flow-rates were
1 mL/min for analytical, 3 mL/min for semi-preparative and 10 mL/min for preparative columns.
All samples were dissolved in ultrapure water with a minimum of MeCN added and filtrated
before injection.
8.2 Characterisation
Nuclear Magnetic Resonance Spectroscopy (NMR)
NMR spectra were recorded at Varian instruments (INOVA 600, INOVA 500, VNMRS 300
and Mercury VX 300). Chemical shifts are quoted in ppm (TMS = 0 ppm). The resonances
of the rest protons of deuterated solvents were taken as internal standards. Multiplicities are
abbreviated as follows: s = singlet, d = doublet, t = triplet, q = quartet, quin = quintet,
m = multiplet, sbr = broad singlet. Coupling constants J are stated in Hz. 13C spectra were
recorded as broadband decoupled ATP spectra. Data from [H,H]-COSY, HSQC and HMBC
experiments were used to interpret the signals.
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Mass Spectrometry (MS)
Electron Spray Ionisation (ESI) spectra as well as high resolution ESI (HR-MS) spectra were
recorded at micrOTOF (ESI-TOF-MS), maXis (ESI-QTOF-MS) or APEX IV (FT-ICR-MS)
spectrometer from Bruker Daltonik. The values are given as m/z relations.
8.3 Analytical and Spectroscopic Methods
8.3.1 UV/Vis Spectroscopy
UV/vis-spectra were recorded with a NanoDrop 2000c spectrophotometer from Thermo Fisher
Scientific with a sample size of 2 µL per measurement. Blank probe of the corresponding
solvent was measured before each set of measurements. Each probe was measured three-times.
8.3.2 Bradford Assay[145]
Concentrations of peptides 6, 7, 8, 10 and 11 were determined by Bradford assay. Standard
curve was determined by serial dilution (0, 40, 100, 400, 1000, 2000, 3000, 4000 µg/mL)
of Bovine serum albumin (BSA). All samples (10 µL) were mixed with Bradford reagent
(40 µL, 0.01 % (w/v) Coomassie® Brilliant Blue G 250, 4.70 % (w/v) ethanol, 8.50 % (w/v)
phosphoric acid) and after 5 min absorption at 595 nm was measured (five times for standard
curve and ten-times for unknown sample) by NanoDrop 2000c spectrophotometer from Thermo
Fisher Scientific. Unknown concentrations were calculated and averaged by standard curve.
8.3.3 BCA Assay[146]
Concentrations of peptides 6 and 36 were determined by BCA assay. The following reagents
were used:
• micro-BCA assay reagent A (Na2CO3 (645 mm), NaK Tartrat tetrahydrate (70 mm), pH
11.25),
• micro-BCA assay reagent B (Bicinchoninic acid (BCA, 116 mm)),
• micro-BCA assay reagent C (copper(II) sulfate pentahydrate (160 mm)),
• micro-BCA assay solution (reagent A/B/C (49/49/2, v/v/v)).
Standard curve was determined by serial dilution (0, 0.5, 2.5, 5.0, 10, 15, 20 µg) of BSA.
All samples (500 µL) were mixed with micro-BCA assay solution (500 µL), vortexed, and
incubated 15 min at 60 °C. Afterwards, samples were cooled to room temperature, vortexed
and absorbance at 562 nM was measured five times by NanoDrop 2000c spectrophotometer





Photocleavage experiments were performed using a mercury UV lamp from Newport equipped
with a mirror filter (280 – 460 nm) and set to 650 W. For irradiation, the sample (500 µL) was
transferred to a QS Makro quartz glass cuvette (110-QS, light path: 10 mm, volume: 3500 µL,
outer dimensions: 12.5 x 12.5 x 46 mm) from Hellma Analytics and positioned centred ∼5 cm
in front of the UV lamp opening. For smaller volumes, the sample (200 µL) was transferred to
a QS Micro Fluorescence Cell quartz glass cuvette (115F-QS, light path: 10 x 2 mm, volume:
400 µL, outer dimensions: 12.5 x 12.5 x 40 mm) and positioned with the longer light path,
centred ∼5 cm in front of the UV lamp opening. Irradiation time was varied between 30 s
and 180 s. Directly after irradiation, the sample was analysed by analytical RP-HPLC. For
binding studies using ∆NOG complexes (chapter 8.3.9), samples (100 µL) of caged Syb-2 (36,
100 µm in H2O/MeCN (1/1, v/v)) were irradiated for corresponding times in the micro quartz
cuevette, transferred to Eppendorf tubes, directly frozen in liquid nitrogen and transported
on ice.
8.3.5 SNARE Protein Constructs, Expression and Purification
The following purified SNARE proteins were kindly provided by Dr. H. Yavuz, Prof. R. Jahn’s
work group, Department of Neurobiology, Max-Planck-Institute for Biophysical Chemistry
Göttingen, expressed and purified as previously published:[11, 18, 60] Syntaxin-1A (183 – 288),
Syntaxin-1A (180 – 262), SNAP-25 (1 – 206) no Cys mutant, SNAP-25 (1 – 206) C130-
OG, Synaptobrevin-2 (1 – 96) C28-OG, Synaptobrevin-2 (1 – 96), chinese hamster NSF[59],
bovine α-SNAP wild-type[59], Complexin I (1 – 134)[72], Complexin I (1 – 134) C105S, E39C
OG-labeled[72]. The soluble unlabeled stabilized Q-SNARE acceptor complex (∆N complex)
consisting of Syntaxin-1A (183 – 262), SNAP-25 (no cys) and the C-terminal Synaptobrevin-2
fragment (46 – 96) as well as the OG-labeled ∆N complex (∆NOG) consisting of Syntaxin-1A
(183 – 262), SNAP-25 (no Cys) and Synaptobrevin-2 (46 – 96) C79-OG were assembled and
purified as described earlier.[11, 18, 60]
8.3.6 SNARE Complex Assembly
• Labeled ternary SNARE complex from monomers: For assembly of labeled ternary
SNARE complexes, Syntaxin-1A (183 – 288), SNAP-25 (1 – 206) C130-OG and
Synaptobrevin-2 (28 – 84) wt (6) or mutants (7, 8, 10 and 11) were mixed in molar
ratio of 1.0/1.0/1.5 in HEPES buffer (20 mm, NaCl (300 mm), TCEP (0.1 mm), CHAPS
(2 %), pH 7.4) and incubated at room temperature for 2 h under exclusion of light. The
distinct concentrations and components used are described in table 8.2. These complexes
were used for disassembly experiments (chapter 4.5.3 and 8.3.9) after co-floatation assays
(chapter 4.5.1 and 8.3.8).
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Table 8.2: Components, final concentrations as well as final volume (fV) for SNARE assembly with
synthesised Syb-2 (28 – 84) wild-type (6) and adamantyl-modified Synaptobrevin-2 derivatives










Syx-1A 20 µm 25 µm 7.3 µm 25 µm 25 µm
SN-25-OG 19 µm 25 µm 7.4 µm 25 µm 25 µm
Syb-2 X 27 µm 40 µm 11.2 µm 37 µm 36 µm
buffer 40 µL 40 µL 40 µL 40 µL 40 µL
fV 141 µL 147 µL 135.5 µL 147 µL 147 µL
• Unlabeled soluble ternary SNARE complex from ∆N complex: For assembly
of unlabeled soluble ternary SNARE complexes, ∆N complexes (25 µm), consisting
of Syntaxin-1A (183 – 262), SNAP-25 (1 – 206) no cys mutant, and the C-terminal
Synaptobrevin-2 fragment (46 – 96), were mixed with Synaptobrevin-2 (28 – 84) wt
(6) or mutants (7 or 10) (37.5 µm) in HEPES buffer (20 mm, NaCl (300 mm), TCEP
(0.1 mm), pH 7.4) and incubated overnight at 4 °C. These complexes were used for
Complexin binding studies (chapter 4.6.2, 4.6.3, and 8.3.9). Note that under these
conditions no complex formation was obtained for Synaptobrevin-2 (28 – 84) Q58N(Ad)
(10).
• Labeled soluble ternary SNARE complex from ∆N complex: For assembly of
labeled soluble ternary SNARE complexes, ∆N complexes (25 µm), consisting of Syntaxin-
1A (183 – 262), SNAP-25 (1 – 206) no cys mutant, and the C-terminal Synaptobrevin-2
fragment (46 – 96) C79-OG, were mixed with Synaptobrevin-2 (28 – 84) wt (6) or
mutants (7 or 10) (37.5 µm) in HEPES buffer (20 mm, NaCl (300 mm), TCEP (0.1 mm),
pH 7.4) and incubated overnight at 4 °C. These complexes were used for rough validation
of complex formation by Fluorescence Anisotropy (chapter 4.6.3, and 8.3.9). Note that
under these conditions no complex formation was obtained for Synaptobrevin-2 (28 – 84)
Q58N(Ad) (10).
• Unlabeled soluble ternary SNARE complex from monomers: For assembly of
unlabeled soluble ternary SNARE complexes, Syntaxin-1A (180 – 262) (25 µm), SNAP-
25 (1 – 206) no cys mutant (25 µm), and Synaptobrevin-2 (28 – 84) wt (6) or mutant
(10) (37.5 µm) were mixed in HEPES buffer (20 mm, NaCl (300 mm), TCEP (0.1 mm),
pH 7.4) and incubated at room temperature overnight. These complexes were used
for Complexin binding studies (chapter 4.6.2, 4.6.3, and 8.3.9). Note that under these




• Unlabled ternary SNARE complex from monomers: For assembly of unlabeled
ternary SNARE complexes, Syntaxin-1A (183 – 288) (25 µm), SNAP-25 (1 – 206) no cys
mutant (25 µm), and Synaptobrevin-2 (28 – 84) Q58N(Ad) (10) (37.5 µm) were mixed
in HEPES buffer (20 mm, NaCl (300 mm), TCEP (0.1 mm), CHAPS (1 %), pH 7.4) and
incubated at room temperature overnight. These complexes were used for Complexin
binding studies (chapter 4.6.3, and 8.3.9).
• Unlabeled binary complex from monomers: For assembly of unlabeled binary com-
plexes SNAP-25 (1 – 206) no cys mutant (25 µm) and Syntaxin-1A (183 – 262) (50 µm)
were mixed in HEPES buffer (20 mm, NaCl (300 mm), TCEP (0.1 mm), pH 7.4) and
incubated overnight at room temperature. These complexes were used for Complexin
binding studies (chapter 4.6.3, and 8.3.9).
• Labeled binary complex from monomers: For assembly of OG-labeled binary com-
plexes SNAP-25 (1 – 206) C130-OG (25 µm) and Syntaxin-1A (183 – 262) (50 µm) were
mixed in HEPES buffer (20 mm, NaCl (300 mm), TCEP (0.1 mm), pH 7.4) and incubated
overnight at room temperature. These complexes were used for rough validation of
complex formation by Fluorescence Anisotropy (chapter 4.6.3, and 8.3.9).
For SNARE complex assembly with Synaptobrevin-2 (28 – 84) Q58N(Ad) (10), it was crucial
to use detergent-containing HEPES buffer (20 mm, NaCl (300 mm), TCEP (0.1 mm), CHAPS
(1 %), pH 7.4) and Syntaxin-1A (183 – 288) to obtain the ternary SNARE complex.
8.3.7 Reconstitution of SNAREs into Small Liposomes
SNARE complexes were reconstituted by applying co-micellization method[11, 18]. With this
method small unilamellar vesicles (SUVs) are obtained by mixing lipids and proteins in a
detergent containing buffer and removal of the detergent by size-exclusion chromatography.
The used lipid mix consisted of phosphatidylcholine (PC), phosphatidylethanolamine (PE),
phosphatidylserine (PS) and cholesterol (molar ratio 5/2/2/1) in HEPES buffer (20 mm, KCl
(150 mm), EDTA (1 mm), DTT (1 mm), NaCholate (5 %, w/v), pH 7.4). Lipid mix and
protein mix were combined in a protein to lipid ratio of 1:1000 (table 8.3). The concentrations
of formed SNARE complexes were roughly estimated by UV absorption measurements at 280 nm
(1 Abs = 1 mg/mL) using NanoDrop 1000 spectrophotometer from Thermo Fisher Scientific.
The mixture with the final Volume (fV) was applied to a Sephadex G-50 column equilibrated
with detergent free HEPES buffer (20 mm, KCl (150 mm), EDTA (1 mm), DTT (1 mm), pH
7.4). Due to OG-labeled SNARE complexes, collected fraction with highest emission under UV
lamp was chosen for further experiments.
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Table 8.3: Concentrations of formed SNARE complexes with synthesised Syb-2 (28 – 84) wild-
type (6) and adamantyl-modified Synaptobrevin-2 derivatives (7, 8, 10, 11), final concentrations










c(cplx) ∼18 µm ∼14 µm ∼8.6 µm ∼14 µm ∼14 µm
fc(lipid) 7.7 mm 6.9 mm 5.3 mm 6.9 mm 6.9 mm
fc(cplx) 7.7 µm 6.9 µm 5.2 µm 6.9 µm 6.9 µm
fV(lipid/cplx) 157.5 µL 177 µL 179 µL 177 µL 177 µL
8.3.8 Co-floatation Assay
Co-floatation assays were performed as previously published.[18, 60] Reconstituted SNARE
complexes in SUVs (50 µL) were transferred in a centrifuge insert and mixed with Nycodenz®
(Axis Shield, 80 %, 50 µL). A second Nycodenz® layer (30 %, 50 µL) was carefully applied
followed by a layer of HEPES buffer (20 mm, KCl (150 mm), EDTA (1 mm), pH 7.4).
Afterwards, the density gradient was centrifuged with a Beckman TL-100 ultracentrifuge
(TLS55 rotor, 100000 x g, 4 °C, 1.5 h). 20 µL aliquots were carefully taken from the top
of the gradient (fractions F1 – F8) and analysed by SDS-PAGE. For each analysed SNARE
complex, co-floatation assay was performed twice: once for analysis by SDS-PAGE and second
for purification before disassembly experiments.
For SDS-PAGE Schaegger gels (Tricin, 10 %) in Tris buffer (3 m, SDS (0.3 %), pH 8.45) were
used. Electrophoresis was performed with anode buffer (Tris (0.2 m), pH 8.9), cathode buffer
(Tris (0.1 m), Tricine (0.1 m), SDS (0.1 %), pH 8.25) and 120 V applied. Afterwards, gels
were scanned with Typhoon FLA 7000 laser scanner from GE Healthcare with excitation set to
470 nm and emission to 520 nm for Oregon Green (OG).
8.3.9 Fluorescence Anisotropy Experiments
Anisotropy experiments were carried out as previously published[11, 18, 60] using a Fluorolog 3
(model FL322, Jobin Yvon) spectrometer in T-configuration equipped with in-built polarizers.
Excitation and emission wavelengths were set to 488 nm and 520 mn.
• Disassembly experiments: Data was collected with the manufacturer’s software. G-
factors were re-measured for every set of epxeriments and slit widths were adjusted
to obtain fluorescent counts between 50000 and 100000. All disassembly experiments
were performed at 37 °C with 5 µL of respective sample (combined fractions F1 and
F2 derived from co-floatation assays) in 600 µL of buffer containing HEPES (50 mm),
potassium acetate (20 mm, KAc), potassium glutamate (120 mm, KGlu) at pH 7.4.
Unless stated otherwise, MgCl2 (5 mm) and 2Na-ATP (2 mm) were added to activate
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NSF, and α-SNAP (1 µm) and NSF (60 nm) were added at the indicated times. Initial
anisotropy of OG-labeled SNARE complexes was measured until equilibration. Upon
addition binding or disassembly processes were observed by changes in anisotropy.
• Complexin binding experiments: Data was collected with FluorEssence V3.5 and G-
factor was set to 0.45 for all experiments. Slit widths were adjusted for each experiment to
obtain fluorescent counts between 50000 and 100000. All Complexin binding experiments
were performed at room temperature in 1.2 mL of buffer containing HEPES (20 mm),
NaCl (300 mm), TCEP (0.1 mm) at pH 7.4. If used SNARE complexes were formed
in detergent containing buffer, the same buffer was also used for Complexin binding
studies. Initial anisotropy of OG-labeled Complexin was measured until equilibration.
Upon addition of SNARE complexes binding processes were observed by changes in
anisotropy.
• ∆N complex experiments: Data was collected with FluorEssence V3.5 and G-factor
was set to 0.45 for all experiments. Slit widths were adjusted for each experiment to
obtain fluorescent counts between 50000 and 100000. All ∆N complex experiments
were performed at room temperature in 1.2 mL of buffer containing HEPES (20 mm),
NaCl (300 mm), TCEP (0.1 mm) and octyl β-d-glucopyranoside (OctGlu, 1 %, w/v)
at pH 7.4. Initial anisotropy of OG-labeled ∆N complex (80 nm) was measured until
equilibration. Upon addition of Synaptobrevin-2 (1 – 96), Synaptobrevin-2 (28 – 84) wt
or mutants (6, 7, 10 and 36) dissociations of OG-labeled Synaptobrevin-2 (49 – 96)
fragment were detected by changes in anisotropy. The used concentrations and addition
times are stated in Fig. 4.10 and 5.16.
8.4 General Synthesis Procedures (GSP)
Solid Phase Peptide Synthesis
For all peptide syntheses preloaded Wang resin with low loading density (0.3 – 0.4 mmol/g)
was used for synthesis. The following amino acid building blocks were used in the presented
peptide syntheses:
Fmoc-Ala-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Cys(Trt)-
OH, Fmoc-Gln(Trt)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Gly-OH, Fmoc-Ile-OH, Fmoc-Leu-OH,
Fmoc-Lys(Boc)-OH, Fmoc-Met-OH, Fmoc-Phe-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH,
Fmoc-Tyr(tBu)-OH, Fmoc-Val-OH. Unnatural amino acids are used as stated in the protocols.
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8.4.1 GSP 1: Manual Solid Phase Peptide Synthesis[124]
For manual solid phase peptide synthesis an acid- and base-resistant Becton Dickinson
DiscarditTM II (BD)-syringe equipped with a polyethylene-frit was used as reaction vessel.
The resin was swollen in NMP (∼10 mL/g resin) by shaking for at least 1 h before starting
reaction. The batch size was varied for each experiment, the protocol shown here is for
0.05 mmol (about 250 mg of resin) in a 2 mL-BD-syringe.
1. Deprotection: The Fmoc protecting group was removed with piperidine (20 %, v/v)
in NMP (2 x 2 mL) for 15 min each. Afterwards, the resin was washed with NMP
(5 x 2 mL), DCM (5 x 2 mL) and NMP (5 x 2 mL).
2. Coupling: The respective amino acid (5.00 eq.) was dissolved in NMP (0.2 m) and
HBTU/HOBt (4.90/5.00 eq., 0.49/0.50 m in DMF) was added. Directly before trans-
ferring the coupling mixture to the resin DIPEA (10.0 eq.) was added to activate the
mixture. The resin was shaken for 30 – 60 min (dependent on used amino acid and
sequence-length). For double coupling, the amino acid mixture was added to the resin a
second time before washing. Afterwards, the resin was washed with NMP (5 x 2 mL),
DCM (5 x 2 mL) and NMP (5 x 2 mL).
3. Capping: A solution of Ac2O (10 %, v/v) and DIPEA (5 %, v/v) in NMP (2 x 2 mL)
was added to the resin and shaken for 10 min each. Afterwards, the resin was washed
with NMP (5 x 2 mL), DCM (5 x 2 mL) and NMP (5 x 2 mL).
4. Repetition: Steps 1 – 3 were repeated as often as required to complete the sequence.
In case of longer breaks during synthesis the resin was washed with DCM (10 x 2 mL)
and dried under reduced pressure. After complete synthesis, the last Fmoc protecting
group was removed according to step 1 and the resin was washed with NMP (10 x 2 mL),
DCM (10 x 2 mL) and dried under reduced pressure.
8.4.2 GSP 2: Automated Solid Phase Peptide Synthesis
CEM Liberty12 peptide synthesizer
Automated solid phase peptide synthesis was conducted by using standard-Fmoc-protocol at
a microwave-supported peptide synthesizer Liberty12 from CEM (Kamp-Lintfort, Germany)
which consist of a Liberty unit and a Discover microwave. All resins, reagents and solvents
necessary for the reaction were connected to the Liberty unit. In the case of the Liberty12
unit it was possible to attach 20 natural and five unnatural amino acids as well as twelve resins.
All amino acids were applied as 0.2 m solutions in NMP. Standard reagents were used for
deprotection (piperidine (20 %, v/v) in NMP), coupling (HBTU/HOBt (0.5 m) in DMF, DIPEA
(2.0 m) in NMP), capping (Ac2O (20 %, v/v) in NMP) and washing (NMP). All reactions were
conducted microwave-supported and under nitrogen. The standard cycle for the batch size of
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0.10 mmol with double coupling procedure (0.10-Double-Capping) was used if not stated in the
corresponding synthesis protocol. The standard cycle consisted of two deprotection steps (30 s,
40 °C, 35 W and 180 s, 75 °C, 35 W), two coupling steps (120 s, 75 °C, 25 W and 300 s, 75 °C,
25 W), a capping reaction (180 s, 75 °C, 25 W) and washing (NMP) in between and afterwards.
For the amino acids Cys (0.10-Double-Capping 50C) and Arg (0.10-Double-Capping Arg (KM))
special programs were used as well as for long sequences for the N-terminal amino acids (0.10-
Double-Capping 10 min). At the end of the synthesis, the terminal Fmoc protecting group was
removed. After completion of the automated synthesis, the resin was transferred from a Falcon
Tube into a 10 mL-BD-syringe, washed with DCM (15 x 8 mL) and dried under reduced pressure.
CEM LibertyBlue peptide synthesizer
Automated solid phase peptide synthesis was conducted by using standard-Fmoc-protocol at a
microwave-supported peptide synthesizer LibertyBlue from CEM (Kamp-Lintfort, Germany)
which consist of a Liberty unit and a Discover microwave. All reagents and solvents necessary
for the reaction were connected to the Liberty unit. In the case of the LibertyBlue unit it was
possible to attach 20 natural and seven unnatural amino acids. All amino acids were applied
as 0.2 m solutions in DMF. Standard reagents were used for deprotection (piperidine (20 %,
v/v), HOBt (0.1 m) in DMF), coupling (DIC (0.5 m) in DMF, Oxyma (1.0 m) in DMF) and
washing (NMP). All reactions were conducted microwave-supported and under nitrogen. The
standard cycle for the batch size of 0.10 mmol with double coupling procedure for high-swelling
resins (0.10-Double Coupling (HS)) was used if not stated in the corresponding synthesis
protocol. The standard cycle consisted of one deprotection step (15 s, 75 °C, 155 W, followed
by 50 s, 90 °C, 35 W), two coupling steps (15 s, 75 °C, 170 W and 110 s, 90 °C, 30 W) and
washing (NMP) between deprotection and coupling. For the amino acids Cys (0.10-Double
50°C Coupling (HS)) and Arg (0.10-Double Arg Coupling (HS)) special programs were used.
Deprotection and coupling steps for Cys were proceeded at max. 50 °C. Arg was coupled with
elongated coupling time and decreased temperature (25 min, 25 °C, 0 W and 120 s, 75 °C,
30 W). After completion of the automated synthesis the resin was transferred from the reaction
vessel in a 10 mL-BD-syringe, washed with DCM (15 x 8 mL) and dried under reduced pressure.
8.4.3 GSP 3: Peptide Cleavage from Solid-Support[124]
For peptide cleavage from solid-support and deprotection of amino acid side chains a solution
of TFA, TIS and H2O (95/2.5/2.5, v/v/v) was added 10 mL/g to the dry resin and shaken
for 2 h at room temperature. In the case of Cys or Met within the peptide sequence a solution
of TFA, TIS, EDT and H2O (94/1.0/2.5/2.5, v/v/v/v) was used. The solution was collected
and the resin was washed with TFA (3 x 10 mL/g). The solvent was removed by nitrogen
stream and the peptide precipitated in cold Et2O (2 – 10 mL), suspended by ultrasonic bath,
stored for 20 – 30 min at -18 °C and centrifugated (14000 rpm, -18 °C, 10 min). The ether
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was decanted and the precipitation repeated twice. The crude peptide was dried under reduced
pressure and purified by HPLC.
8.4.4 GSP 4: Kaiser Test[147]
Successful amino acid coupling during manual SPPS (chapter 8.4.1) was checked by performing
Kaiser test[147]. After coupling step and washing a small amount of the resin was washed
again with DCM, dried and a few drops of the following solutions were added in that order:
1. Phenol (42.5 m) in EtOH,
2. Ninhydrin (0.3 m) in EtOH,
3. KCN (20.0 µm) in pyridine.
The mixture was heated for 5 min to 120 °C. In the case of blue coloured solution, the coupling
step was repeated due to evidence of primary amines. A successful coupling was achieved, if
the solution showed a yellow colour.[147]
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N-Fmoc-Asp-OtBu (1, 1.00 g, 2.43 mmol, 1.50 eq.), HOBt (0.33 g, 2.43 mmol, 1.50 eq.)
and HBTU (0.92 g, 2.43 mmol, 1.50 eq.) were dissolved in dry DMF (5 mL) under argon
atmosphere and activated by addition of DIPEA (0.55 mL, 0.42 g, 3.24 mmol, 2.00 eq.). The
reaction mixture was stirred for 5 min before addition of 1-adamantylamino hydrochloride (2,
0.30 g, 1.62 mmol, 1.00 eq.) in dry DMF (3 mL). The reaction was stirred overnight at room
temperature. The solvent was removed under reduced pressure and the residue dissolved in
EtOAc (30 mL). The organic layer was washed with NH4Cl solution (0.1 m, 3 x 25 mL), dried
over MgSO4 and the sovlent removed under reduced pressure. The crude product was purified
by flash chromatography on silica gel (EtOAc/n-pentane, 1/2) and the pure target compound
(3, 0.65 g, 1.19 mmol, 74 %) obtained as colorless foam.
TLC: R f = 0.67 (EtOAc/n-pentane, 1/2).
1H-NMR (300 MHz, CDCl3): δ (ppm) = 1.48 (s, 9 H, t-Bu), 1.67 (s, 6 H, 3 x Ad-4’-
H2), 1.98 (s, 6 H, 3 x Ad-2’-H2), 2.07 (s, 3 H, 3 x Ad-3’-H), 2.71 (ddd, J = 15.7 Hz,
J = 4.6 Hz, J = 3.9 Hz, 2 H, β-H2), 4.23 (t, J = 7.1 Hz, 1 H, Fmoc-9”-H), 4.28 – 4.49
(m, 3 H, α-H, Fmoc-10”-H2), 5.20 (s, 1 H, NH), 6.16 (s, 1 H, NH), 7.31 (t, J = 7.4 Hz,
2 H, Fmoc-2”-H, Fmoc-7”-H), 7.40 (t, J = 7.4 Hz, 2 H, Fmoc-3”-H, Fmoc-6”-H), 7.62 (d,
J = 7.4 Hz, 2 H, Fmoc-1”-H, Fmoc-8”-H), 7.76 (d, J = 7.4 Hz, 2 H, Fmoc-4”-H, Fmoc-5”-H).
ESI-MS(+) (m/z (%)): 545.3 (12) [M+H]+, 567.3 (50) [M+Na]+, 1089.5 (16) [2M+H]+,
1111.5 (100) [2M+Na]+.
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HR-MS (ESI):
calculated for [C33H41N2O5]+ ([M+H]+): 545.3010; found: 545.3006,



































Compound 3 (0.65 g, 1.19 mmol, 1.00 eq.) in TFA/H2O (5 mL, 95/5, v/v) was stirred for 2 h.
The solvent was removed by nitrogen stream and residual TFA was coevaporated three times
by toluene. The residue was dissolved in EtOAc (50 mL), washed with NH4Cl solution (0.1 m,
3 x 25 mL), dried over MgSO4 and the solvent removed under reduced pressure. The crude
product was purified by flash chromatography on silica gel (DCM/MeOH/AcOH, 90/10/0.5)
and the pure target compound (4, 0.56 g, 1.15 mmol, 96 %) obtained as light brown foam.
TLC: R f = 0.28 (DCM/MeOH/AcOH, 90/10/0.5).
1H-NMR (300 MHz, CDCl3): δ (ppm) = 1.68 (s, 6 H, 3 x Ad-4’-H2), 2.00 (s, 6 H, 3 x Ad-2’-
H2), 2.10 (s, 3 H, 3 x Ad-3’-H), 2.70 (dd, J = 15.7 Hz, J = 9.4 Hz, 1 H, βa-H), 2.85 (dd,
J = 15.7 Hz, J = 2.3 Hz, 1 H, βb-H) 4.21 (t, J = 7.1 Hz, 1 H, Fmoc-9”-H), 4.32 – 4.45
(m, 3 H, 2-H, Fmoc-10”-H2), 5.64 (sbr, 1 H, OH), 5.84 (s, 1 H, NH), 6.14 (s, 1 H, NH), 7.31
(t, 3JHH = 7.4 Hz, 2 H, Fmoc-2”-H, Fmoc-7”-H ), 7.41 (t, J = 7.4 Hz, 2 H, Fmoc-3”-H,
Fmoc-6”-H), 7.59 (d, J = 7.4 Hz, 2 H, Fmoc-1”-H, Fmoc-8”-H), 7.77 (d, J = 7.4 Hz, 2 H,
Fmoc-4”-H, Fmoc-5”-H).
13C-NMR (75 MHz, CDCl3): δ (ppm) = 29.24 (3 x Ad-C-3’), 36.07 (3 x Ad-C-4’), 28.67
(C-β), 41.10 (C-α), 46.95 (Fmoc-C-9”), 50.75 (3 x Ad-C-2’), 53.13 (Ad-C-1’), 67.29 (Fmoc-C-
10”), 119.96 (Fmoc-C-4”, Fmoc-C-5”), 125.09 (Fmoc-C-1”, Fmoc-C-8”), 127.06 (Fmoc-C-2”,
Fmoc-C-7”), 127.72 (Fmoc-C-3”, Fmoc-C-6”), 141.21 (Fmoc-C-4”a, Fmoc-C-4”b), 143.54
(Fmoc-C-8”a, Fmoc-C-9”a), 156.04 (Fmoc-C-11’), 171.06 (γ-CO), 172.75 (CO2H).
ESI-MS(+) (m/z (%)): 489.2 (52) [M+H]+, 511.2 (100) [M+Na]+, 999.5 (45) [2M+Na]+,
1487.7 (45) [3M+Na]+.
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ESI-MS(−) (m/z (%)): 487.2 (100) [M−H]−, 975.4 (23) [2M−H]−.
HR-MS (ESI):
calculated for [C29H33N2O5]+ ([M+H]+): 489.2384; found: 489.2376,
calculated for [C29H31N2O5]− ([M−H]−): 487.2238; found: 487.2234,
calculated for [C29H32N2O5Na]+ ([M+Na]+): 511.2203; found: 511.2199.
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8.6 Adamantyl modified Synaptobrevin-2 analogues[119]
8.6.1 Synthesis of Synaptobrevin-2 (66 – 84) (5)




Peptide 5 was synthesized according to GSP 2 (chapter 8.4.2) by automated solid phase peptide
synthesis (0.10 mmol) on a preloaded Fmoc-Leu-Wang resin (0.30 mmol/g) using the CEM
Liberty12 peptide synthesizer. The following amino acid derivatives were used:
Fmoc-Ala-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Gluc(OtBu)-
OH, Fmoc-Gly-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Phe-OH, Fmoc-Ser(tBu)-OH,
Fmoc-Thr(tBu)-OH. According to GSP 3 (chapter 8.4.3) a small amount of peptide 5 was
cleaved from the resin and completely deprotected for analysis by HPLC and mass spectrometry.
The residual amount was used resin-bound for further syntheses (peptides 6 – 11).
HPLC (Macherey-Nagel NUCLEODUR® RP-C18 ec analytical column (100 Å, 5 µm, 250 x 4.6 mm),
gradient: 10 – 90 % B in 30 min): tR, netto = 11.78 min, tR, brutto = 15.86 min.
ESI-MS(+) (m/z (%)): 968.5 (100) [M+2H]2+, 1936.0 (3) [M+H]+.
ESI-MS(−) (m/z (%)): 965.5 (47) [M−2H]2−, 1934.0 (12) [M−H]−.
HR-MS (ESI):
calculated for [C82H138N25O29]3+ ([M+3H]3+): 645.6692; found: 645.6705,
calculated for [C82H133N25O29]2− ([M−2H]2−): 965.9856; found: 965.9871,
calculated for [C82H137N25O29]2+ ([M+2H]2+): 968.0002; found: 968.0008,
calculated for [C82H136N25O29]+ ([M+H]+): 1934.9930; found: 1934.9935,
calculated for [C82H135N25O29Na]+ ([M+Na]+): 1956.9750; found: 1956.9765.
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8.6.2 Synthesis of Synaptobrevin-2 (28 – 84) (6)




Peptide 6 was synthesized according to GSP 2 (chapter 8.4.2) by automated solid phase peptide
synthesis (0.10 mmol) on a preloaded Fmoc-Leu-Wang resin (0.30 mmol/g) using the CEM
Liberty12 peptide synthesizer. The synthesis was performed in two sections (Syb-2 (57 – 84)
followed by Syb-2 (28 – 56)) due to reagent capacities of the peptide synthesizer. Between
the two sections a small amount of peptide Syb-2 57 – 84 was cleaved from the resin and
completely deprotected according to GSP 3 (chapter 8.4.3) for analysis by HPLC and mass
spectrometry. The residual amount was used resin-bound for further synthesis of peptide 6.
The following amino acid derivatives were used:
Fmoc-Ala-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Gln(Trt)-
OH, Fmoc-Glu(OtBu)-OH, Fmoc-Gly-OH, Fmoc-Ile-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH,
Fmoc-Met-OH, Fmoc-Phe-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Val-OH.
Alternatively, Peptide 6 was synthesized according to GSP 1 (chapter 8.4.1) by manual solid
phase peptide synthesis (0.05 mmol) on the preloaded resin (250 mg) obtained from synthesis
of peptide 5 (chapter 8.6.1). The following amino acid derivatives were used:
Fmoc-Ala-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Gln(Trt)-
OH, Fmoc-Glu(OtBu)-OH, Fmoc-Gly-OH, Fmoc-Ile-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH,
Fmoc-Met-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Val-OH.
Until amino acid D51 a coupling time of 30 min was applied except for R56, E55 (2 x 45 min)
and V53 (2 x 30 min). From amino acid V50 on coupling time was elongated to 2 x 45 min
except for R47 (2 x 1 h) and R31, R30 (3 x 1 h). After coupling of ten amino acid residues a
testcleavage was performed by using small amount of the resin and cleavage of the peptide
according to GSP 3 (chapter 8.4.3). Synthesis progress was then analysed by mass spectrometry
and analytical HPLC.
After complete synthesis peptide 6 was cleaved from resin and completely deprotected accord-
ing to GSP 3 (chapter 8.4.3). After three times purification by HPLC peptide 6 (1.50 mg,
0.23 µmol, 0.47 %) was obtained.
HPLC (Macherey-Nagel NUCLEODUR® RP-C18 ec analytical column (100 Å, 5 µm, 250 x 4.6 mm),
gradient: 40 – 50 % B in 30 min): tR,netto = 17.98 min, tR, brutto = 22.52 min.
ESI-MS(+) (m/z (%)): 915.3 (100) [M+7H]7+, 1067.7 (100) [M+6H]6+, 1281.1 (24)
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[M+5H]5+, 6397.3 (100) [M] (deconvoluted).
HR-MS (ESI):
calculated for [C268H457N84O95S]7+ ([M+7H]7+): 915.3330; found: 915.3325,
calculated for [C268H456N84O95S]6+ ([M+6H]6+): 1067.7200; found: 1067.7221,
calculated for [C268H455N84O95S]5+ ([M+5H]5+): 1281.0626; found: 1281.0655,
calculated for C268H450N84O95S [M]: 6397.3; found: 6397.3 (deconvoluted).
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Peptide 7 was synthesized according to GSP 1 (chapter 8.4.1) by manual solid phase peptide
synthesis (0.05 mmol) on the preloaded resin (225 mg) obtained from synthesis of peptide 5
(chapter 8.6.1). The following amino acid derivatives were used:
Fmoc-Ala-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Asn(Ad)-OH (4), Fmoc-Asp-
(OtBu)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Gly-OH, Fmoc-Ile-OH, Fmoc-
Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Met-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-
Val-OH.
Until amino acid D51 a coupling time of 30 min was applied except for R56 (2 x 45 min) and
V53 (2 x 30 min). From amino acid V50 on coupling time was elongated to 2 x 45 min except
for R47 (2 x 1 h) and R31, R30 (3 x 1 h). Coupling time for amino acid building block 4
was elongated to 2 x 45 min. After coupling of ten amino acid residues a testcleavage was
performed by using a small amount of the resin and cleavage of the peptide according to GSP 3
(chapter 8.4.3). Synthesis progress was then analysed by mass spectrometry and analytical
HPLC. After complete synthesis peptide 7 was cleaved from resin and completely deprotected
according to GSP 3 (chapter 8.4.3). After three times purification by HPLC peptide 7 (1.37 mg,
0.21 µmol, 0.41 %) was obtained.
HPLC (Macherey-Nagel NUCLEODUR® RP-C18 ec analytical column (100 Å, 5 µm, 250 x
4.6 mm), gradient: 45 – 55 % B in 30 min): tR,netto = 15.12 min, tR, brutto = 19.36 min.
ESI-MS(+) (m/z (%)): 832.57 (18) [M+8H]8+, 951.37 (100) [M+7H]7+, 1109.76 (66)
[M+6H]6+, 1331.50 (8) [M+5H]5+, 6652.52 (100) [M+H]+.
HR-MS (ESI):
calculated for [C287H485N86O93S]7+ ([M+7H]7+): 951.3661; found: 951.3663,
calculated for [C287H484N86O93S]6+ ([M+6H]6+): 1109.7593; found: 1109.7589,
calculated for [C287H479N86O93S]+ ([M+H]+): 6652.51; found: 6652.52.
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Peptide 8 was synthesized according to GSP 1 (chapter 8.4.1) by manual solid phase peptide
synthesis (0.05 mmol) on the preloaded resin (250 mg) obtained from synthesis of peptide 5
(chapter 8.6.1). The following amino acid derivatives were used:
Fmoc-Ala-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Asn(Ad)-OH (4), Fmoc-Asp-
(OtBu)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Gly-OH, Fmoc-Ile-OH, Fmoc-
Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Met-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-
Val-OH.
Until amino acid D51 a coupling time of 30 min was applied except for R56 (2 x 45 min) and
V53 (2 x 30 min). From amino acid V50 on coupling time was elongated to 2 x 45 min except
for R47 (2 x 1 h) and R31, R30 (3 x 1 h). Coupling time for amino acid building block 4
was elongated to 2 x 45 min. After coupling of ten amino acid residues a testcleavage was
performed by using a small amount of the resin and cleavage of the peptide according to GSP 3
(chapter 8.4.3). Synthesis progress was then analysed by mass spectrometry and analytical
HPLC. After complete synthesis peptide 8 was cleaved from resin and completely deprotected
according to GSP 3 (chapter 8.4.3). After three times purification by HPLC peptide 8 (1.29 mg,
0.19 µmol, 0.39 %) was obtained.
HPLC (Macherey-Nagel NUCLEODUR® VarioPrep RP-C18 ec semipreperative column (100 Å,
5 µm, 250 x 10.0 mm), gradient: 45 – 55 % B in 30 min): tR,netto = 14.65 min, tR, brutto = 20.51 min.
ESI-MS(+) (m/z (%)): 832.57 (12) [M+8H]8+, 951.37 (100) [M+7H]7+, 1109.76 (82)
[M+6H]6+, 1331.51 (12) [M+5H]5+, 1664.38 (1) [M+4H]4+, 6652.53 (100) [M+H]+.
HR-MS (ESI):
calculated for [C287H485N86O93S]7+ ([M+7H]7+): 951.3661; found: 951.3659,
calculated for [C287H484N86O93S]6+ ([M+6H]6+): 1109.7593; found: 1109.7584,
calculated for [C287H479N86O93S]+ ([M+H]+): 6652.51; found: 6652.53.
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Peptide 9 was synthesized according to GSP 1 (chapter 8.4.1) by manual solid phase peptide
synthesis (0.05 mmol) on the preloaded resin (250 mg) obtained from synthesis of peptide 5
(chapter 8.6.1). The following amino acid derivatives were used:
Fmoc-Ala-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Asn(Ad)-OH (4), Fmoc-Asp-
(OtBu)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Gly-OH, Fmoc-Ile-OH, Fmoc-
Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Met-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-
Val-OH.
Until amino acid D51 a coupling time of 30 min was applied except for R56 (2 x 45 min) and
V53 (2 x 30 min). From amino acid V50 on coupling time was elongated to 2 x 45 min except
for R47 (2 x 1 h) and R31, R30 (3 x 1 h). Coupling time for amino acid building block 4
was elongated to 2 x 45 min. After coupling of ten amino acid residues a testcleavage was
performed by using a small amount of the resin and cleavage of the peptide according to GSP 3
(chapter 8.4.3). Synthesis progress was then analysed by mass spectrometry and analytical
HPLC. After complete synthesis peptide 9 was cleaved from resin and completely deprotected
according to GSP 3 (chapter 8.4.3). After three times purification by HPLC peptide 9 (1.09 mg,
0.16 µmol, 0.32 %) was obtained.
HPLC (Macherey-Nagel NUCLEODUR® RP-C18 ec analytical column (100 Å, 5 µm, 250 x 4.6 mm),
gradient: 45 – 55 % B in 30 min): tR,netto = 21.98 min, tR, brutto = 26.34 min.
ESI-MS(+) (m/z (%)): 849.22 (28) [M+8H]8+, 970.39 (100) [M+7H]7+, 1131.95 (50)
[M+6H]6+, 1358.14 (7) [M+5H]5+, 1697.41 (1) [M+4H]4+, 6785.65 (100) [M+H]+.
HR-MS (ESI):
calculated for [C297H501N87O92S]8+ ([M+8H]8+): 849.2120; found: 849.2119,
calculated for [C297H500N87O92S]7+ ([M+7H]7+): 970.3841; found: 970.3842,
calculated for [C297H499N87O92S]6+ ([M+6H]6+): 1131.9469; found: 1131.9465,
calculated for [C297H493N87O92S]+ ([M+H]+): 6785.64; found: 6785.65.
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Peptide 10 was synthesized according to GSP 1 (chapter 8.4.1) by manual solid phase peptide
synthesis (0.05 mmol) on the preloaded resin (250 mg) obtained from synthesis of peptide 5
(chapter 8.6.1). The following amino acid derivatives were used:
Fmoc-Ala-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Asn(Ad)-OH (4), Fmoc-Asp-
(OtBu)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Gly-OH, Fmoc-Ile-OH, Fmoc-
Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Met-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-
Val-OH.
Until amino acid D51 a coupling time of 30 min was applied except for R56, E55 (2 x 45 min)
and V53 (2 x 30 min). From amino acid V50 on coupling time was elongated to 2 x 45 min
except for R47 (2 x 1 h) and R31, R30 (3 x 1 h). Coupling time for amino acid building
block 4 was elongated to 2 x 45 min. After coupling of ten amino acid residues a testcleavage
was performed by using a small amount of the resin and cleavage of the peptide according
to GSP 3 (chapter 8.4.3). Synthesis progress was then analysed by mass spectrometry and
analytical HPLC. After complete synthesis peptide 10 was cleaved from resin and completely
deprotected according to GSP 3 (chapter 8.4.3). After three times purification by HPLC
peptide 10 (1.47 mg, 0.23 µmol, 0.45 %) was obtained.
HPLC (Macherey-Nagel NUCLEODUR® RP-C18 ec analytical column (100 Å, 5 µm, 250 x 4.6 mm),
gradient: 45 – 55 % B in 30 min): tR,netto = 14.19 min, tR, brutto = 18.55 min.
ESI-MS(+) (m/z (%)): 816.06 (9) [M+8H]8+, 932.49 (100) [M+7H]7+, 1087.74 (73)
[M+6H]6+, 1305.07 (12) [M+5H]5+, 6520.39 (100) [M+H]+.
HR-MS (ESI):
calculated for [C277H470N84O95S]8+ ([M+8H]8+): 816.0536; found: 816.0542,
calculated for [C277H469N84O95S]7+ ([M+7H]7+): 932.4888; found: 932.4886,
calculated for [C277H468N84O95S]6+ ([M+6H]6+): 1087.7357; found: 1087.7357,
calculated for [C277H462N84O95S]+ ([M+H]+): 6520.37; found: 6520.39.
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Peptide 11 was synthesized according to GSP 1 (chapter 8.4.1) by manual solid phase peptide
synthesis (0.05 mmol) on the preloaded resin (225 mg) obtained from synthesis of peptide 5
(chapter 8.6.1). The following amino acid derivatives were used:
Fmoc-Ala-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Asn(Ad)-OH (4), Fmoc-Asp-
(OtBu)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Gly-OH, Fmoc-Ile-OH, Fmoc-
Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Met-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-
Val-OH.
Until amino acid D51 a coupling time of 30 min was applied except for R56, E55 (2 x 45 min)
and V53 (2 x 30 min). From amino acid V50 on coupling time was elongated to 2 x 45 min
except for R47 (2 x 1 h) and R31, R30 (3 x 1 h). Coupling time for amino acid building
block 4 was elongated to 2 x 45 min. After coupling of ten amino acid residues a testcleavage
was performed by using a small amount of the resin and cleavage of the peptide according
to GSP 3 (chapter 8.4.3). Synthesis progress was then analysed by mass spectrometry and
analytical HPLC. After complete synthesis peptide 11 was cleaved from resin and completely
deprotected according to GSP 3 (chapter 8.4.3). After three times purification by HPLC
peptide 11 (1.63 mg, 0.25 µmol, 0.50 %) was obtained.
HPLC (Macherey-Nagel NUCLEODUR® RP-C18 ec analytical column (100 Å, 5 µm, 250 x 4.6 mm),
gradient: 45 – 55 % B in 30 min): tR,netto = 11.15 min, tR, brutto = 14.69 min.
ESI-MS(+) (m/z (%)): 815.93 (15) [M+8H]8+, 932.35 (100) [M+7H]7+, 1087.57 (78)
[M+6H]6+, 1304.88 (16) [M+5H]5+, 6519.40 (100) [M+H]+.
HR-MS (ESI):
calculated for [C277H470N85O94S]7+ ([M+7H]7+): 932.3482; found: 932.3484,
calculated for [C277H469N85O94S]6+ ([M+6H]6+): 1087.5717; found: 1087.5720,
calculated for [C277H463N85O94S]+ ([M+H]+): 6519.39; found: 6519.40.
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8.7 Photocleavable Amino Acid Building Blocks
8.7.1 Synthesis of caged lysine N-Fmoc buidling block (16)[132, 137]





















4,5-Dimethoxy-2-nitrobenzylalcohol (12, 5.03 g, 23.6 mmol, 1.00 eq.) and p-nitrophenylchloro-
formate (13, 9.43 g, 47.0 mmol, 2.00 eq.) were suspended in dry DCM (50 mL). After addition
of DIPEA (8.35 mL, 47.0 mmol, 2.00 eq.) the reaction mixture became homogeneous and was
stirred overnight at room temperature. The solvent was removed under reduced pressure and
the residue was recrystallized from EtOH, filtrated and washed with hot EtOH (2 x 10 mL).
Drying under reduced pressure yielded the target compound (14, 4.95 g, 13.1 mmol, 55 %) as
a light yellow solid.
1H-NMR (300 MHz, CDCl3): δ (ppm) = 3.98 (s, 3 H, OMe), 4.02 (s, 3 H, OMe), 5.71 (s,
2 H, 7-H2), 7.01 (s, 1 H, 6-H), 7.41 (d, J = 9.3 Hz, 2 H, 2’-H, 6’-H), 7.77 (s, 1 H, 3-H), 8.29
(d, J = 9.3 Hz, 2 H, 3’-H, 5’-H).
13C-NMR(125 MHz, CDCl3): δ (ppm) = 56.84 (OMe), 56.93 (OMe), 68.04 (C-7), 108.77
(C-3), 111.01 (C-6), 122.06 (C-2’, C-6’), 125.42 (C-1), 125.72 (C-3’, C-5’), 140.38 (C-2),
145.89 (C-4’), 149.17 (C-4), 152.41 (C=O), 154.04 (C-5), 155.69 (C-1’).
ESI-MS(+) (m/z (%)): 396.1 (100) [M+NH4]+, 401.1 (88) [M+Na]+, 417.0 (12) [M+K]+,
779.1 (62) [2M+Na]+.
HR-MS (ESI):
calculated for [C16H18N3O9]+ ([M+NH4]+): 396.1038; found: 396.1041,
calculated for [C16H14N2O9Na]+ ([M+Na]+): 401.0592; found: 401.0593,
calculated for [C16H14N2O9K]+ ([M+K]+): 417.0331; found: 417.0328.
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Fmoc-Lys-OH (15, 1.95 g, 5.29 mmol, 1.00 eq.) was suspended in H2O/1,4-dioxane/MeCN
(1/1/1, 45 mL) and Na2CO3 (0.56 g, 5.29 mmol, 1.00 eq.) was added. Afterwards, additional
amount of H2O (10 mL) and MeCN (5 mL) were added to transfer all solids into solution.
4,5-Dimethoxy-2-nitrobenzyl-4’-nitrophenylcarbonate (14, 2.00 g, 5.29 mmol, 1.00 eq.) was
suspended in 1,4-dioxane (25 mL) and added drop-wise to the reaction mixture. After addition
the mixture was stirred under exclusion of light at room temperature overnight. The solvent
was removed under reduced pressure and the residue was dissolved in aqueous NaHSO4 solution
(1 m, 75 mL) and DCM (125 mL). The phases were seperated and the aqueous phase was
extracted with DCM (125 mL). The combined organic layers were dried over MgSO4 and the
solvent was removed under reduced pressure. Purification by flash chromatography on silica
gel (n-pentane/EtOAc, 1/1 → DCM/MeOH/AcOH, 95/5/0.5) yielded the target compound
(16, 2.43 g, 4.00 mmol, 76 %) as a yellow solid.
TLC: R f = 0.47 (DCM/MeOH/AcOH, 95/5/0.5).
1H-NMR (300 MHz, dmso-d6): δ (ppm) = 1.26 – 1.53 (m, 4 H, γ-H2, δ-H2), 1.53 –
1.80 (m, 2 H, β-H2), 3.03 (dd, J = 12.1, 6.2 Hz, 2 H, ε-H2), 3.85 (s, 3 H, 3’-OMe), 3.88 (s,
3 H, 4’-OMe), 3.90 – 4.00 (m, 1 H, α-H), 4.17 – 4.25 (m, 1 H, 9”-H), 4.25 – 4.32 (m, 2 H,
10”-H2), 5.33 (s, 2 H, 7’-H2), 7.16 (s, 1 H, 5’-H), 7.31 (t, J = 7.4 Hz, 2 H, 2”-H, 7”-H), 7.40 (t,
J = 7.4 Hz, 3 H, 3”-H, 6”-H, ε-NH), 7.56 (d, J = 8.0 Hz, 1 H, α-NH), 7.67 (s, 1 H, 2’-H), 7.71
(d, J = 7.4 Hz, 2 H, 1”-H, 8”-H), 7.86 (d, J = 7.4 Hz, 2 H, 4”-H, 5”-H), 12.51 (sbr, 1 H, CO2H).
13C-NMR(125 MHz, dmso-d6): δ (ppm) = 22.86 (C-γ), 28.89 (C-δ), 30.41 (C-β), 40.04
(C-ε), 46.65 (C-9”), 53.74(C-α), 56.01 (OMe), 56.12 (OMe), 62.16 (C-7’), 65.56 (C-10”),
108.13 (C-2’), 110.52 (C-5’), 119.98 (C-4”, C-5”), 125.16 (C-1”, C-8”), 126.96 (C-2”, C-7”),
127.53 (C-3”, C-6”), 128.11 (C-6’), 139.27 (C-1’), 140.64 (C-4”a, C-4”b), 143.75 (C-8”a,
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C-9”a), 147.67 (C-3’), 153.30 (C-4’), 155.63 (C-8’), 156.11 (C-11”), 173.85 (CO2H).
ESI-MS(+) (m/z (%)): 608.2 (3) [M+H]+, 630.2 (90) [M+Na]+, 646.2 (100) [M+K]+,
1237.4 (13) [2M+Na]+, 1253.4 (8) [2M+K]+.
ESI-MS(−) (m/z (%)): 606.2 (100) [M−H]−.
HR-MS (ESI):
calculated for [C31H32N3O10]− ([M−H]−): 606.2093; found: 606.2095,
calculated for [C31H34N3O10]+ ([M+H]+): 608.2239; found: 608.2231,
calculated for [C31H33N3O10Na]+ ([M+Na]+): 630.2058; found: 630.2054.
calculated for [C31H33N3O10K]+ ([M+K]+): 646.1798; found: 646.1795.
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8.7.2 Synthesis of caged arginine N-Fmoc building block (21)[134, 138]


























S-methylisothiourea semisulfate (17, 2.59 g, 18.6 mmol, 2.00 eq.) was suspended in DCM
(26 mL). After addition of aqueous sodium hydroxide solution (4 m, 2.60 mL, 10.4 mmol,
1.12 eq.), a clear solution was obtained. A suspension of 4,5-dimethoxy-2-nitrobenzyl-4’-
nitrophenylcarbonate (14, 3.52 g, 9.31 mmol, 1.00 eq.) in DCM (34 mL) was added at 0 °C.
The reaction mixture was stirred overnight and was allowed to warm slowly to room temperature.
Afterwards, H2O (10 mL) was added and the layers were separated. The aqueous layer was
extracted with DCM (3 x 50 mL) and the combined organic layers were washed with hydrochloric
acid (0.1 m, 2 x 50 mL), H2O (3 x 50 mL) and saturated aqueous sodium chloride solution
(100 mL). The organic layer was dried over MgSO4 and the solvent was removed under reduced
pressure. After purification by flash chromatography on silica gel (n-pentane/EtOAc, 3/1 →
1/1→ 3/7) the target compound (18, 1.85 g, 5.63 mmol, 60 %) was obtained as a yellow solid.
1H-NMR (300 MHz, dmso-d6): δ (ppm) = 2.34 (s, 3 H, SCH3), 3.87 (s, 3 H, OMe),
3.88 (s, 3 H, OMe), 5.33 (s, 2 H, 7-H2), 7.17 (s, 1 H, 6-H), 7.68 (s, 1 H, 3-H), 8.69 (sbr, 2 H,
NH).
13C-NMR (125 MHz, dmso-d6): δ (ppm) = 13.07 (SCH3), 56.11 (OMe), 56.18 (OMe),
63.18 (C-7), 108.16 (C-3), 111.29 (C-6), 127.33 (C-1), 139.73 (C-2), 147.84 (C-4), 153.17
(C-5), 160.42 (C=N), 173.18 (C=O).
ESI-MS(+) (m/z (%)): 330.1 (80) [M+H]+, 352.1 (76) [M+Na]+, 368.1 (100) [M+K]+,
659.2 (7) [2M+H]+, 681.1 (39) [2M+Na]+.




calculated for [C12H14N3O6S]- ([M−H]−): 328.0609; found: 328.0602,
calculated for [C12H16N3O6S]+ ([M+H]+): 330.0754; found: 330.0752,
calculated for [C12H15N3O6SNa]+ ([M+Na]+): 352.0574; found: 352.0573.
calculated for [C12H15N3O6SK]+ ([M+K]+): 368.0313; found: 368.0313.
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Fmoc-Orn(Boc)-OH (19, 5.00 g, 11.0 mmol, 1.00 eq.) was dissolved in TFA/DCM (1/1,
120 mL) and stirred for 2 h at room temperature. Afterwards, the solvent was removed by nitro-
gen stream and the residue was co-evaporated with Et2O (5 x 30 mL) and toluene (2 x 30 mL)
under reduced pressure. Suspension in H2O/MeCN (10/1, 100 mL) and lyophilisation yielded
the target compound (20, 5.10 g, 10.9 mmol, 99 %) as colorless solid.
1H-NMR (300 MHz, dmso-d6): δ (ppm) = 1.53 – 1.72 (m, 3 H, β-Ha, γ-H2), 1.72 –
1.89 (m, 1 H, β-Hb), 2.73 – 2.88 (m, 2 H, δ-H2), 3.91 – 4.02 (m, 1 H, α-H), 4.18 – 4.37 (m,
3 H, 9’-H, 10’-H2), 7.33 (t, J = 7.4 Hz, 2 H, 2’-H, 7’-H), 7.41 (t, J = 7.4 Hz, 2 H, 3’-H,
6’-H), 7.64 (d, J = 8.1 Hz, 1 H, α-NH), 7.72 (d, J = 7.4 Hz, 2 H, 1’-H, 8’-H), 7.79 (sbr, 2 H,
δ-NH2), 7.89 (d, J = 7.4 Hz, 2 H, 4’-H, 5’-H), 12.89 (sbr, 1 H, CO2H).
13C-NMR(125 MHz, dmso-d6): δ (ppm) = 23.88 (C-γ), 27.69 (C-β), 38.45 (C-δ), 46.62
(C-9’), 53.33 (C-α), 65.62 (C-10’), 120.03 (C-4’, C-5’), 125.16 (C-1’, C-8’), 127.01 (C-2’,
C-7’), 127.57 (C-3’, C-6’), 140.66 (C-4’a, C-4’b), 143.73 (C-8’a, C-9’a), 156.11 (C-11’), 173.38
(CO2H).
ESI-MS(+) (m/z (%)): 179.1 (33) [M+2H]2+, 355.2 (100) [M+H]+, 393.1 (5) [M+K]+,
709.4 (2) [2M+H]+.
ESI-MS(−) (m/z (%)): 467.2 (89) [M+TFA−H]−.
HR-MS (ESI):
calculated for [C20H23N2O4]+ ([M+H]+): 355.1652; found: 355.1654,
calculated for [C22H23F3N2O6]- ([M+TFA−H]−): 467.1435; found: 467.1436.
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Imino(methylthio)methyl carbamic acid-6-nitroveratryl ester (18, 4.05 g, 12.3 mmol, 2.00 eq.)
and Fmoc-Orn-OH·TFA (20, 2.88 g, 6.15 mmol, 1.00 eq.) were dissolved in dry DMF (70 mL)
and 2,6-lutidine (7.14 mL, 6.59 g, 61.5 mmol, 10.0 eq.) was slowly added at room tempera-
ture. The reaction mixture was stirred under light exclusion at room temperature overnight.
The resulted precipitate was filtered and the filtrate concentrated under reduced pressure.
Purification by flash chromatography on silical gel (n-pentane/EtOAc, 1/2 → DCM/MeOH/A-
cOH, 10/1/0.5) yielded the target compound (21, 1.35 g, 2.12 mmol, 35 %) as light yellow solid.
TLC: R f = 0.37 (DCM/MeOH/AcOH, 10/1/0.5).
1H-NMR (300 MHz, dmso-d6): δ (ppm) = 1.39 – 1.68 (m, 3 H, β-Ha, γ-H2), 1.68 –
1.83 (m, 1 H, β-Hb), 3.07 – 3.19 (m, 2 H, ε-H2), 3.84 (s, 3 H, 3’-OMe), 3.85 (s, 3 H, 4’-OMe),
3.87 – 3.95 (m, 1 H, α-H), 4.16 – 4.37 (m, 3 H, 9”-H, 10”-H2), 5.29 (s, 2 H, 7’-H2), 7.16 (s,
1 H, 5’-H), 7.30 (t, J = 7.3 Hz, 2 H, 2”-H, 7”-H), 7.38 (t, J = 7.3 Hz, 2 H, 3”-H, 6”-H),
7.64 (s, 1 H, 2’-H), 7.69 (d, J = 7.3 Hz, 2 H, 1”-H, 8”-H), 7.84 (d, J = 7.3 Hz, 2 H, 4”-H,
5”-H), 8.33 (sbr, 1 H, CO2H).
13C-NMR(125 MHz, dmso-d6): δ (ppm) = 25.25 (C-γ), 29.12 (C-β), 39.75 (C-ε), 46.79
(C-9”), 54.65 (C-α), 56.05 (OMe), 56.10 (OMe), 62.43 (C-7’), 65.47 (C-10”), 108.06 (C-2’),
110.39 (C-5’), 120.04 (C-4”, C-5”), 125.18, 125.23 (C-1”, C-8”), 127.04, 127.26 (C-2”, C-7”),
127.58 (C-3”, C-6”), 128.75 (C-6’), 139.36 (C-1’), 140.73 (C-4a”, C-4b”), 143.83, 143.95,
(C-8a”, C-8b”), 147.56 (C-4’), 153.31 (C-3’), 158.10, 158.35 (C-11’, C=NH), 161.41 (C-8’).
ESI-MS(+) (m/z (%)): 636.2 (100) [M+H]+, 658.2 (63) [M+Na]+, 674.2 (57) [M+K]+,
1293.4 (7) [2M+Na]+.
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ESI-MS(−) (m/z (%)): 634.2 (100) [M−H]−, 748.2 (11) [M+TFA−H]−.
HR-MS (ESI):
calculated for [C31H32N5O10]- ([M−H]−): 634.2155; found: 634.2132,
calculated for [C31H34N5O10]+ ([M+H]+): 636.2300; found: 636.2306,
calculated for [C31H33N5O10Na]+ ([M+Na]+): 658.2120; found: 658.2129.
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8.7.3 Synthesis of caged aspartic acid N-Fmoc building block
(27)[107, 135]













3,4-Dimethoxyphenylacetone (22, 1.87 mL, 2.09 g, 10.8 mmol, 1.00 eq.) was added drop wise
to a suspension of sodium hydride (60 % in parrafin oil, 0.43 g, 10.8 mmol, 1.00 eq.) in dry
THF (25 mL) and stirred for 30 min at room temperature. The solution was cooled to 0 °C,
methyl iodide (0.80 mL, 1.82 g, 12.8 mmol, 1.19 eq.) added and afterwards stirred for 30 min
at 0 °C. The cooling bath was removed and the reaction mixture was stirred for 1 h at room
temperature. The reaction was quenched by addition of sat. NaHCO3 solution (100 mL) and
the aqueous layer was extracted with EtOAc (3 x 10 mL). The combined organic layers were
washed with saturated aqueous NaCl solution (100 mL) and dried over MgSO4. The solvent
was removed under reduced pressure to obtain the target compound (23, 2.22 g, 10.6 mmol,
99%) as a brown oil. It was used for further synthesis without purification.
TLC: R f = 0.45 (n-pentane/EtOAc (5/1)).
1H-NMR (300 MHz, CDCl3): δ (ppm) = 1.36 (d, J = 7.0 Hz, 3 H, 4-H3), 2.05 (s, 3 H,
1-H3), 3.68 (q, J = 7.0 Hz, 1 H, 3-H), 3.86 (s, 6 H, 2 x OMe), 6.69 (d, J = 1.9 Hz, 2’-H),
6.72 – 6.85 (m, 2 H, 5’-H, 6’-H).
ESI-MS(+) (m/z (%)): 209.2 (100) [M+H]+, 231.2 (54) [M+Na]+, 247.2 (34) [M+K]+.
HR-MS (ESI):
calculated for [C12H17O3]+ ([M+H]+): 209.1631; found: 209.1627,
calculated for [C12H16O3Na]+ ([M+Na]+): 231.1529; found: 231.1532.
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Sodium borohydride (0.90 g, 23.8 mmol, 2.50 eq.) was added at room temperature to a solution
of 3-(3,4-dimethoxyphenyl)-butan-2-one (23, 2.00 g, 9.61 mmol, 1.00 eq.) in THF/2-propanol
(30 mL, 1/2 (v/v)). The reaction mixture was stirred for 2 h at room temperature and
afterwards unreacted sodium borohydride was quenched with 1 m HCl at 0 °C. H2O (200 mL)
and EtOAc (100 mL) were added and the aqueous layer was extracted with EtOAc (100 mL).
The combined organic layers were washed with H2O (150 mL) and saturated aqueous NaCl
solution (50 mL), dried over MgSO4 and the solvent was removed under reduced pressure.
Purification by flash chromatography on silica gel (n-pentane/acetone, 5/1) yielded the target
compound (24, 1.28 g, 6.09 mmol, 63 %) as an erythro-threo (1/2) mixture of an light yellow
solid.
TLC: R f = 0.54 (n-pentane/acetone, 4/1).
1H-NMR (500 MHz, CDCl3): δ (ppm) = 1.08 (d, J = 6.2 Hz, 1 H, 3-CH3 (erythro)),
1.22 (d, J = 6.2 Hz, 2 H, 3-CH2 (threo)), 1.24 (d, J = 7.1 Hz, 2 H, 1-H3 (threo)), 1.29 (d,
J = 7.1 Hz, 1 H, 1-H3 (erythro)), 1.50 (sbr, 1 H, OH), 2.60 (quin, J = 7.1 Hz, 0.7 H, 2-H
(threo)), 2.68 (quin, J = 7.1 Hz, 0.3 H, 2-H (erythro)), 3.75 – 3.82 (m, 0.7 H, 3-H (threo)),
3.81 – 3.85 (m, 0.3 H, 3-H (erythro)), 3.85 (s, 1 H, OMe (erythro)), 3.86 (s, 2 H, OMe (threo)),
3.87 (s, 1 H, OMe (erythro)), 3.87 (s, 2 H, OMe (threo)), 6.71 – 6.85 (m, 3 H, 2’-H, 5’-H, 6’-H).
13C-NMR (125 MHz, CDCl3): δ (ppm) = 15.91 (C-4), 20.56 (C-1), 47.64 (C-3), 55.83, 55.86
(OMe), 72.40 (C-2), 111.16 (C-2’), 111.35 (C-5’), 119.80 (C-6’), 136.05 (C-1’), 147.80 (C-4’),
148.99 (C-3’).





calculated for [C12H18O3Na]+ ([M+Na]+): 233.1148; found: 233.1154,
calculated for [C12H18O3K]+ ([M+K]+): 249.0888; found: 249.0886.
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Nitronium tetrafluoroborate (1.09 g, 8.22 mmol, 1.40 eq.) was dissolved in dry acetonitrile
(15 mL) at −30 °C, 2-picoline (0.87 mL, 0.82 g, 8.81 mmol, 1.50 eq.) was added drop-wise and
the mixture was stirred for 30 min at −30 °C. A solution of 3-(3,4-dimethoxyphenyl)-butan-2-ol
(24, 1.23 g, 5.87 mmol, 1.00 eq.) in dry acetonitrile (10 mL) was slowly added and the
reaction mixture was stirred for 1 h at −30 °C and allowed to warm up to room temperature
overnight. The reaction was quenched by addition of sat. NaHCO3 solution (100 mL) and
the aqueous layer was extracted with EtOAc (2 x 100 mL). The combined organic layers were
washed with H2O (100 mL), saturated aqueous NaCl solution (50 mL), dried over MgSO4
and the solvent was removed under reduced pressure. Purification by flash chromatography
on silica gel (n-pentane/acetone, 4/1) yielded the target compound (25, 0.56 g, 2.19 mmol,
37 %) as an erythro/threo (1/2) mixture of an light yellow solid.
TLC: R f = 0.59 (n-pentane/acetone, 4/1).
1H-NMR (500 MHz, CDCl3): δ (ppm) = 1.18 (d, J = 6.2 Hz, 1 H, 3-CH3 (erythro)),
1.24 (d, J = 6.2 Hz, 2 H, 3-CH2 (threo)), 1.30 (d, J = 7.0 Hz, 2 H, 1-H3 (threo)), 1.33
(d, J = 7.0 Hz, 1 H, 1-H3 (erythro)), 1.69 (sbr, 1 H, OH), 3.53 (p, J = 7.0 Hz, 1 H, 2-H),
3.85 – 3.94 (m, 1 H, 3-H), 3.91 (s, 3 H, OMe), 3.95 (s, 3 H, OMe), 6.92 (s, 0.3 H, 6’-H
(erythro)), 6.96 (s, 0.7 H, 6’-H (threo)), 7.38 (s, 0.7 H, 3’-H (threo)), 7.41 (s, 0.3 H, 3’-H
(erythro)).
13C-NMR(125 MHz, CDCl3): δ (ppm) = 15.02 (C-4), 21.57 (C-1), 40.77 (C-3), 56.23
(OMe), 72.33 (C-2), 107.64 (C-3’), 109.72 (C-6’), 133.28 (C-1’), 143.18 (C-2’), 147.02 (C-4’),
152.70 (C-5’).




calculated for [C12H17NO5Na]+ ([M+Na]+): 278.0999; found: 278.0999.
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Synthesis of N-Fmoc-δ-[3-(4,5-dimethoxy-2-nitrophenyl)-2-butyl]-L-aspartic acid tert-


































3-(4,5-dimethoxy-2-nitrophenyl)-butan-2-ol (25, 0.56 g, 2.19 mmol, 1.00 eq.) was dissolved
in dry DCM (20 mL) and Fmoc-Asp-OtBu (1, 0.90 g, 2.19 mmol, 1.00 eq.), DCC (0.45 g,
2,19 mmol, 1.00 eq.) and DMAP (0.02 g, 0.18 mmol, 0.08 eq.) were added in this order.
The reaction mixture was stirred overnight at room temperature. Afterwards, sat. NaHCO3
solution (100 mL) was added and the aqueous layer was extracted with EtOAc (2 x 100 mL).
The combined organic layers were washed with water (100 mL) and saturated aqueous NaCl
solution (100 mL), dried over MgSO4 and the solvent was removed under reduced pres-
sure. Purification by flash chromatography on silica gel (n-pentane/acetone, 5/1) yielded the
target compound (26, 1.10 g, 1.69 mmol, 77 %) as a mixture of four isomers and as yellow solid.
TLC: R f = 0.57 (n-pentane/acetone, 5/1).
1H-NMR (500 MHz, CDCl3): δ (ppm) = 1.12 – 1.17 (m, 1 H, 1’-CH3 (erythro)), 1.21 – 1.27
(m, 2 H, 1’-CH3 (threo)), 1.28 – 1.35 (m, 3 H, 3’-CH3), 1.42, 1.44, 1.45, 1.47 (4 x s, 9 H,
OtBu), 2.60 – 3.05 (m, 2 H, β-H2), 3.72 – 3.97 (m, 7 H, 3’-H, 4”-OMe, 5”-OMe), 4.18 – 4.56
(m, 4 H, α-H, Fmoc-9-H, Fmoc-10-H2), 5.11 – 5.25 (m, 1 H, 2’-H), 5.55 – 5.78 (m, 1 H, NH),
6.74 – 6.90 (m, 1 H, 6”-H), 7.30 (t, J = 7.4 Hz, 2 H, Fmoc-2-H, Fmoc-7-H), 7.36 – 7.43
(m, 3 H, 3”-H, Fmoc-3-H, Fmoc-6-H), 7.54 – 7.62 (m, 2 H, Fmoc-1-H, Fmoc-8-H), 7.76 (d,
J = 7.4 Hz, 2 H, Fmoc-4-H, Fmoc-5-H).
13C-NMR(125 MHz, CDCl3): δ (ppm) = 16.65 (C-3’), 18.12 (C-1’), 27.84 (OC(CH3)3),
36.87 (C-β), 38.08 (C-3’), 47.06 (Fmoc-C-9), 50.89 (C-α), 56.15 (OMe), 56.21 (OMe),
67.20 (Fmoc-C-10), 74.48 (C-2’), 82.64 (OC(CH3)3), 107.68 (C-3”), 109.69 (C-6”), 119.95
(Fmoc-C-4, Fmoc-C-5), 125.09, 125.14 (Fmoc-C-1, Fmoc-C-8), 127.03 (Fmoc-C-2, Fmoc-C-7),
127.68 (Fmoc-C-3, Fmoc-C-6), 131.83 (C-1”), 141.23 (Fmoc-C-4a, Fmoc-C-4b), 142.89 (C-2”),
143.77, 143.84 (Fmoc-C-8a, Fmoc-C-9a), 147.21 (C-4”), 152.51 (C-5”), 155.85 (Fmoc-CO),
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169.37 (CO2tBu), 170.24 (δ-CO).
ESI-MS(+) (m/z (%)): 649.3 (10) [M+H]+, 671.3 (100) [M+Na]+, 687.2 (5) [M+K]+,
1319.5 (59) [2M+Na]+.
HR-MS (ESI):
calculated for [C35H40N2O10Na]+ ([M+Na]+): 671.2575; found: 671.2569.
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Fmoc-Asp(DMNPB)-OtBu (26, 1.04 g, 1.61 mmol, 1.00 eq.) was dissolved in a mixture of
TFA/DCM (1/1, (v/v), 100 mL) and the solution was stirred at room temperature for 2 h.
The solvent was removed by nitrogen stream and the residue was coevaporated by Et2O (3 x)
and toluene (3 x) under reduced pressure. Purification by flash chromatography on silica gel
(DCM/MeOH/AcOH, 20/1/0.05 (v/v/v)) followed by preperative RP-HPLC (65 % – 100 %,
30 min) and lyophilisation yielded the target compound (27, 0.70 g, 1.18 mmol, 73 %) as a
light-yellow solid.
TLC: R f = 0.45 (DCM/MeOH, 20/1 (v/v)).
HPLC (Macherey-Nagel NUCLEODUR® RP-C18 ec analytical column (100 Å, 5 µm, 250 x 4.6 mm),
gradient: 50 – 100 % B in 30 min): tR, netto = 16.77 min, tR, brutto = 19.79 min.
1H-NMR (300 MHz, CDCl3): δ (ppm) = 1.16 (d, J = 6.2 Hz, 1 H, 1’-CH3 (erythro)),
1.23 – 1.35 (m, 5 H, 1’-CH3 (threo), 3’-CH3), 2.65 – 2.98 (m, 2 H, β-H2), 3.75 – 3.96 (m,
7 H, 3’-H, 4”-OMe, 5”-OMe), 4.17 – 4.49 (m, 3 H, Fmoc-9-H, Fmoc-10-H2), 4.54 – 4.63 (m,
1 H, α-H), 5.21 (dq, J = 6.2, 2.2 Hz, 1 H, 2’-H), 5.72 (t, J = 8.7 Hz, 1 H, NH), 6.84 (d,
J = 3.3 Hz, 1 H, 6”-H), 7.30 (t, J = 7.3 Hz, 2 H, Fmoc-2-H, Fmoc-7-H), 7.35 (s, 1 H, 3”-H),
7.39 (t, J = 7.3 Hz, 3 H, Fmoc-3-H, Fmoc-6-H, 3”-H), 7.58 (d, J = 7.3 Hz, 2 H, Fmoc-1-H,
Fmoc-8-H), 7.75 (d, J = 7.3 Hz, 2 H, Fmoc-4-H, Fmoc-5-H).
13C-NMR (125 MHz, CDCl3): δ (ppm) = 16.38 (C-3’), 17.99 (C-1’), 36.50 (C-β), 38.42
(C-3’), 47.03 (Fmoc-C-9), 50.17 (C-α), 56.18 (OMe), 56.25 (OMe), 67.40 (Fmoc-C-10), 74.95
(C-2’), 107.72 (C-3”), 109.60 (C-6”), 119.98 (Fmoc-C-4, Fmoc-C-5), 125.10, 125.15 (Fmoc-C-
143
8 Experimental Part
1, Fmoc-C-8), 127.07 (Fmoc-C-2, Fmoc-C-7), 127.73 (Fmoc-C-3, Fmoc-C-6), 131.85 (C-1”),
141.26 (Fmoc-C-4a, Fmoc-C-4b), 142.81 (C-2”), 143.65, 143.71 (Fmoc-C-8a, Fmoc-C-9a),
147.27 (C-4”), 152.57 (C-5”), 156.00 (Fmoc-CO), 170.16 (δ-CO), 174.40 (CO2H).
ESI-MS(+) (m/z (%)): 593.2 (7) [M+H]+, 615.2 (100) [M+Na]+, 631.2 (7) [M+K]+,
1207.5 (41) [2M+Na]+.
ESI-MS(−) (m/z (%)): 591.2 (100) [M−H]−, 705.2 (5) [M+TFA−H]−.
HR-MS (ESI):
calculated for [C31H31N2O10]− ([M−H]−): 591.1984; found: 591.1985,
calculated for [C31H32N2O10Na]+ ([M+Na]+): 615.1949; found: 615.1950.
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8.8 Caged Synaptobrevin-2 analogues
8.8.1 Synthesis of Test Peptides 28 – 33






































Peptide 28 was synthesized according to GSP 1 (chapter 8.4.1) by manual solid phase peptide
synthesis (25 µmol) on a preloaded Fmoc-Leu-Wang resin (0.32 mmol/g). The following
amino acid derivatives were used:
Fmoc-Arg(Nvoc)-OH (21), Fmoc-Asp(OtBu)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Glu(OtBu)-OH,
Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH.
Single coupling was performed with a coupling time of 30 min (45 min for 21) and successful
coupling was checked by performing a Kaiser test (chapter 8.4.4).
After complete synthesis peptide 28 was cleaved from the resin (∼120 mg) and completely
deprotected according to GSP 3 (chapter 8.4.3). After purification by HPLC peptide 28 could
not be obtained probably due to instability of caged amino acid building block under SPPS
conditions. A compound was isolated with a difference of mass to charge ratio of ∆m
z
= −50








































Peptide 29 was synthesized according to GSP 1 (chapter 8.4.1) by manual solid phase peptide
synthesis (0.05 mmol) on a preloaded Fmoc-Leu-Wang resin (0.32 mmol/g). The following
amino acid derivatives were used:
Fmoc-Arg(Pbf)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-
Leu-OH, Fmoc-Lys(Nvoc)-OH (16).
Single coupling was performed with a coupling time of 30 min (45 min for 16) and successful
coupling was checked by performing a Kaiser test (chapter 8.4.4).
After complete synthesis peptide 29 was cleaved from half of the resin (∼120 mg) and com-
pletely deprotected according to GSP 3 (chapter 8.4.3). The rest of the resin-bound peptide
(∼120 mg) was used for synthesis of peptide 30. After purification by HPLC peptide 29
(14.4 mg, 12.6 µmol, 51 %) was obtained as light-yellow solid.
HPLC (Macherey-Nagel NUCLEODUR® RP-C18 ec analytical column (100 Å, 5 µm, 250 x 4.6 mm),
gradient: 10 – 60 % B in 30 min): tR,netto = 22.56 min, tR,brutto = 26.59 min.
UV-vis (H2O/MeCN (9/1), 500 µm): λmax (nm) = 204, 242, 300, 347.
ESI-MS(+) (m/z (%)): 570.8 (100) [M+2H]2+, 1140.5 (7) [M+H]+.
HR-MS (ESI):
calculated for [C48H79N13O19]2+ ([M+2H]2+): 570.7802; found: 570.7807,
calculated for [C48H78N13O19]+ ([M+H]+): 1140.5531; found: 1140.5526.
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Peptide 30 was synthesized according to GSP 1 (chapter 8.4.1) by manual solid phase peptide
synthesis (25 µmol) on the preloaded Wang resin (∼120 mg) obtained from the synthesis of
peptide 29. The following amino acid derivatives were used:
Fmoc-Asp(OtBu)-OH, Fmoc-Lys(Nvoc)-OH (16), Fmoc-Val-OH.
Single coupling was performed with a coupling time of 30 min (45 min for 16) and successful
coupling was checked by performing a Kaiser test (chapter 8.4.4).
After the complete synthesis, peptide 30 was cleaved from the resin and completely depro-
tected according to GSP 3 (chapter 8.4.3). After purification by HPLC peptide 30 (20.3 mg,
11.77 µmol, 47 %) was obtained as light-yellow solid.
HPLC (Macherey-Nagel NUCLEODUR® RP-C18 ec analytical column (100 Å, 5 µm, 250 x 4.6 mm),
gradient: 30 – 75 % B in 30 min): tR,netto = 17.36 min, tR,brutto = 20.40 min.
UV-vis (H2O/MeCN (1/1), 500 µm): λmax (nm) = 210, 242, 303, 353.
ESI-MS(+) (m/z (%)): 861.4 (64) [M+2H]2+, 1720.8 (100) [M] (deconvoluted).
HR-MS (ESI):
calculated for [C73H114N18O30]2+ ([M+2H]2+): 861.3969; found: 861.3970,
calculated for [C73H112N18O30] [M]: 1720.8; found: 1720.8 (deconvoluted).
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Peptide 31 was synthesized according to GSP 1 (chapter 8.4.1) by manual solid phase peptide
synthesis (25 µmol) on preloaded Fmoc-Leu-Wang resin (0.32 mmol/g). The following amino
acid derivatives were used:
Fmoc-Arg(Pbf)-OH, Fmoc-Asp(DMNPB)-OH (27), Fmoc-Gln(Trt)-OH, Fmoc-Glu(OtBu)-OH,
Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH.
Single coupling was performed with a coupling time of 30 min (45 min for 27) and successful
coupling was checked by performing a Kaiser test (chapter 8.4.4).
After the complete synthesis, peptide 31 was cleaved from the resin and completely depro-
tected according to GSP 3 (chapter 8.4.3). After purification by HPLC, peptide 31 (22.6 mg,
19.9 µmol, 79 %) was obtained as a light-yellow solid.
HPLC (Macherey-Nagel NUCLEODUR® RP-C18 ec analytical column (100 Å, 5 µm, 250 x 4.6 mm),
gradient: 10 – 60 % B in 30 min): tR,netto = 21.05 min, tR,brutto = 24.97 min.
UV-vis (H2O/MeCN (9/1), 500 µm): λmax (nm) = 199, 246, 304, 348.
ESI-MS(+) (m/z (%)): 380.2 (100) [M+3H]3+, 569.8 (43) [M+2H]2+, 1138.6 (1) [M+H]+.
HR-MS (ESI):
calculated for [C50H86N13O17]3+ ([M+3H]3+): 380.2083; found: 380.2087,
calculated for [C50H85N13O17]2+ ([M+2H]2+): 569.8088; found: 569.8085,
calculated for [C50H84N13O17]+ ([M+H]+): 1138.6103; found: 1138.6105.
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Peptide 32 was synthesized according to GSP 1 (chapter 8.4.1) by manual solid phase peptide
synthesis (50 µmol) on preloaded Fmoc-Leu-Wang resin (0.32 mmol/g). The following amino
acid derivatives were used:
Fmoc-Arg(Pbf)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-
Leu-OH, Fmoc-Lys(Boc)-OH.
Single coupling was performed with a coupling time of 30 min and successful coupling was
checked by performing a Kaiser test (chapter 8.4.4).
After the complete synthesis peptide 32 was cleaved from half of the resin (∼120 mg) and
completely deprotected according to GSP 3 (chapter 8.4.3). The rest of the resin-bound
peptide (∼120 mg) was used for synthesis of peptide 33. After purification by HPLC peptide
32 was obtained as colorless solid.
HPLC (Macherey-Nagel NUCLEODUR® RP-C18 ec analytical column (100 Å, 5 µm, 250 x 4.6 mm),
gradient: 10 – 60 % B in 30 min): tR,netto = 10.17 min, tR,brutto = 14.04 min.
ESI-MS(+) (m/z (%)): 301.2 (38) [M+3H]3+, 451.3 (100) [M+2H]2+, 901.5 (14) [M+H]+.
HR-MS (ESI):
calculated for [C38H71N12O13]3+ ([M+3H]3+): 301.1749; found: 301.1755,
calculated for [C38H70N12O13]2+ ([M+2H]2+): 451.2587; found: 451.2588,
calculated for [C38H69N12O13]+ ([M+H]+): 901.5102; found: 901.5100.
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Peptide 33 was synthesized according to GSP 1 (chapter 8.4.1) by manual solid phase peptide
synthesis (25 µmol) on the preloaded Wang resin (∼120 mg) obtained from the synthesis of
peptide 32. The following amino acid derivatives were used:
Fmoc-Asp(OtBu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Val-OH.
Single coupling was performed with a coupling time of 30 min and successful coupling was
checked by performing a Kaiser test (chapter 8.4.4).
After the complete synthesis, peptide 33 was cleaved from the resin and completely deprotected
according to GSP 3 (chapter 8.4.3). After purification by HPLC peptide 33 was obtained as
colorless solid.
HPLC (Macherey-Nagel NUCLEODUR® RP-C18 ec analytical column (100 Å, 5 µm, 250 x 4.6 mm),
gradient: 10 – 75 % B in 30 min): tR,netto = 11.20 min, tR,brutto = 15.17 min.
ESI-MS(+) (m/z (%)): 415.2 (100) [M+3H]3+, 622.3 (49) [M+2H]2+, 1243.7 (1) [M+H]+.
HR-MS (ESI):
calculated for [C53H97N16O18]3+ ([M+3H]3+): 415.2383; found: 415.2388,
calculated for [C53H96N16O18]2+ ([M+2H]2+): 622.3539; found: 622.3531,
calculated for [C53H95N16O18]+ ([M+H]+): 1243.7005; found: 1243.6985.
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H OHS E L D DR A D A L QA GA S QF E T S A A K L
Peptide 34 was synthesized according to GSP 2 (chapter 8.4.2) by automated solid phase
peptide synthesis (0.10 mmol) on a preloaded Fmoc-Leu-Wang resin (0.32 mmol/g) using
the CEM LibertyBlue peptide synthesizer. The following amino acid derivatives were used:
Fmoc-Ala-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Glu(OtBu)-
OH, Fmoc-Gly-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Phe-OH, Fmoc-Ser(tBu)-OH,
Fmoc-Thr(tBu)-OH.
According to GSP 3 (chapter 8.4.3) a small amount of peptide 34 was cleaved from the resin
and completely deprotected for analysis by HPLC and mass spectrometry. The residual amount
was used resin-bound for further syntheses (peptides 35 and 36).
HPLC (Macherey-Nagel NUCLEODUR® RP-C18 ec analytical column (100 Å, 5 µm, 250 x 4.6 mm),
gradient: 10 – 90 % B in 30 min): tR,netto = 13.65 min, tR,brutto = 16.82 min.
ESI-MS(+) (m/z (%)): 624.6 (7) [M+4H]4+, 832.4 (100) [M+3H]3+, 1248.1 (24) [M+2H]2+,
2493.2 (100) [M] (deconvoluted).
HR-MS (ESI):
calculated for [C104H172N30O41]4+ ([M+4H]4+): 624.3069; found: 624.3066,
calculated for [C104H171N30O41]3+ ([M+3H]3+): 832.0734; found: 832.0742,
calculated for [C104H170N30O41]2+ ([M+2H]2+): 1247.6064; found: 1247.6071,
calculated for [C104H168N30O41] ([M]): 2493.2; found: 2493.2 (deconvoluted).
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H OHDK V L E R D QK L S E L D DR A D A L QA GA S QF E T S A A K L
Nvoc DMNPB
Nvoc
Peptide 35 was synthesized according to GSP 1 (chapter 8.4.1) by manual solid phase peptide
synthesis (100 µmol) on the preloaded Wang resin (∼544 mg) obtained from the synthesis of
peptide 34. The following amino acid derivatives were used:
Fmoc-Arg(Pbf)-OH, Fmoc-Asp(DMNPB)-OH (27), Fmoc-Asp(OtBu)-OH, Fmoc-Gln(Trt)-
OH, Fmoc-Glu(OtBu)-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Lys(Nvoc)-OH (16),
Fmoc-Val-OH.
Double coupling was performed with a coupling time of 2 x 30 min (2 x 45 min for 16 and 27)
and successful coupling was checked by performing a Kaiser test (chapter 8.4.4).
According to GSP 3 (chapter 8.4.3) a small amount of peptide 35 was cleaved from the resin
and completely deprotected for analysis by HPLC and mass spectrometry. The residual amount
was used resin-bound for further synthesis (peptide 36).
HPLC (Macherey-Nagel NUCLEODUR® RP-C18 ec analytical column (100 Å, 5 µm, 250 x 4.6 mm),
gradient: 10 – 90 % B in 30 min): tR,netto = 21.66 min, tR,brutto = 24.97 min.
ESI-MS(+) (m/z (%)): 888.0 (9) [M+5H]5+, 1109.8 (100) [M+4H]4+, 1479.3 (19) [M+3H]3+,
4433.1 (100) [M] (deconvoluted).
HR-MS (ESI):
calculated for [C189H298N49O74]5+ ([M+5H]5+): 887.6207; found: 887.6210,
calculated for [C189H297N49O74]4+ ([M+4H]4+): 1109.2740; found: 1109.2754,
calculated for [C189H296N49O74]3+ ([M+3H]3+): 1478.6963; found: 1478.6975,
calculated for [C189H293N49O74] ([M]): 4433.1; found: 4433.1 (deconvoluted).
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8.8.4 Synthesis of Synaptobrevin-2 (28 – 84) K52K(Nvoc),
D57D(DMNPB), K59K(Nvoc) (36)






Peptide 36 was synthesized according to GSP 2 (chapter 8.4.2) by automated solid phase
peptide synthesis (0.10 mmol) on the preloaded Wang resin obtained from the synthesis
of peptide 35 using the CEM LibertyBlue peptide synthesizer. Standard coupling methods
were applied expect for R30, R31 (0.10-Tripple Arg Coupling (HS)). The following amino acid
derivatives were used:
Fmoc-Ala-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Gln(Trt)-
OH, Fmoc-Glu(OtBu)-OH, Fmoc-Ile-OH, Fmoc-Leu-OH, Fmoc-Met-OH, Fmoc-Ser(tBu)-OH,
Fmoc-Thr(tBu)-OH, Fmoc-Val-OH.
After the complete synthesis, peptide 36 was cleaved from the resin and completely depro-
tected according to GSP 3 (chapter 8.4.3). After purification by HPLC peptide 36 (5.50 mg,
7.73 µmol, 1.6 %) was obtained only in insufficient purity as a colorless solid.
HPLC (Macherey-Nagel NUCLEODUR® RP-C18 ec semipreperative column (100 Å, 5 µm,
250 x 10.0 mm), gradient: 20 – 70 % B in 30 min): tR,netto = 16.45 min, tR,brutto = 21.55 min.
ESI-MS(+) (m/z (%)): 1017.5 (25) [M+7H]7+, 1187.1 (100) [M+6H]6+, 1424.3 (45)
[M+5H]5+, 1779.9 (13) [M+4H]4+, 7112.4 (100) [M] (deconvoluted).
HR-MS (ESI):
calculated for [C300H490N87O111S]7+ ([M+7H]7+): 1017.5020; found: 1017.5006,
calculated for [C300H489N87O111S]6+ ([M+6H]6+): 1187.0848; found: 1187.0858,
calculated for [C300H488N87O111S]5+ ([M+5H]5+): 1424.3003; found: 1424.3017,
calculated for [C300H487N87O111S]4+ ([M+4H]4+): 1779.8730; found: 1779.8716,
calculated for [C300H483N87O111S] ([M]): 7112.5; found: 7112.4 (deconvoluted).
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8.9 Labelled SNARE transmembrane domains[139–142, 144]
8.9.1 Synthesis of Syntaxin-4 (262 – 297) Homo sapiens (37)




Peptide 37 was synthesised according to GSP 2 (chapter 8.4.2) by using the CEM Liberty12
peptide synthesizer. For the synthesis the batch size of 0.10 mmol with douple coupling proce-
dure (0.10-Double-Capping) was used as well as the Fmoc-Gly-Wang resin LL (0.3 mmol/g,
333 mg). For the amino acids Cys (0.10-Double-Capping 50C) and Arg (0.10-Double-Capping
Arg (KM)) special programs were used. After completion of the automated synthesis the resin
was transferred from Falcon Tube in a 10 mL-BD-syringe, washed with DCM (15 x 8 mL) and
dried under reduced pressure. A small amount of the peptide 37 was cleaved from the resin and
completely deprotected according to GSP 3 (chapter 8.4.3) by using 250 µL of cleavage mix-
ture containing EDT. The rest of the resin was used for labelling reactions (peptides 41 and 45).
ESI-MS(+) (m/z (%)): 758.68 (29) [M+5H]5+, 948.10 (31) [M+4H]4+, 3788.37 (60)
[M+H]+.
HR-MS (ESI):
calculated for [C174H321N46O44S]5+ ([M+5H]5+): 758.6809; found: 758.6812,
calculated for [C174H320N46O44S]4+ ([M+4H]4+): 948.0993; found: 948.0987,
calculated for [C174H317N46O44S]+ ([M+H]+): 3788.37; found: 3788.37.
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H OHAVKYQSKARRKKI M I I I CCVI LGI VI ASTVGGI FA
Peptide 38 was synthesised according to GSP 2 (chapter 8.4.2) by using the CEM Liberty12
peptide synthesizer. For the synthesis the batch size of 0.10 mmol with douple coupling proce-
dure (0.10-Double-Capping) was used as well as the Fmoc-Ala-Wang resin LL (0.38 mmol/g,
263 mg). For the amino acids Cys (0.10-Double-Capping 50C) and Arg (0.10-Double-Capping
Arg (KM)) special programs were used. After completion of the automated synthesis the resin
was transferred from Falcon Tube in a 10 mL-BD-syringe, washed with DCM (15 x 8 mL) and
dried under reduced pressure. A small amount of the peptide 38 was cleaved from the resin
and completely deprotected according to GSP 3 (chapter 8.4.3) by using 250 µL of cleavage
mixture containing EDT. The rest of the resin was used for labelling reactions (peptide 42, 46
and 48).
ESI-MS(+) (m/z (%)): 628.4 (12) [M+6H]6+, 753.9 (100) [M+5H]5+, 942.1 (87) [M+4H]4+,
1255.7 (8) [M+3H]3+, 3762.2 (100) [M] (deconvoluted).
HR-MS (ESI):
calculated for [C172H306N46O41S3]6+ ([M+6H]6+): 628.0400; found: 628.0392,
calculated for [C172H305N46O41S3]5+ ([M+5H]5+): 753.4466; found: 753.4467,
calculated for [C172H304N46O41S3]5+ ([M+4H]4+): 941.5564; found: 941.5568,
calculated for [C172H303N46O41S3]5+ ([M+3H]3+): 1255.0728; found: 1255.0727,
calculated for [C172H300N46O41S3] [M]: 3762.2; found: 3762.2 (deconvoluted).
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H OHAVKYQSKARRAAI M I I I CCVI LGI VI ASTVGGI FA
Peptide 39 was synthesised according to GSP 2 (chapter 8.4.2) by using the CEM Liberty12
peptide synthesizer. For the synthesis the batch size of 0.10 mmol with douple coupling proce-
dure (0.10-Double-Capping) was used as well as the Fmoc-Ala-Wang resin LL (0.38 mmol/g,
263 mg). For the amino acids Cys (0.10-Double-Capping 50C) and Arg (0.10-Double-Capping
Arg (KM)) special programs were used. After completion of the automated synthesis the resin
was transferred from Falcon Tube in a 10 mL-BD-syringe, washed with DCM (15 x 8 mL) and
dried under reduced pressure. A small amount of the peptide 39 was cleaved from the resin
and completely deprotected according to GSP 3 (chapter 8.4.3) by using 250 µL of cleavage
mixture containing EDT. The rest of the resin was used for labelling reactions (peptide 43).
HR-MS (ESI):
calculated for [C166H290N44O41S3]4+ ([M+4H]4+): 913.03; found: 913.02,
calculated for [C166H289N44O41S3]3+ ([M+3H]3+): 1217.03; found: 1217.03,
calculated for [C166H286N44O41S3] [M]: 3648.1; found: 3648.1 (deconvoluted).
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Peptide 40 was synthesised according to GSP 2 (chapter 8.4.2) by using the CEM Liberty12
peptide synthesizer. For the synthesis the batch size of 0.10 mmol with douple coupling proce-
dure (0.10-Double-Capping) was used as well as the Fmoc-Gly-Wang resin LL (0.3 mmol/g,
333 mg). For the amino acids Cys (0.10-Double-Capping 50C) and Arg (0.10-Double-Capping
Arg (KM)) special programs were used. After completion of the automated synthesis the resin
was transferred from Falcon Tube in a 10 mL-BD-syringe, washed with DCM (15 x 8 mL) and
dried under reduced pressure. A small amount of the peptide 40 was cleaved from the resin
and completely deprotected according to GSP 3 (chapter 8.4.3) by using 250 µL of cleavage
mixture containing EDT. The rest of the resin was used for labelling reactions (peptide 44, 47
and 49).
ESI-MS(+) (m/z (%)): 670.0 (33) [M+5H]5+, 837.5 (100) [M+4H]4+, 1116.0 (19) [M+3H]3+,
1673.5 (8) [M+2H]2+, 3343.9 (100) [M] (deconvoluted).
HR-MS (ESI):
calculated for [C154H271N42O38S]5+ ([M+5H]5+): 669.8052; found: 669.8051,
calculated for [C154H270N42O38S]4+ ([M+4H]4+): 837.0046; found: 837.0046,
calculated for [C154H269N42O38S]3+ ([M+3H]3+): 1116.0047; found: 1116.0062,
calculated for [C154H268N42O38S]2+ ([M+2H]2+): 1673.5034; found: 1673.5022,
calculated for [C154H266N42O38S] [M]: 3344.0; found: 3344.0 (deconvoluted).
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8.9.5 Synthesis of Atto647N-labelled Syntaxin-4 262 – 297 Homo
sapiens (41)[139, 141]















The resin-bound peptide 37 (chapter 8.9.1) was swollen in NMP (2.00 mL) for 1 h and to
remove the final Fmoc-protecting group piperidine (20 %) in NMP (2 x 1.00 mL) was added
and shaken for 15 min. The resin was washed with NMP (5 x 2.00 mL), DCM (5 x 2.00 mL)
and NMP (5 x 2.00 mL). Afterwards, a solution of Atto647N-NHS-ester (1.00 mg, 1.19 µmol,
1.00 eq.), PyBOP (1.23 mg, 2.37 µmol, 2.00 eq.) and DIPEA (10.0 µL, 51.8 µmol, 44.0 eq.)
in NMP (150 µL) was added to the resin-bound peptide 37 (11.0 mg, 2.37 µmol, 2.00 eq.) and
shaken overnight under light exclusion. The solution was filtrated and the resin was washed
with NMP (5 x 2.00 mL) and DCM (5 x 2.00 mL) and dried under reduced pressure. The
peptide 41 was cleaved from the resin and completely deprotected according to GSP 3 (chapter
8.4.3) by using EDT containing cleavage mixture (500 µL). After precipitation and drying
under reduced pressure, the crude peptide was suspended in H2O/MeCN and lyophilised to
obtain peptide 41 as a dark blue solid.
ESI-MS(+) (m/z (%)): 883.95 (18) [M+5H]5+, 1104.69 (32) [M+4H]4+, 1472.58 (25)
[M+3H]3+, 4414.75 (48) [M] (deconvoluted).
HR-MS (ESI):
calculated for [C216H371N49O46S]5+ ([M+5H]5+): 883.9534; found: 883.9538,
calculated for [C216H370N49O46S]4+ ([M+4H]4+): 1104.6942; found: 1104.6944,
calculated for [C216H369N49O46S]3+ ([M+3H]3+): 1472.5821; found: 1472.5825,
calculated for [C216H366N49O46S] [M]: 4414.75; found: 4414.75 (deconvoluted).
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The resin-bound peptide 38 (chapter 8.9.2) was swollen in NMP (2.00 mL) for 1 h and to
remove the final Fmoc-protecting group piperidine (20 %) in NMP (2 x 1.00 mL) was added
and shaken for 2 x 15 min. The resin was washed with NMP (5 x 2.00 mL), DCM (5 x 2.00 mL)
and NMP (5 x 2.00 mL). Afterwards, a solution of Atto647N-NHS-ester (1.00 mg, 1.19 µmol,
1.00 eq.) and DIPEA (10.0 µL, 51.8 µmol, 44.0 eq.) in NMP (250 µL) was added to the
resin-bound peptide 38 (11.4 mg, 2.37 µmol, 2.00 eq.) and shaken overnight under light
exclusion. The solution was filtrated and the resin was washed with NMP (5 x 2.00 mL) and
DCM (10 x 2.00 mL) and dried under reduced pressure. The peptide 42 was cleaved from the
resin and completely deprotected according to GSP 3 (chapter 8.4.3) by using EDT containing
cleavage mixture (500 µL). After precipitation and drying under reduced pressure, the crude
peptide was suspended in H2O/MeCN and lyophilised to obtain peptide 42 as a dark blue solid.
ESI-MS(+) (m/z (%)): 733.1 (52) [M+6H]6+, 879.3 (100) [M+5H]5+, 1098.9 (66) [M+4H]4+,
4389.6 (100) [M] (deconvoluted).
HR-MS (ESI):
calculated for [C214H355N49O43S3]6+ ([M+6H]6+): 732.6038; found: 732.6035,
calculated for [C214H354N49O43S3]5+ ([M+5H]5+): 878.9231; found: 878.9219,
calculated for [C214H353N49O43S3]4+ ([M+4H]4+): 1098.4021; found: 1098.3996,
calculated for [C214H349N49O43S3] [M]: 4389.6; found: 4389.6 (deconvoluted).
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8.9.7 Synthesis of Atto647N-labelled Syntaxin-1A (254 – 288)
















The resin-bound peptide 39 (chapter 8.9.3) was swollen in NMP (2.00 mL) for 1 h and to
remove the final Fmoc-protecting group piperidine (20 %) in NMP (2 x 1.00 mL) was added
and shaken for 2 x 15 min. The resin was washed with NMP (5 x 2.00 mL), DCM (5 x 2.00 mL)
and NMP (5 x 2.00 mL). Afterwards, a solution of Atto647N-NHS-ester (1.00 mg, 1.19 µmol,
1.00 eq.) and DIPEA (10.0 µL, 51.8 µmol, 44.0 eq.) in NMP (300 µL) was added to the
resin-bound peptide 39 (11.1 mg, 2.37 µmol, 2.00 eq.) and shaken overnight under light
exclusion. The solution was filtrated and the resin was washed with NMP (5 x 2.00 mL) and
DCM (10 x 2.00 mL) and dried under reduced pressure. The peptide 43 was cleaved from the
resin and completely deprotected according to GSP 3 (chapter 8.4.3) by using EDT containing
cleavage mixture (500 µL). After precipitation and drying under reduced pressure, the crude
peptide was suspended in H2O/MeCN and lyophilised to obtain peptide 43 as a dark blue solid.
HR-MS (ESI):
calculated for [C208H339N47O43S3]4+ ([M+4H]4+): 1069.87; found: 1069.87,
calculated for [C208H335N47O43S3] [M]: 4275.5; found: 4275.4 (deconvoluted).
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8.9.8 Synthesis of Atto647N-labelled Syntaxin-1A (257 – 288)
















The resin-bound peptide 40 (chapter 8.9.4) was swollen in NMP (2.00 mL) for 1 h and to
remove the final Fmoc-protecting group piperidine (20 %) in NMP (2 x 1.00 mL) was added
and shaken for 15 min. The resin was washed with NMP (5 x 2.00 mL), DCM (5 x 2.00 mL)
and NMP (5 x 2.00 mL). Afterwards, a solution of Atto647N-NHS-ester (1.00 mg, 1.19 µmol,
1.00 eq.), PyBOP (1.23 mg, 2.37 µmol, 2.00 eq.) and DIPEA (10.0 µL, 51.8 µmol, 44.0 eq.)
in NMP (150 µL) was added to the resin-bound peptide 40 (11.0 mg, 2.37 µmol, 2.00 eq.) and
shaken overnight under light exclusion. The solution was filtrated and the resin was washed
with NMP (5 x 2.00 mL) and DCM (5 x 2.00 mL) and dried under reduced pressure. The
peptide 44 was cleaved from the resin and completely deprotected according to GSP 3 (chapter
8.4.3) by using EDT containing cleavage mixture (500 µL). After precipitation and drying
under reduced pressure, the crude peptide was suspended in H2O/MeCN and lyophilised to
obtain peptide 44 as a dark blue solid.
ESI-MS(+) (m/z (%)): 795.68 (21) [M+5H]5+, 994.35 (35) [M+4H]4+, 1325.47 (28)
[M+3H]3+, 3971.37 (45) [M] (deconvoluted).
HR-MS (ESI):
calculated for [C196H321N45O40S]5+ ([M+5H]5+): 795.6839; found: 795.6841,
calculated for [C196H320N45O40S]4+ ([M+4H]4+): 994.3530; found: 994.3529,
calculated for [C196H319N45O40S]3+ ([M+3H]3+): 1325.4683; found: 1325.4693,
calculated for [C196H316N45O40S] [M]: 3971.37; found: 3971.37 (deconvoluted).
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8.9.9 Synthesis of RhodamineRed-labelled Syntaxin-4 (262 – 297)
Homo sapiens (45)[139, 141]












The resin-bound peptide 37 (chapter 8.9.1) was swollen in NMP (2.00 mL) for 1 h and to
remove the final Fmoc-protecting group piperidine (20 %) in NMP (2 x 1.00 mL) was added and
shaken for 15 min. The resin was washed with NMP (5 x 2.00 mL), DCM (5 x 2.00 mL) and
NMP (5 x 2.00 mL). Afterwards, a solution of RhodamineRedTM-succinimidylester (0.74 mg,
0.96 µmol, 1.00 eq.) and DIPEA (10.0 µL, 60.0 µmol, 62.5 eq.) in NMP (150 µL) was added
to the resin-bound peptide 37 (10.0 mg, 2.00 µmol, 2.08 eq.) and shaken overnight under
light exclusion. The solution was filtrated and the resin was washed with NMP (5 x 2.00 mL)
and DCM (5 x 2.00 mL) and dried under reduced pressure. The peptide 45 was cleaved
from the resin and completely deprotected according to GSP 3 (chapter 8.4.3) by using EDT
containing cleavage mixture (500 µL). After precipitation and drying under reduced pressure, the
crude peptide was suspended in H2O/MeCN and lyophilised to obtain peptide 45 as a pink solid.
ESI-MS(+) (m/z (%)): 742.35 (12) [M+6H]6+, 889.53 (7) [M+5H]5+, 1111.41 (12)
[M+4H]4+, 1482.69 (12) [M+3H]3+, 4441.60 (9) [M+H]+.
HR-MS (ESI):
calculated for [C207H356N49O51S3]+ ([M+H]+): 4441.59; found: 4441.60.
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The resin-bound peptide 38 (chapter 8.9.2) was swollen in NMP (2.00 mL) for 1 h and to
remove the final Fmoc-protecting group piperidine (20 %) in NMP (2 x 1.00 mL) was added and
shaken for 2 x 15 min. The resin was washed with NMP (5 x 2.00 mL), DCM (5 x 2.00 mL) and
NMP (5 x 2.00 mL). Afterwards, a solution of RhodamineRedTM-succinimidylester (1.00 mg,
1.30 µmol, 1.00 eq.) and DIPEA (10.0 µL, 60.0 µmol, 46.2 eq.) in NMP (250 µL) was added
to the resin-bound peptide 38 (12.5 mg, 2.00 µmol, 2.00 eq.) and shaken overnight under
light exclusion. The solution was filtrated and the resin was washed with NMP (5 x 2.00 mL)
and DCM (10 x 2.00 mL) and dried under reduced pressure. The peptide 46 was cleaved
from the resin and completely deprotected according to GSP 3 (chapter 8.4.3) by using EDT
containing cleavage mixture (500 µL). After precipitation and drying under reduced pressure, the
crude peptide was suspended in H2O/MeCN and lyophilised to obtain peptide 46 as a pink solid.
ESI-MS(+) (m/z (%)): 884.5 (100) [M+5H]5+, 1105.6 (79) [M+4H]4+, 1473.8 (9) [M+3H]3+,
4415.4 (100) [M] (deconvoluted).
HR-MS (ESI):
calculated for [C205H345N49O48S5]6+ ([M+6H]6+): 736.9105; found: 736.9135,
calculated for [C205H344N49O48S5]5+ ([M+5H]5+): 884.0912; found: 884.0934,
calculated for [C205H343N49O48S5]4+ ([M+4H]4+): 1104.8622; found: 1104.8644,
calculated for [C205H339N49O48S5] ([M]): 4415.4; found: 4415.4 (deconvoluted).
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8.9.11 Synthesis of RhodamineRed-labelled Syntaxin-1A (257 – 288)













The resin-bound peptide 40 (chapter 8.9.4) was swollen in NMP (2.00 mL) for 1 h and to
remove the final Fmoc-protecting group piperidine (20 %) in NMP (2 x 1.00 mL) was added and
shaken for 2 x 15 min. The resin was washed with NMP (5 x 2.00 mL), DCM (5 x 2.00 mL) and
NMP (5 x 2.00 mL). Afterwards, a solution of RhodamineRedTM-succinimidylester (1.00 mg,
1.30 µmol, 1.00 eq.) and DIPEA (10.0 µL, 60.0 µmol, 46.2 eq.) in NMP (150 µL) was added
to the resin-bound peptide 40 (12.0 mg, 2.60 µmol, 2.00 eq.) and shaken overnight under
light exclusion. The solution was filtrated and the resin was washed with NMP (5 x 2.00 mL)
and DCM (10 x 2.00 mL) and dried under reduced pressure. The peptide 47 was cleaved
from the resin and completely deprotected according to GSP 3 (chapter 8.4.3) by using EDT
containing cleavage mixture (500 µL). After precipitation and drying under reduced pressure, the
crude peptide was suspended in H2O/MeCN and lyophilised to obtain peptide 47 as a pink solid.
ESI-MS(+) (m/z (%)): 1000.3 (50) [M+4H]4+, 1333.1 (31) [M+3H]3+, 1999.6 (2) [M+2H]2+,
3998.21 (48) [M] (deconvoluted).
HR-MS (ESI):
calculated for [C187H309N45O45S3]4+ ([M+4H]4+): 1000.3104; found: 1000.3110,
calculated for [C187H308N45O45S3]3+ ([M+3H]3+): 1333.4114; found: 1333.4124,
calculated for [C187H307N45O45S3]2+ ([M+2H]2+): 1999.6134; found: 1999.6164.
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8.9.12 Synthesis of OregonGreen 488-labelled Syntaxin-1A














The resin-bound peptide 38 (chapter 8.9.2) was swollen in NMP (2.00 mL) for 1 h and to
remove the final Fmoc-protecting group piperidine (20 %) in NMP (2 x 1.00 mL) was added and
shaken for 2 x 15 min. The resin was washed with NMP (5 x 2.00 mL), DCM (5 x 2.00 mL) and
NMP (5 x 2.00 mL). Afterwards, a solution of OregonGreen® 488-X succinimidylester (1.00 mg,
1.61 µmol, 1.00 eq.) and DIPEA (10.0 µL, 60.0 µmol, 37.3 eq.) in NMP (250 µL) was added
to the resin-bound peptide 38 (15.4 mg, 3.21 µmol, 2.00 eq.) and shaken overnight under light
exclusion. The solution was filtrated and the resin was washed with NMP (5 x 2.00 mL) and
DCM (10 x 2.00 mL) and dried under reduced pressure. The peptide 48 was cleaved from the
resin and completely deprotected according to GSP 3 (chapter 8.4.3) by using EDT containing
cleavage mixture (1.00 mL). After precipitation and drying under reduced pressure, the crude
peptide was suspended in H2O/MeCN and lyophilised to obtain peptide 48 as a yellow solid.
ESI-MS(+) (m/z (%)): 855.3 (83) [M+5H]5+, 1068.9 (100) [M+4H]4+, 1424.8 (32)
[M+3H]3+, 4269.3 (100) [M] (deconvoluted).
HR-MS (ESI):
calculated for [C199H325N47O48S3]6+ ([M+6H]6+): 712.5589; found: 712.5599,
calculated for [C199H324N47O48S3]5+ ([M+5H]5+): 854.8692; found: 854.8680,
calculated for [C199H323N47O48S3]4+ ([M+4H]4+): 1068.3347; found: 1068.3323,
calculated for [C199H322N47O48S3]3+ ([M+3H]3+): 1424.1105; found: 1424.1095,
calculated for [C199H319N47O48S3] ([M]): 4269.3; found: 4269.3 (deconvoluted).
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8.9.13 Synthesis of OregonGreen 488-labelled Syntaxin-1A














The resin-bound peptide 40 (chapter 8.9.4) was swollen in NMP (2.00 mL) for 1 h and to
remove the final Fmoc-protecting group piperidine (20 %) in NMP (2 x 1.00 mL) was added and
shaken for 2 x 15 min. The resin was washed with NMP (5 x 2.00 mL), DCM (5 x 2.00 mL) and
NMP (5 x 2.00 mL). Afterwards, a solution of OregonGreen® 488-X succinimidylester (1.00 mg,
1.61 µmol, 1.00 eq.) and DIPEA (10.0 µL, 60.0 µmol, 37.3 eq.) in NMP (250 µL) was added
to the resin-bound peptide 40 (14.6 mg, 3.21 µmol, 2.00 eq.) and shaken overnight under light
exclusion. The solution was filtrated and the resin was washed with NMP (10 x 2.00 mL) and
DCM (10 x 2.00 mL) and dried under reduced pressure. The peptide 49 was cleaved from the
resin and completely deprotected according to GSP 3 (chapter 8.4.3) by using EDT containing
cleavage mixture (1.00 mL). After precipitation and drying under reduced pressure, the crude
peptide was suspended in H2O/MeCN and lyophilised to obtain peptide 49 as a yellow solid.
ESI-MS(+) (m/z (%)): 964.3 (21) [M+4H]4+, 1285.4 (11) [M+3H]3+, 3851.1 (27) [M]
(deconvoluted).
HR-MS (ESI):
calculated for [C181H290F2N43O45S]5+ ([M+5H]5+): 771.2277; found: 771.2269,
calculated for [C181H289F2N43O45S]4+ ([M+4H]4+): 963.7829; found: 963.7822,
calculated for [C181H288F2N43O45S]3+ ([M+3H]3+): 1284.7081; found: 1284.7081,
calculated for [C181H285F2N43O45S] ([M]): 3851.1; found: 3851.1 (deconvoluted).
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Peptide 50 was synthesised according to GSP 2 (chapter 8.4.2) by using the CEM LibertyBlue
peptide synthesizer. For the synthesis the batch size of 0.10 mmol with douple coupling
procedure (0.10-Double-Coupling (HS)) was used as well as the Fmoc-Ser(OtBu)-Wang resin
LL (0.31 mmol/g, 323 mg). For the amino acids Cys (0.10-Double 50°C Couplin (HS)) special
program were used. After completion of the automated synthesis the resin was transferred from
the reaction vessel in a 10 mL-BD-syringe, washed with DCM (15 x 8 mL) and dried under
reduced pressure. A small amount of the peptide 50 was cleaved from the resin and completely
deprotected according to GSP 3 (chapter 8.4.3) by using 250 µL of cleavage mixture containing
EDT. The rest of the resin was used for labelling reactions (peptide 53 and peptide 56).
ESI-MS(+) (m/z (%)): 821.7 (85) [M+5H]5+, 1027.1 (100) [M+4H]4+, 1368.8 (22)
[M+3H]3+, 4100.4 (100) [M] (deconvoluted).
HR-MS (ESI):
calculated for [C200H326N47O39S3]5+ ([M+5H]5+): 821.6832; found: 821.6826,
calculated for [C200H325N47O39S3]4+ ([M+4H]4+): 1026.8522; found: 1026.8509,
calculated for [C200H321N47O39S3] [M]: 4101.4; found: 4101.4 (deconvoluted).
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Peptide 51 was synthesised according to GSP 2 (chapter 8.4.2) by using the CEM LibertyBlue
peptide synthesizer. For the synthesis the batch size of 0.10 mmol with douple coupling
procedure (0.10-Double-Coupling (HS)) was used as well as the Fmoc-Thr(OtBu)-Wang resin
LL (0.35 mmol/g, 286 mg). For the amino acids Cys (0.10-Double 50°C Couplin (HS)) and
Arg (0.10-Double Arg Coupling (HS)) special programs were used. After completion of the
automated synthesis the resin was transferred from the reaction vessel in a 10 mL-BD-syringe,
washed with DCM (15 x 8 mL) and dried under reduced pressure. A small amount of the
peptide 51 was cleaved from the resin and completely deprotected according to GSP 3 (chapter
8.4.3) by using 500 µL of cleavage mixture containing EDT. The rest of the resin was used for
labelling reactions (peptide 54 and peptide 57).
ESI-MS(+) (m/z (%)): 874.4 (28) [M+5H]5+, 1092.9 (14) [M+4H]4+, 1456.6 (7) [M+3H]3+,
4364.6 (11) [M] (deconvoluted).
HR-MS (ESI):
calculated for [C215H362N48O43S2]4+ ([M+4H]4+): 1092.9283; found: 1092.9281,
calculated for [C215H358N48O43S2][M]: 4364.7; found: 4364.6 (deconvoluted).
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Peptide 52 was synthesised according to GSP 2 (chapter 8.4.2) by using the CEM LibertyBlue
peptide synthesizer. For the synthesis the batch size of 0.10 mmol with douple coupling
procedure (0.10-Double-Coupling (HS)) was used as well as the Fmoc-Thr(OtBu)-Wang resin
LL (0.35 mmol/g, 286 mg). For the amino acids Cys (0.10-Double 50°C Couplin (HS)) special
program were used. After completion of the automated synthesis the resin was transferred from
the reaction vessel in a 10 mL-BD-syringe, washed with DCM (15 x 8 mL) and dried under
reduced pressure. A small amount of the peptide 52 was cleaved from the resin and completely
deprotected according to GSP 3 (chapter 8.4.3) by using 500 µL of cleavage mixture containing
EDT. The rest of the resin was used for labelling reactions (peptide 55).
ESI-MS(+) (m/z (%)): 904.1 (12) [M+5H]5+, 1130.2 (20) [M+4H]4+, 4515.6 (19) [M]
(deconvoluted).
HR-MS (ESI):
calculated for [C219H358N51O45S3]5+ ([M+5H]5+): 904.1; found: 904.1,
calculated for [C219H357N51O45S3]4+ ([M+4H]4+): 1130.2; found: 1130.2,
calculated for [C219H353N51O45S3] [M]: 4515.6; found: 4515.6 (deconvoluted).
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The resin-bound peptide 50 (chapter 8.9.14) was swollen in NMP (2.00 mL) for 1 h and to
remove the final Fmoc-protecting group piperidine (20 %) in NMP (2 x 1.00 mL) was added
and shaken for 2 x 15 min. The resin was washed with NMP (5 x 2.00 mL), DCM (5 x 2.00 mL)
and NMP (5 x 2.00 mL). Afterwards, a solution of Atto647N-NHS-ester (1.00 mg, 1.19 µmol,
1.00 eq.) and DIPEA (10.0 µL, 51.8 µmol, 44.0 eq.) in NMP (200 µL) was added to the
resin-bound peptide 50 (17.1 mg, 2.37 µmol, 2.00 eq.) and shaken overnight under light
exclusion. The solution was filtrated and the resin was washed with NMP (5 x 2.00 mL) and
DCM (10 x 2.00 mL) and dried under reduced pressure. The peptide 53 was cleaved from the
resin and completely deprotected according to GSP 3 (chapter 8.4.3) by using EDT containing
cleavage mixture (500 µL). After precipitation and drying under reduced pressure, the crude
peptide was suspended in H2O/MeCN and lyophilised to obtain peptide 53 as a dark blue solid.
ESI-MS(+) (m/z (%)): 947.4 (23) [M+5H]5+, 1183.9 (14) [M+4H]4+, 4630.7 (18) [M]
(deconvoluted).
HR-MS (ESI):
calculated for [C242H375N50O41S3]5+ ([M+5H]5+): 947.1597; found: 947.1590,
calculated for [C242H374N50O41S3]4+ ([M+4H]4+): 1183.9489; found: 1183.9467,
calculated for [C242H370N50O41S3] [M]: 4730.7; found: 4730.7 (deconvoluted).
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The resin-bound peptide 51 (chapter 8.9.15) was swollen in NMP (2.00 mL) for 1 h and to
remove the final Fmoc-protecting group piperidine (20 %) in NMP (2 x 1.00 mL) was added
and shaken for 2 x 15 min. The resin was washed with NMP (5 x 2.00 mL), DCM (5 x 2.00 mL)
and NMP (5 x 2.00 mL). Afterwards, a solution of Atto647N-NHS-ester (1.00 mg, 1.19 µmol,
1.00 eq.) and DIPEA (10.0 µL, 51.8 µmol, 44.0 eq.) in NMP (200 µL) was added to the
resin-bound peptide 51 (14.8 mg, 2.37 µmol, 2.00 eq.) and shaken overnight under light
exclusion. The solution was filtrated and the resin was washed with NMP (5 x 2.00 mL) and
DCM (10 x 2.00 mL) and dried under reduced pressure. The peptide 54 was cleaved from the
resin and completely deprotected according to GSP 3 (chapter 8.4.3) by using EDT containing
cleavage mixture (1.00 mL). After precipitation and drying under reduced pressure, the crude
peptide was suspended in H2O/MeCN and lyophilised to obtain peptide 54 as a dark blue solid.
ESI-MS(+) (m/z (%)): 1249.8 (11) [M+4H]4+.
HR-MS (ESI):
calculated for [C257H412N51O45S2]5+ ([M+5H]5+): 1000.2212; found: 1000.2210,
calculated for [C257H411N51O45S2]4+ ([M+4H]4+): 1249.0215; found: 1249.0185,
calculated for [C257H407N51O45S2] [M]: 4992.1; found: 4992.1 (deconvoluted).
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The resin-bound peptide 52 (chapter 8.9.16) was swollen in NMP (2.00 mL) for 1 h and to
remove the final Fmoc-protecting group piperidine (20 %) in NMP (2 x 1.00 mL) was added
and shaken for 2 x 15 min. The resin was washed with NMP (5 x 2.00 mL), DCM (5 x 2.00 mL)
and NMP (5 x 2.00 mL). Afterwards, a solution of Atto647N-NHS-ester (1.00 mg, 1.19 µmol,
1.00 eq.) and DIPEA (10.0 µL, 51.8 µmol, 44.0 eq.) in NMP (150 µL) was added to the
resin-bound peptide 52 (16.5 mg, 2.37 µmol, 2.00 eq.) and shaken overnight under light
exclusion. The solution was filtrated and the resin was washed with NMP (5 x 2.00 mL) and
DCM (10 x 2.00 mL) and dried under reduced pressure. The peptide 55 was cleaved from the
resin and completely deprotected according to GSP 3 (chapter 8.4.3) by using EDT containing
cleavage mixture (500 µL). After precipitation and drying under reduced pressure, the crude
peptide was suspended in H2O/MeCN and lyophilised to obtain peptide 55 as a dark blue solid.
ESI-MS(+) (m/z (%)): 858.2 (9) [M+6H]6+, 1029.6 (24) [M+5H]5+, 5142.0 (11) [M]
(deconvoluted).
HR-MS (ESI):
calculated for [C261H408N54O47S3]6+ ([M+6H]6+): 858.2; found: 858.2,
calculated for [C261H407N54O47S3]5+ ([M+5H]5+): 1029.6; found: 1029.6,
calculated for [C261H402N54O47S3] [M]: 5142.0; found: 5142.0 (deconvoluted).
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8.9.20 Synthesis of RhodamineRed-labelled VAMP-3













The resin-bound peptide 50 (chapter 8.9.14) was swollen in NMP (2.00 mL) for 1 h and to
remove the final Fmoc-protecting group piperidine (20 %) in NMP (2 x 1.00 mL) was added and
shaken for 2 x 15 min. The resin was washed with NMP (5 x 2.00 mL), DCM (5 x 2.00 mL) and
NMP (5 x 2.00 mL). Afterwards, a solution of RhodamineRedTM-succinimidylester (1.00 mg,
1.30 µmol, 1.00 eq.) and DIPEA (10.0 µL, 60.0 µmol, 46.2 eq.) in NMP (150 µL) was added
to the resin-bound peptide 50 (19.2 mg, 2.60 µmol, 2.00 eq.) and shaken overnight under
light exclusion. The solution was filtrated and the resin was washed with NMP (5 x 2.00 mL)
and DCM (10 x 2.00 mL) and dried under reduced pressure. The peptide 56 was cleaved
from the resin and completely deprotected according to GSP 3 (chapter 8.4.3) by using EDT
containing cleavage mixture (500 µL). After precipitation and drying under reduced pressure, the
crude peptide was suspended in H2O/MeCN and lyophilised to obtain peptide 56 as a pink solid.
ESI-MS(+) (m/z (%)): 952.5 (9) [M+5H]5+, 1190.7 (10) [M+4H]4+, 4754.6 (8) [M]
(deconvoluted).
HR-MS (ESI):
calculated for [C233H365N50O46S5]5+ ([M+5H]5+): 952.5; found: 952.5,
calculated for [C233H364N50O46S5]4+ ([M+4H]4+): 1190.7; found: 1190.7,
calculated for [C233H360N50O46S5] ([M]): 4754.6; found: 4754.6 (deconvoluted).
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The resin-bound peptide 51 (chapter 8.9.15) was swollen in NMP (2.00 mL) for 1 h and to
remove the final Fmoc-protecting group piperidine (20 %) in NMP (2 x 1.00 mL) was added and
shaken for 2 x 15 min. The resin was washed with NMP (5 x 2.00 mL), DCM (5 x 2.00 mL) and
NMP (5 x 2.00 mL). Afterwards, a solution of RhodamineRedTM-succinimidylester (1.00 mg,
1.30 µmol, 1.00 eq.) and DIPEA (10.0 µL, 60.0 µmol, 46.2 eq.) in NMP (200 µL) was added
to the resin-bound peptide 51 (16.2 mg, 2.60 µmol, 2.00 eq.) and shaken overnight under
light exclusion. The solution was filtrated and the resin was washed with NMP (5 x 2.00 mL)
and DCM (10 x 2.00 mL) and dried under reduced pressure. The peptide 57 was cleaved from
the resin and completely deprotected according to GSP 3 (chapter 8.4.3) by using EDT con-
taining cleavage mixture (1.00 mL). After precipitation and drying under reduced pressure, the
crude peptide was suspended in H2O/MeCN and lyophilised to obtain peptide 57 as a pink solid.
ESI-MS(+) (m/z (%)): 1005.2 (17) [M+5H]5+, 1256.5 (19) [M+4H]4+, 5017.9 (16) [M]
(deconvoluted).
HR-MS (ESI):
calculated for [C248H402N51O50S4]5+ ([M+5H]5+): 1005.1887; found: 1005.1853,
calculated for [C248H401N51O50S4]4+ ([M+4H]4+): 1256.4848; found: 1256.4863,





α-SNAP α-soluble NSF attachment protein
δ Chemical shift
δa Two-photon cross-section
δu Two-photon action cross-section
λmax Wavelength of maximal absorption
ε Extinction coefficient
[M] Molecule peak (deconvoluted)




m/z Mass to charge ratio
p-NPCl p-Nitrophenyl chloroformate
tBu tert-Butyle





AAA+ ATPases associated with various cellular activities


















































EPL Expressed protein ligation
eq Equivalent(s)















HMBC Heteronuclear multiple bond correlation
HOAt 1-Hydroxy-7-azabenzotriazole
HOBt 1-Hydroxybenzotriazole
HPLC High performance liquid chromatography
HR-MS High resolution mass spectrometry
HS High-swelling
































































SDS-PAGE Sodium dodecylsulfate polyacrylamide gel electrophoresis
Ser Serine
SM Sec1/Munc18-like
SN25 25 kDa synaptosomal-associated protein
SNAP-25 25 kDa synaptosomal-associated protein
SNARE Soluble NSF attachment protein receptor
SPPS Solid phase peptide synthesis
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